WHEREAS
Whereas, in accordance with the provisions of Article 46, Section I, of the Federal Law on Metrology and Standardisation, the Ministry of Labour and Social Welfare submitted to the National Consultative Committee for the Standardisation of Occupational Safety and Health, at its Twelfth Ordinary Session, held on 17 December 2013, the Preliminary Draft Amendment to Official Mexican Standard NOM-010-STPS-1999, Safety and hygiene conditions at workplaces where chemical substances capable of generating contamination of the working environment are handled, transported, processed or stored, to become PROY-NOM-010-STPS-2013, Chemical Contaminants of the Working Environment - Recognition, Evaluation and Control, and the said Committee considered it appropriate and agreed that it be published as a Draft in the Official Gazette of the Federation; Whereas, on the basis of the provisions of Articles 69-E and 69-H of the Federal Administrative Procedure Law, the corresponding Draft was submitted for the consideration of the Federal Regulatory Improvement Commission, which issued a favourable ruling in relation thereto; Whereas, pursuant to Article 47, Section I, of the Federal Law on Metrology and Standardisation, the Draft Amendment to Official Mexican Standard NOM-010-STPS-1999, Safety and hygiene conditions at workplaces where chemical substances capable of generating contamination of the working environment are handled, transported, processed or stored, to become PROY-NOM-010-STPS-2013, Chemical Contaminants of the Working Environment - Recognition, Evaluation and Control, was published for a sixty-day public consultation in the Official Gazette of the Federation of 26 December 2013, so that interested parties could submit their comments to the National Consultative Committee for the Standardisation of Occupational Safety and Health during that period; Whereas, having received comments from twelve proponents, the said Committee proceeded to study them and resolved them in due course, for which reason this authority published the respective responses in the Official Gazette of the Federation of 9 April 2014, in accordance with the provisions of Article 47, Section III, of the Federal Law on Metrology and Standardisation; Whereas, as a result of the incorporation of the comments submitted on the Draft Amendment to Official Mexican Standard NOM-010-STPS-1999, Safety and hygiene conditions at workplaces where chemical substances capable of generating contamination of the working environment are handled, transported, processed or stored, to become PROY-NOM-010-STPS-2013, Chemical Contaminants of the Working Environment - Recognition, Evaluation and Control, as well as the final review of the draft itself, various amendments were made for the purpose of providing clarity, consistency and legal certainty regarding the provisions applicable at workplaces; and Whereas, in view of the foregoing considerations and given that the National Consultative Committee for the Standardisation of Occupational Safety and Health granted its respective approval, the following is hereby issued: OFFICIAL MEXICAN STANDARD NOM-010-STPS-2014, CHEMICAL CONTAMINANTS OF THE WORKING ENVIRONMENT - RECOGNITION, EVALUATION AND CONTROL
CONTENTS
Transitional Provisions
Appendix I Exposure limit values for chemical contaminants of the working environment Appendix II Hazard code of chemical substances and its description Guide A (Non-mandatory) Example for calculating exposure limit values for contaminant mixtures in the working environment
1. Objective
To establish the processes and measures to prevent risks to the health of personnel occupationally exposed to chemical contaminants of the working environment.
2. Scope
This Official Mexican Standard applies throughout the national territory and to all workplaces where chemical contaminants of the working environment are present.
3. References
For the correct interpretation of this Standard, the following official Mexican standards and Mexican standard in force, or those replacing them, shall be consulted:
3.1 NOM-017-STPS-2008, Personal protective equipment - Selection, use and handling at workplaces.
3.2 NOM-018-STPS-2000, System for the identification and communication of hazards and risks of hazardous chemical substances at workplaces.
3.3 NOM-026-STPS-2008, Safety and hygiene colours and signals, and identification of hazards from fluids conveyed in pipework.
3.4 NOM-116-STPS-2009, Safety - Personal protective equipment - Negative-pressure air-purifying respirators against harmful particles - Specifications and test methods.
3.5 NOM-047-SSA1-2011, Environmental health - Biological exposure indices for personnel occupationally exposed to chemical substances.
3.6 NMX-R-019-SCFI-2011, Harmonised System for the Classification and Communication of Chemical Product Hazards.
4. Definitions
For the purposes of this Standard, the following definitions are established:
4.1 Aerosol: Solid or liquid particles dispersed in a gaseous medium, normally air.
4.2 Chemical contaminants of the working environment: Substances or mixtures capable of modifying the environmental conditions of the workplace which, owing to their properties, concentration, level and duration of exposure or action, may impair the health of workers.
4.3 Simple asphyxiant: Inert gases that displace air, thereby reducing the oxygen concentration, without other significant effects.
4.4 Labour authority: The competent administrative units of the Ministry of Labour and Social Welfare that carry out inspection and enforcement functions in occupational safety and health matters, and the corresponding units of the federative entities and the Federal District that act in support thereof.
4.5 Chain of custody: The administrative mechanism for tracking samples during the stages of the evaluation - sampling, analytical determination and recording of results -, which shall include the dates of their receipt and delivery at each of the stages, as well as the names of the persons responsible involved in these acts. Its purpose is to prevent the alteration, contamination, damage and replacement of the samples.
4.6 CAS: The English acronym for the Chemical Abstracts Service.
4.7 Workplaces: All places, such as buildings, premises, installations and areas, where production, marketing, transport and storage activities or the provision of services are carried out, in which persons subject to an employment relationship work.
4.8 Concentration measured in the working environment (CMA): The value of the contaminant concentration in the working environment, captured during a working day.
4.9 Time-weighted average concentration (CMA-PPT): The sum of the products of each concentration and its exposure time, divided by the sum of the measurement times during a working day.
4.10 Normal temperature and pressure conditions (TPN): Those corresponding to an environment at a temperature of 298 K (25°C) and a pressure of 101.3 kPa (760 mmHg).
4.11 Control: The process by which the relevant preventive or corrective actions are implemented, derived from the evaluation of chemical contaminants of the working environment, so as not to exceed the exposure limit values.
4.12 Additive effect: The result of the health effects of two or more chemical substances which, when used in combination, produce a total effect equal to the sum of their independent effects, and which affect the same organ, apparatus or system of the human body.
4.13 Independent effects: The result of the health effects of chemical substances that act independently and affect different organs, apparatus or systems of the body.
4.14 Evaluation: The process by which sampling, the analytical determination of chemical contaminants of the working environment and the comparison of results are carried out, in accordance with the exposure limit values.
4.15 Inhalable fraction: The ratio between the mass of particles suspended in the air that can be inhaled through the nose and mouth and the total present at the workplace.
4.16 Respirable fraction: The ratio between the mass of particles suspended in the air that can penetrate beyond the non-ciliated respiratory airways and the total present at the workplace.
4.17 Thoracic fraction: The ratio between the mass of particles suspended in the air that can penetrate beyond the larynx and the total present at the workplace.
4.18 Fibres: All solid particles with a length greater than 5 µm and a diameter of 3 µm or less, and a length/diameter ratio greater than 3:1.
4.19 Gases: Amorphous fluids that occupy the entire space of their container.
4.20 Homogeneous exposure group(s): A group of two or more occupationally exposed persons exposed to the same chemical substance(s) with similar concentrations and the same exposure time during their working days, who carry out similar work.
4.21 Combustion fumes: Solid particles suspended in the air, produced by the incomplete combustion of organic materials.
4.22 Metal fumes: Metallic solid particles suspended in the air, produced in metal smelting processes.
4.23 Result report: The document issued by a testing laboratory, accredited and approved under the terms established by the Federal Law on Metrology and Standardisation and its Regulations, by means of which it records the quantified results of the test elements captured, measured or analysed.
4.24 Testing laboratories: Individuals or legal entities, accredited and approved under the terms established by the Federal Law on Metrology and Standardisation and its Regulations, whose purpose is to carry out the recognition and/or evaluation (sampling, analysis or testing) established in the official Mexican standards on occupational safety and health.
4.25 Upper confidence limit (LSC): The statistical estimate of the concentration measured in the working environment (CMA), for a given confidence level, obtained from the sum of the average value of that concentration and the uncertainty generated during the measurement and analysis stages.
4.26 Handling: The use, transfer, decanting, storage or processing of a chemical substance at the workplace.
4.27 Sampling: The procedure for capturing chemical contaminants of the working environment.
4.28 Mist: Liquid particles suspended in the air produced by mechanical disruption.
4.29 Action level (NA): Half of the time-weighted average exposure limit value (VLE-PPT) of the chemical substances set out in Appendix I of this Standard.
4.30 Occupationally exposed personnel; POE: Workers who, in the course of and in connection with their occupation, are exposed to chemical contaminants of the working environment.
4.31 Dust(s): Solid particles suspended in the air, resulting from the process of disintegration of matter.
4.32 Process; Industrial process: The industrial activities and operations associated with chemical substances at the workplace, such as reaction, neutralisation, separation, reduction-oxidation, fractional crystallisation and synthesis, among others.
4.33 Recognition: The process by which the following are identified: chemical contaminants of the working environment; their properties or characteristics; the routes of entry into the human body; their health effects; the sources emitting contaminants; the areas or zones where there is a risk of exposure; the homogeneous exposure groups, their positions and the activities they carry out, as well as the exposure times and frequencies.
4.34 Health risk(s): The probability that a chemical substance may directly or indirectly cause temporary or permanent injury, or the death of the worker, through ingestion, inhalation or contact.
4.35 Fog: Liquid particles suspended in the air produced by the condensation of vapours.
4.36 Ministry: The Ministry of Labour and Social Welfare.
4.37 Hazardous chemical substances: Those which, owing to their physical and/or chemical properties, when handled, transported, stored or processed, present a risk of explosiveness, flammability, combustibility, reactivity, corrosivity, radioactivity, toxicity or irritability, and which, on entering the body via the respiratory, dermal or digestive route, may cause exposed workers intoxication, burns or organic injuries, depending on the level, concentration of the substance and duration of exposure.
4.38 Verification units: Individuals or legal entities, accredited and approved under the terms established by the Federal Law on Metrology and Standardisation and its Regulations, that carry out verification activities.
4.39 Exposure limit value (VLE): The reference concentration of a chemical contaminant of the working environment in the air, which may be time-weighted, short-time or peak. It is expressed in milligrams per cubic metre (mg/m3) or fibres per cubic centimetre (f/cm3), under current sampling conditions, and in parts per million (ppm), under normal temperature and pressure conditions (TPN).
4.40 Short-time exposure limit value (VLE-CT): The maximum concentration of a chemical contaminant of the working environment to which workers may be continuously exposed for a maximum period of fifteen minutes, with intervals of at least one hour without exposure between each exposure period and a maximum of four exposures in a working day of eight hours, and which does not exceed the time-weighted average exposure limit value (VLE-PPT).
4.41 Peak exposure limit value (VLE-P): The concentration of a chemical contaminant of the working environment that must not be exceeded at any time during the working day.
4.42 Time-weighted average exposure limit value (VLE-PPT): The maximum time-weighted average concentration of a chemical contaminant of the working environment at which the majority of exposed workers, during a working day of eight hours and a working week of forty hours, report no harm to their health.
4.43 Vapour: The gaseous phase of a chemical substance that is normally solid or liquid under ambient conditions.
4.44 Route of entry: The path by which a chemical contaminant of the working environment enters the worker's body.
4.45 Volatility: An indication of the ease of suspension and dispersion in the air of chemical substances, according to their state: a) Solid, through the generation of dust or sublimation, depending on particle size and shape, and b) Liquid, by means of the boiling point of the substance, that is, the temperature at which its vapour pressure equals atmospheric pressure.
5. Units of measurement
5.1 °C; degrees centigrade or Celsius: Unit of temperature measurement in the decimal metric system.
5.2 f/cm3; fibres per cubic centimetre: Unit of measurement for fibres.
5.3 g/mol; grams per mole: Molecular weight expressed in grams.
5.4 K; Kelvin: Unit of absolute temperature measurement.
5.5 kPa; kilopascals: Unit of pressure.
5.6 l/mol; molar volume; litres per mole: Litres occupied by one mole of gas under normal temperature and pressure conditions (TPN).
5.7 mg/m3; milligrams per cubic metre: Unit of concentration for dust, combustion and metal fumes, mists and fogs.
5.8 mmHg; millimetres of mercury: Unit of pressure.
5.9 ppm; parts per million: Unit of concentration expressed as a volume-to-volume ratio of one part of chemical substance in one million parts of air, used for gases and vapours.
5.10 µm; micron; micrometre: Unit of measurement of particle size equivalent to one millionth of a metre (1X10-6 m).
6. Obligations of the employer
6.1 Have available the updated study of chemical contaminants of the working environment, on the basis set out in Chapter 8 of this Standard.
6.2 Have available the recognition of chemical contaminants of the working environment, in accordance with the provisions of Chapter 9 of this Standard.
6.3 Post caution, mandatory action and prohibition signs, as appropriate, at the entrance to areas where there is exposure to chemical contaminants of the working environment, to prevent risks to the health of workers, especially those not involved in handling the chemical substances, in accordance with the provisions of NOM-026-STPS-2008, or those replacing it.
6.4 Have available the evaluation of the concentration of chemical contaminants of the working environment, carried out by a testing laboratory, and have the evaluation report available, in accordance with the provisions of Chapter 10 of this Standard.
6.5 Carry out biological monitoring for chemical exposure of occupationally exposed personnel and comply with the provisions of NOM-047-SSA1-2011, or those replacing it.
6.6 Implement control actions, on the basis of the provisions of Chapter 11 of this Standard, so as not to expose workers to concentrations higher than the exposure limit values set out in Appendix I of this Standard.
6.7 Provide occupationally exposed personnel with personal protective equipment specific to the risk, in accordance with the provisions of NOM-017-STPS-2008, or those replacing it.
6.8 Carry out medical examinations of occupationally exposed personnel as part of their health surveillance, and keep the results on file, in accordance with the provisions of Chapter 12 of this Standard.
6.9 Inform workers about the health risks from exposure to chemical contaminants of the working environment.
6.10 Provide training and instruction to occupationally exposed personnel on the handling of chemical substances and the type of control applied to prevent contamination of the working environment, on the basis of the provisions of Chapter 13 of this Standard.
6.11 Keep records of the recognition, evaluation and control carried out and the medical examinations performed.
6.12 Inform occupationally exposed personnel of the results of the annual medical examinations performed on them.
6.13 Prohibit minors aged 14 to 16 and women who are pregnant or breastfeeding from being exposed to chemical contaminants of the working environment.
6.14 Present to the labour authority, when so requested, the information and documentation that this Standard requires it to prepare or possess.
7. Obligations of occupationally exposed personnel
7.1 Observe the occupational safety and health preventive measures set out in this Standard, as well as those established by the employer for risk prevention.
7.2 Immediately notify the employer and the safety and hygiene committee of any unsafe conditions observed and of any occupational accidents occurring in connection with the handling of chemical substances, and cooperate in their investigation.
7.3 Use and keep in good condition the personal protective equipment provided by the employer.
7.4 Comply with the control measures indicated by the employer to prevent risks.
7.5 Keep their workplaces and common areas tidy and clean.
7.6 Conduct themselves at the workplace in a safe manner to avoid any risk to health.
7.7 Undergo the medical examinations administered by the employer.
7.8 Take part in the training and instruction on risk prevention and emergency response provided by the employer or by the persons designated by the employer.
8. Study of chemical contaminants of the working environment
8.1 The study of chemical contaminants of the working environment shall include the following: a) The updated list of all chemical contaminants of the working environment present at the workplace, and b) Information on the chemical contaminants of the working environment existing at the workplace, comprising at least: 1) The quantity handled per working day, expressed in: i. Grams or millilitres; ii. Kilograms or litres, or iii. Tonnes or cubic metres; 2) The physical state of the chemical contaminants of the working environment, in accordance with the following Table 1, and Table 1 Physical state of the chemical substance in the working environment
3) Its toxicological information, covering: i. The route(s) of entry into the body, and ii. The Health Risk Grade or the Health Hazard Category, in accordance with the hazard and risk communication system used at the workplace.
| Solids | Liquids | Gases |
| Dust | Mist | Vapour |
| Fume | Fog | Gas |
| Fibre | - | - |
8.2 The study shall be supplemented with the safety data sheets of all chemical substances handled at the workplace, identifying those included in Appendix I of this Standard from those that are not.
8.3 The study of chemical contaminants of the working environment shall be updated when: a) The chemical substances handled at the workplace are replaced or others are introduced, or b) The installations, processes, machinery and equipment handling chemical substances are modified.
8.4 The study of chemical contaminants of the working environment shall be kept for at least five years.
9. Recognition
9.1 The recognition of chemical contaminants of the working environment may be carried out by the employer or by a testing laboratory, in accordance with the provisions of this Chapter.
9.2 The recognition of chemical contaminants of the working environment shall comprise the identification of: a) The workplace where it is carried out; b) The chemical substance(s) or mixtures handled at the workplace, when they involve risks to the health of workers owing to their properties, concentration, level and duration of exposure or action; c) The emitting sources and characteristics of the area, process and job; d) The chemical substance(s) or mixtures to be sampled; e) The homogeneous exposure groups to chemical contaminants of the working environment; f) The occupationally exposed personnel to be considered for sampling, and g) The administrative and/or technical controls that may exist at the workplace, as applicable.
9.3 The identification of the chemical substance(s) or mixtures to be sampled that are handled at the workplace, when they involve risks to the health of workers, shall be determined on the basis of the following criteria: a) In accordance with item 9.4 of this Standard, where prior result reports on contaminants of the working environment prepared by a testing laboratory are available, or b) In accordance with item 9.5 of this Standard, where no prior result reports on contaminants of the working environment prepared by a testing laboratory are available.
9.4 Where prior result reports on contaminants of the working environment prepared by a testing laboratory are available, the following shall be carried out: a) Compare the concentration measured in the working environment (CMA) of the chemical contaminants with their respective time-weighted average (VLE-PPT) or short-time (VLE-CT) exposure limit value and place the result in the ranges indicated in Table 2, and Table 2 Sampling priority of the chemical contaminant to be evaluated, considering its concentration measured in the working environment (CMA) Sampling Priority VLE Range (PPT or CT)
b) Sample the chemical substances with Very High, High and Moderate priority.
| Low | CMA | ≤ 0.25 VLE | |
| Moderate | 0.25 VLE < | CMA | ≤ 0.50 VLE |
| High | 0.50 VLE < | CMA | ≤ VLE |
| Very High | VLE < | CMA |
9.5 Where no prior result reports on chemical contaminants of the working environment prepared by a testing laboratory are available, the following information shall be available for each chemical substance: a) The quantity of the substance handled in the area, process or job, in accordance with item 9.6; b) The risk classification, based on the Health Risk Grade or the Health Hazard Category, in accordance with item 9.7 of this Standard, and c) The volatility of solid chemical substances or of those in a liquid or gaseous state. Where the safety data sheet does not contain this information on the substance, it may be obtained in accordance with item 9.8.
9.6 The quantity of substance handled per day in the area, process or job, in accordance with the categories set out in Table 3. Table 3 Quantity of Substance Handled Quantity handled/day Grams/millilitres Kilos/litres Tonnes/cubic metres (1 or more) Any quantity of a carcinogenic (A1 or A2), teratogenic or mutagenic chemical substance
9.7 The risk classification shall be determined on the basis of the Health Risk Grade or the Health Hazard Category of the chemical substance, from the hazard and risk communication system used at the workplace, as indicated in Table 4. Table 4 Risk Classification Health Risk Grade NOM-018-STPS-2000, Health Hazard Category Risk Classification Rectangle Model NMX-R-019-SCFI-2011 (see Table 5) (see Table 6) Grade 0, 0 Category 5 Minimally hazardous Grade 1, 1 Category 4 Slightly hazardous Grade 2, 2 Category 3 Moderately hazardous Grade 3, 3 Category 2 Seriously hazardous Grade 4, 4 Category 1 Severely hazardous a) The Health Risk Grade of the chemical substance, considering its route of entry into the body (oral, dermal and/or inhalation) and the Lethal Concentration 50 (CL 50), shall be selected in accordance with the provisions of Table 5, or Table 5 Health Risk Grade Route of Entry / LD50 or LC50 Health Risk to the
Oral(1) Dermal(2) Inhalation(3)
Health
LC50 greater than 20 up to Grade 1, Slightly LD50 greater than 500 LD50 greater than 1,000 200 mg/l or greater than 2,000 hazardous up to 5,000 mg/kg. up to 5,000 mg/kg. up to 10,000 in ppm. LC50 greater than 2 up to 20 Grade 2, Moderately LD50 greater than 50 LD50 greater than 200 mg/l or greater than 200 up to hazardous up to 500 mg/kg. up to 1,000 mg/kg. 1,000 in ppm. LC50 greater than 0.2 up to 2 Grade 3, Seriously LD50 greater than 20 LD50 greater than 20 mg/l or greater than 20 up to
hazardous up to 50 mg/kg. up to 200 mg/kg.
200 ppm. Grade 4, Severely LC50 up to 0.2 mg/l or up to LD50 up to 1 mg/kg. LD50 up to 20 mg/kg. hazardous 20 ppm. (1) The lethal doses 50 (LD50) are based on laboratory experiments administering the substance orally to rats. (2) The lethal doses 50 (LD50) were obtained from laboratory experiments administering the substance dermally to rabbits or rats. (3) The lethal concentrations 50 (LC50) were determined in laboratory experiments administering the substance by inhalation to rats. b) The Health Hazard Category of the chemical substance, determined in accordance with the hazard statement code of the Globally Harmonised System for the Classification and Communication of Hazards of Chemical Substances, in accordance with the provisions of Table 6. Table 6 Health Hazard Category Category Hazard Statement Code (1) of Hazard H333; (H303 + H333); (H313 + H333), and (H303 + H313 + H333). 5 H332; (H302 + H332); (H312 + H332), and (H302 + H312 + H332). 4 H331; H335; H336; (H301 + H331); (H311 + H331), and (H301 + H311 + H331). 3 H305; H341; H351; H361; H371 and H373. 2 H304; H330; H334; H340; H350; H360; H370; H372; (H300 + H330); (H310 + H330), and 1 (H300 + H310 + H330). (1) See the code and its hazard description in Appendix II.
| mg/kg | mg/kg mg/l or ppm | |
| Grade 0, Minimally | LD50 greater | than LD50 greater than 5,000 CL50 greater than 200 mg/l or |
| hazardous | 5,000 mg/kg. | mg/kg. greater than 10,000 ppm. |
9.8 The volatility of solid chemical substances or of those in a liquid or gaseous state may be obtained as follows: a) In the case of solid chemical substances, the generation of dust shall be taken into account, based on particle size, in accordance with Table 7; Table 7 Determination of the volatility of solid chemical substances Volatility Solids Substances in pellet form that have no tendency to break up. Low No dust production is observed during use. e.g. polyvinyl chloride pellets, waxed flakes, among others. Crystalline or granular solid substances. When used, dust Medium production is observed that dissipates or settles rapidly on surfaces after use. e.g. powdered soap, among others. Fine, light, low-density powders. When used, they produce High dust clouds that remain airborne for several minutes. e.g. cement, carbon black, chalk dust, among others. b) In the case of chemical substances in a liquid state, their boiling point and the process operating temperature shall be considered, in accordance with Table 8, and Table 8 Determination of the volatility of chemical substances in a liquid state Volatility Liquids Boiling point above 150°C, with an operating temperature Low of 20 to 55°C. Boiling points between 50°C, with an operating temperature of 20 to Medium 310°C, and 150°C, with an operating temperature of 20 to 55°C. Boiling point below 50°C, with an operating temperature of High 20 to 310°C. c) All gases are considered to have high volatility.
9.9 The determination of the sampling priority of chemical contaminants of the working environment to be sampled shall be carried out as follows: a) List in Table 9 the chemical substances handled in the area, process or job; Table 9 Determination of the sampling priority of chemical substances Weighting Value TOTAL Priority of
b) Assign to each chemical substance in Table 9 the weighting values for the quantity handled, the risk classification and its volatility, indicated in Table 10; Table 10 Weighting values for chemical substances Classification of
Quantity handled/day Value Value Volatility Value
risk (Table 4)
teratogenic or mutagenic. c) Calculate the sum of the three weighting values of each chemical substance in Table 9; d) Indicate in Table 9 the sampling priority (Very Low, Low, Moderate, High or Very High) of the chemical substances, according to the sum of the weighting values, using Table 11, and Table 11 Sampling priority of chemical substances Sum of weighting values Sampling priority From 3 to 4 Very Low From 5 to 7 Low From 8 to 9 Moderate From 10 to 11 High From 12 or more Very High e) Consider for sampling the chemical substances with Very High, High and Moderate priority.
Quantity Risk (Sum of the
Chemical substance Volatility sampling
handled classification weighting
(Table 10) (Table 11)
(Table 10) (Table 10) values)Grams/millilitres (less than 1000). 1 0 1 Low 1
Kilos/litres (From 1 to less than 251). 2 1 2
Medium 2
Kilos/litres (From 251 to less than 1000). 3 2 3
Tonnes/cubic metres (1 or more). 4 3 4
Any quantity of carcinogenic High 4
chemical substances (A1 or A2), 5 4 59.10 The selection of the occupationally exposed personnel for the sampling of chemical substances shall be carried out in accordance with the following: a) Where there is only one worker in the area, process or job, that worker shall be considered for sampling, and b) Where two or more workers are exposed to the same chemical substance(s), with similar concentrations, the same exposure time during their working days and who carry out similar work, the homogeneous exposure groups shall be determined, considering that they share: 1) The same area, process or job, and 2) The same route of entry of the chemical substance into the body.
9.11 The determination of homogeneous exposure groups shall be carried out as follows: a) Select the weighting values for the route(s) of entry, number of occupationally exposed personnel and exposure time from Table 12, and record it for each substance in Table 13; Table 12 Weighting values for defining homogeneous exposure groups
From 3 and up to
Respiratory apparatus 4 from 25 to 100 4 4
less than 7 hours Absorption or irritation From 1 and up to
* Where the working day is longer than 8 hours and up to 11 hours, 8 shall be considered as the weighting value. b) Assign to each chemical substance the weighting values recorded for the route(s) of entry, number of occupationally exposed personnel and exposure time, and record the result in Table 13; Table 13 Determination of homogeneous exposure groups
c) Add up, for each chemical substance present in the area, process or job, the weighting values recorded for the route(s) of entry, number of occupationally exposed personnel and exposure time, and record the result in the column identified as “Total”, of Table 13; d) Identify in Table 14 the sampling priority of the homogeneous exposure groups, considering the result of the sum of the weighting values obtained in Table 13, and Table 14 Sampling priority of homogeneous exposure groups Sampling priority of the groups of Total weighting homogeneous exposure 3 Low 4 to 8 Moderate 9 to 12 High 13 to 24 Very high e) Consider for sampling the homogeneous exposure groups that have a Very High, High and Moderate priority.
| Route(s) of entry into the | Weighting | Number of Weighting | Exposure | Weighting |
| body | value | POE exposed value | time * | value |
| Respiratory apparatus | 8 | More than 100 8 | From 7 and up to 8 | 8 |
| and skin | hours |
| 2 | from 5 to 24 | 2 | 2 | ||
| of the skin | less than 3 hours | ||||
| Eyes or ingestion | 1 | Less than 5 | 1 | Less than 1 hour | 1 |
| Substances | WEIGHTING VALUE | TOTAL | ||
| chemicals present | Sampling | |||
| in the area, process | Route(s) of entry Number of | Exposure | (Sum of the | priority |
| or job | into the body POE exposed | time | weighting | (Table 14) |
| (Table 9) | (Table 12) (Table 12) | (Table 12) | values) |
9.12 The number of occupationally exposed personnel to be considered for sampling of homogeneous exposure groups identified with Very High, High and Moderate priority shall be defined as follows: a) For Very High priority, the number of occupationally exposed personnel to be considered for sampling is obtained based on the number of personnel making up the homogeneous exposure group, in accordance with Table 15, or Table 15 Number of POE to be considered for sampling, Very High Priority Number of POE making up the Homogeneous Exposure Group Number of POE to be considered for sampling 2 1 3 to 8 2 9 to 15 3 16 to 25 5 26 to 50 8 51 to 100 15 More than 100 20 b) For High and Moderate priority, the number of occupationally exposed personnel to be considered for sampling is obtained based on the number of personnel making up the homogeneous exposure group, in accordance with Table 16. Table 16 Number of POE to be considered for sampling, High and Moderate Priority Number of POE making up the Homogeneous Exposure Group Number of POE to be considered for sampling 2 to 5 1 6 to 10 2 11 to 20 3 21 to 30 4 31 to 50 5 51 to 100 7 More than 100 10
9.13 The recognition report of the working environment shall contain the following: a) The identification of the workplace: 1) The name, business name or company name; 2) The Federal Taxpayers Registry; 3) The area, process and job that is the subject of the recognition; 4) Its main activity, and 5) Its address; b) Information on the chemical substance(s) or mixtures handled at the workplace, comprising: 1) The chemical, trade or common name of the substance and its CAS number; 2) The chemical substances making up the mixtures, where applicable, when they contain a quantity equal to or greater than 1% by volume; 3) The following physical and chemical properties: i. Boiling temperature; ii. Molecular weight; iii. Physical state of the chemical substance, and iv. Volatility of solid substances or of those in a liquid or gaseous state; 4) The route(s) of entry of the chemical substance(s) into the body: oral, dermal and respiratory; 5) The duration and frequency of exposure of occupationally exposed personnel to chemical contaminants of the working environment; 6) The Health Risk Grade or the Health Hazard Category, and 7) The exposure limit values; c) The identification of the emitting sources and characteristics of the area, process and job: 1) The identification of the sources emitting the contaminant; 2) The physical location of the emitting sources by contaminant agent; 3) The location of the areas, processes and jobs where there is a risk of exposure; 4) The condition of the place: open or enclosed; 5) Whether or not there are general or local air extraction and/or injection systems; 6) The characteristics of the process: i. Continuous, or ii. Intermittent, and 7) The conditions of the process as to whether or not it involves: i. Generation of the contaminant by combustion; ii. Increase or decrease in temperature; iii. Increase or decrease in pressure, and/or iv. Generation of humidity; d) The determination of the priority of the chemical substance(s) or mixtures to be sampled: 1) The criterion used to determine the chemical substance(s) or mixtures contaminating the working environment to be sampled, based on: i. The concentration measured in the working environment (CMA) from prior result reports prepared by a testing laboratory, and ii. The classification of the quantity of substance handled in the area or job; risk classification, and its volatility, and 2) The sampling priority of the chemical substances, where applicable, based on: i. The quantity of substance handled; ii. The risk classification, based on the Health Risk Grade or the Health Hazard Category, and iii. The determination of the volatility of chemical substances; e) The identification of the homogeneous exposure groups to chemical contaminants of the working environment: 1) The area, process and job where the occupationally exposed personnel or homogeneous exposure groups are located; 2) The jobs involved; 3) The number of exposed workers; 4) The activities carried out; 5) The duration and frequency of exposure, and 6) The personal protective equipment available; f) The determination of the priority of the homogeneous exposure groups, based on: 1) The route(s) of entry into the body; 2) The number of occupationally exposed personnel, and 3) The exposure time; g) The occupationally exposed personnel to be considered for sampling, and h) The description of the administrative and/or technical controls that may exist at the workplace, as applicable.
9.14 The recognition report shall be signed by the person who prepared it and, where applicable, by the person who validated it, and shall be kept for at least five years.
10. Evaluation
10.1 General aspects
10.1.1 The evaluation of the concentration of chemical contaminants of the working environment shall be carried out by a testing laboratory, on the basis of the recognition of such contaminants prepared by the employer or by the laboratory itself.
10.1.2 The testing laboratory shall validate the recognition of chemical contaminants of the working environment where it has been carried out by the employer, in accordance with item 9.1 of this Standard.
10.1.3 If, in carrying out the evaluation referred to in this Chapter, the testing laboratory identifies that the recognition information is incomplete or incorrect, it shall introduce the relevant adjustments.
10.1.4 The evaluation of the concentration of chemical contaminants of the working environment shall comprise the stages of sampling, analytical determination and analysis of results.
10.2 Sampling of chemical contaminants
10.2.1 The equipment required to carry out the sampling shall include the following: a) A sampling pump meeting the following characteristics: 1) Have the model, specifications and serial number; 2) Maintain the required flow constant, with a maximum variation of 5%, during the period of time established for sampling; 3) Have the capacity to adjust the flow (high or low) with the flow calibrator, in accordance with the requirements of the sampling and analytical determination procedures or methods; 4) Be portable and intrinsically safe; 5) Operate continuously for at least 8 hours; 6) Have protection against interference from electromagnetic radiation and radio frequencies; 7) Be compatible with the sampling requirements and with the capture medium used, and 8) Be subject to a periodic maintenance programme; b) A flow calibrator for the sampling pump that satisfies the following: 1) Have the model, specifications and serial number; 2) Have a current national or international calibration certificate or report. The flow calibrator shall be certified every two years, or sooner if it has been repaired as a result of damage; 3) Have the capacity to verify the flow (low and/or high) of the sampling pumps, and 4) Be subject to a periodic maintenance programme; c) Capture media established by the procedure or method for the analytical determination of the chemical substance, and d) Temperature and pressure measuring instruments, which have their corresponding current national or international calibration certificate or report, where required by the sampling and analytical determination procedure or method used. The certification of the equipment shall be carried out every two years, or sooner where it has been repaired as a result of damage.
10.2.2 The sampling pump shall be adjusted, at the beginning and end of sampling, with the flow calibrator at the workplace, in accordance with the procedure or method for the analytical determination of the chemical substance.
10.2.3 For the sampling of chemical substances, the time and number of capture media provided for in the sampling and analytical determination procedure or method shall be considered, and, among others, the following criteria shall apply: Time-Weighted Average a) Continuous sample over the full period: a single sample is taken, without interruptions, covering the working day or at least 7/8 of it; b) Consecutive samples over the full period: sampling is momentarily interrupted several times, but the total sampling time must equal the period of the working day or at least 7/8 of it; c) Consecutive samples over a partial period: several samples are taken during the working day in which occupationally exposed personnel are exposed to the contaminant, and Short-Time and Peak d) Short-time and peak samples: samples shall be taken, without interruptions, over a period of 15 minutes. Figure 1 schematically illustrates the types of samples that can be taken during a working day. Figure 1 TYPES OF SAMPLES
10.2.4 For the sampling of chemical substances, at least the following actions shall be considered: a) Fit the pump to the occupationally exposed personnel, selected in accordance with items 9.10, 9.11 and 9.12 of this Standard, who is closest to the source generating the contaminant; b) Prevent the pump from interfering with the activities carried out by the occupationally exposed personnel; c) Locate the capture medium as close as possible to the breathing zone of the occupationally exposed personnel, and d) Remove the capture media and package them, in accordance with the sampling and analytical determination procedure or method.
10.2.5 The testing laboratory shall have instructions available to preserve the integrity of the sample, as applicable to: a) The maximum storage time; b) Protection against the effects of temperature, light, vibration and humidity, and c) The protective conditions during the transport of the samples to the laboratory that will carry out the analytical determination.
10.2.6 The testing laboratory shall have a chain of custody that includes, at least, the dates and names of the personnel responsible for: a) Carrying out the sampling of the chemical substance(s) at the workplace; b) Sending the sample of the chemical substance(s) to the testing laboratory; c) Receiving the sample of the chemical substance(s) at the testing laboratory; d) Carrying out the analytical determination of the chemical substance(s), and e) Preparing, verifying and endorsing the report.
10.3 Analytical determination of chemical contaminants
10.3.1 The analytical determination of samples of chemical contaminants of the working environment shall be carried out by a testing laboratory that is accredited in the corresponding analytical technique and approved in the sampling and analytical determination procedure or method.
10.3.2 The testing laboratory shall apply, for the corresponding chemical substance, any of the sampling and analytical determination procedures or methods issued by: a) The Occupational Safety and Health Administration of the United States of America, OSHA; b) The National Institute for Occupational Safety and Health of the United States of America, NIOSH; c) The National Institute of Safety and Hygiene at Work, INSHT, of the Ministry of Labour of Spain; d) The Health and Safety Executive of the United Kingdom, HSE, or e) The International Organisation for Standardisation, ISO.
10.3.3 When applying the selected sampling and analytical determination procedure or method, the testing laboratory shall comply with the specifications contained therein on at least the following aspects: a) For sampling: 1) The capture medium, and 2) The pump calibration flow, and b) For the analytical determination: 1) The equipment and complementary elements required; 2) The reagents to be used; 3) The precision and/or accuracy of the analytical technique for the substance; 4) Interferences, where referred to; 5) The preparation of the samples; 6) The calibration and/or adjustment of the equipment and complementary elements, and 7) The adjustment calculations, as applicable.
10.3.4 Where the sampling and analytical determination procedure or method for chemical contaminants of the working environment has been prepared in a language other than Spanish, the testing laboratory shall have a copy of the document in its original language and the Spanish translation.
10.3.5 Where the testing laboratory needs to use a sampling and analytical determination procedure or method other than those set out in item 10.3.2, it shall obtain authorisation for an alternative method, on the basis of the provisions of Articles 49 of the Federal Law on Metrology and Standardisation; 36 of the Regulations of the Federal Law on Metrology and Standardisation, and 8 of the Federal Regulations on Safety, Hygiene and the Working Environment.
10.3.6 To apply for authorisation of alternative sampling and analytical determination procedures or methods, the following documentation shall be submitted: a) The corresponding sampling and analytical determination procedure or method, to which a validation protocol supporting the results shall be attached, taking into account the following aspects: range and sensitivity; precision and accuracy; interferences; advantages and disadvantages; instrumentation and equipment; reagents; procedure; calibration and standards, and the corresponding calculations, stating the specific name of the contaminant chemical substance(s) to be determined; b) Where the proposed sampling and analytical determination procedure or method has been prepared in a language other than Spanish, the Spanish translation and a copy of the document in its original language shall be included, and c) The corresponding safety data sheet, in accordance with NOM-018-STPS-2000 or NMX-R-019-SCFI-2011, or those replacing them.
10.4 Analysis of the results of chemical contaminants
10.4.1 The results of the concentrations measured in the working environment (CMA) of the chemical substances shall be compared with the exposure limit values (VLE) of Appendix I of this Standard, as specified below: a) The time-weighted average concentration (CMA-PPT) shall be calculated using the following equation: Where: CMAi, is the i-th concentration of the contaminant in the working environment during a given time, always in mg/m3 or in ppm. ti, is the i-th time used in each sample taken, always in the same unit of time. b) Where the working day of the occupationally exposed personnel differs from 8 hours a day, within the range of 6 to 12 hours, the correction factor Fcday shall be calculated using the following equation: Where: Fc day, is the correction factor per day. hd, is the duration of the working day in hours. The corrected exposure limit value (corrected VLE), against which the concentration measured in the working environment (CMA) will be compared, shall be calculated using the following equation: The correction factor shall not be applied when comparing the concentration with the short-time or peak (VLE-CT or VLE-P) exposure limit values. c) Where the working week of the occupationally exposed personnel differs from 40 hours a week, within the range of 30 to 60 hours, the correction factor Fcday/week shall be calculated using the following equation: Where: Fc day/week, is the correction factor per day/week. hs, is the duration of the working week in hours. The corrected exposure limit value (corrected VLE), against which the concentration measured in the working environment (CMA) will be compared, shall be calculated using the following equation: d) Where it is necessary to convert units expressed in mg/m 3 to ppm, under normal temperature and pressure conditions (TPN), the following equation may be used: Where: PM, is the molecular weight of the chemical substance in g/mol. 24.45, is the l/mol at TPN. e) Where it is necessary to convert units expressed in ppm to mg/m 3, under normal temperature and pressure conditions (TPN), the following equation may be used: Where: PM, is the molecular weight of the chemical substance in g/mol. 24.45, is the l/mol at TPN. f) Where the worker(s) is (are) simultaneously exposed to two or more chemical contaminants of the working environment with additive health effects on the same organ, apparatus or system of the body, these shall be calculated from the sum of the ratio of each of the concentrations measured in the working environment (CMA) to its exposure limit value (VLE), as follows: Where: CMAi, is the concentration of each of the chemical contaminants of the working environment, and the subscript correlates with each of the VLEs. g) The special case of the additive effect occurs when the source of the contaminant is a liquid mixture and the proportion of its components in the working environment is similar to that of the mixture. The exposure limit value of the mixture (VLEmixture) shall be calculated from the inverse of the result of the sum of the ratio of each component divided by its limit value. The VLE mixture is expressed by the following equation: Where: fi, is the percentage composition by weight of the component, and the subscript is the correlation of each of the exposure limit values expressed in mg/m3. h) Where the chemical contaminants of the working environment have independent effects, the ratios of the concentrations measured in the working environment (CMA) to the exposure limit values (VLE) shall be calculated separately, as follows:
10.4.2 Next, the upper confidence limit (LSC) shall be obtained using a statistical approach, as follows: a) For continuous samples over a full period, the upper confidence limit of 95%, is calculated using the following equation: Where: LSC, is the upper confidence limit. , is the CMA average value. 1.645, constant for the 95% confidence level. , is the total coefficient of variation (measurement and analysis). VLE, is the exposure limit value. b) For consecutive samples over a full period or consecutive samples over a partial period, the upper confidence limit of 95%, is calculated using the following equation: Where: LSC, is the upper confidence limit. , is the CMA average value. 1.645, constant for the 95% confidence level. , is the total coefficient of variation (measurement and analysis). n, is the number of samples. VLE, is the exposure limit value. The total coefficient of variation , is obtained from the data calculated by the laboratory carrying out the evaluation. c) For short-time or peak samples, the upper confidence limit is calculated using the following equation: Where: LSC, is the upper confidence limit. CMA, is the concentration measured in the environment. I, is the Uncertainty determined by the testing laboratory.
10.4.3 The upper confidence limit (LSC) shall be compared with the exposure limit value (VLE), to select the corresponding control action, on the basis of Table 17 and in accordance with the following: Table 17 Control Action to be Implemented Upper Confidence Limit Action to be Implemented LSC < 0.50 VLE Continue with the control measures set out in item 9.2, subparagraph g), of this Standard.
0.50 VLE ≤ LSC ≤ VLE Adapt or implement the technical and/or administrative control measures established in this Standard; carry out specific medical examinations of occupationally exposed personnel, and sample the chemical substances in accordance with the sampling and evaluation period in Table 18 of this Standard. LSC > VLE Implement the technical and administrative control measures provided for in this Standard; carry out specific medical examinations of occupationally exposed personnel, and sample the chemical substances in accordance with the sampling and evaluation period in Table 18 of this Standard. a) Where the upper confidence limit (LSC) is less than 50% of the exposure limit value (VLE), the same control measures referred to in item 9.2, subparagraph g), of this Standard shall continue to be applied; b) Where the upper confidence limit (LSC) is less than or equal to the exposure limit value (VLE) and greater than or equal to 50% of the exposure limit value (VLE), the technical and/or administrative control measures referred to in Chapter 11 of this Standard shall be applied; specific medical examinations of occupationally exposed personnel shall be carried out, on the basis of item 12.2, subparagraph c), of this Standard, and a new evaluation shall be carried out to verify the effectiveness of the controls, in accordance with the sampling and evaluation period in Table 18 of this Standard, and c) Where the upper confidence limit (LSC) is greater than the exposure limit value (VLE), the technical and administrative control measures referred to in Chapter 11 of this Standard shall be applied; specific medical examinations of occupationally exposed personnel shall be carried out, in accordance with item 12.2, subparagraph c), of this Standard, and a new evaluation shall be carried out to verify the effectiveness of the controls, in accordance with the sampling and evaluation period in Table 18 of this Standard.
10.4.4 The concentrations of chemical contaminants of the working environment shall be evaluated when the chemical substances handled at the workplace are replaced or others are introduced; the installations, processes, machinery and equipment handling them are modified, or the validity of the result reports ends.
10.5 Evaluation report
10.5.1 The evaluation report shall contain the following: a) The identification of the workplace: 1) The name, business name or company name of the workplace; 2) The employer registration number; 3) The area, process and job that is the subject of the measurement, and 4) Its address; b) The sampling and analytical determination procedure or method used: 1) The code and name of the analytical procedure or method; 2) The labour authority or international organisation endorsing it, and 3) The analytical technique; c) The sampling data: 1) The contaminant agent that is the subject of the sampling; 2) The sampling method; 3) The sampling locations and points; 4) The personnel or homogeneous exposure groups to be sampled, as applicable; 5) The type of samples or personal readings; 6) The number of capture media and samples; 7) The sampling time, and 8) The sampling dates; d) Information on the occupationally exposed personnel: 1) The name; 2) The job; 3) The specific activities during sampling; 4) The description of the personal protective equipment; 5) The description of the technical controls, if any, in place in the area, process and job, and 6) The description of the administrative controls, if any, applied during the working day; e) The characteristics of the sampling equipment: 1) The type of equipment; 2) The model; 3) Its specifications; 4) Its serial number; 5) The initial calibration, with a minimum of three readings; 6) The final calibration, with a minimum of three readings, and 7) The calibration date; f) The characteristics of the flow calibration equipment: 1) The type of equipment; 2) The model; 3) The equipment specifications; 4) Its serial number, and 5) The calibration certificate or report number and its validity; g) The capture medium used, considering, as applicable: 1) Filter membranes; 2) Solid adsorbents; 3) Bubblers, and/or 4) Sampling bags; h) The atmospheric conditions at the sampling location: 1) Pressure, and 2) Temperature; i) Information on the measurement: 1) The start and end time; 2) The flow; 3) The total volume; 4) The quantity collected; 5) The concentration measured in the working environment; 6) The sampling date, and 7) The descriptive report on the operating conditions under which the sampling was carried out; j) The maximum storage time and transport conditions of the samples to the analysing laboratory; k) The equipment data for the analytical determination: 1) The brand; 2) Its serial number, and 3) The official calibration certificate of the equipment and the purity certificate of the calibration gas, as applicable; l) The results of the concentrations of chemical contaminants present in the working environment; m) The results of the calculation of the upper confidence limit; n) The comparison of the concentrations present in the working environment with the limit values set out in Appendix I of this Standard, with the information supporting them, and o) The testing laboratory data: 1) The business name or company name; 2) The Federal Taxpayers Registry; 3) The accreditation number assigned by the accreditation body; 4) The approval number granted by the Ministry; 5) The validity of the approval; 6) Its full address; 7) The date of issue of the result report; 8) The name of the responsible signatory evaluated and approved, and 9) The name of the legal representative.
10.5.2 The evaluation report shall be signed by the person who prepared it and shall be kept for at least five years.
11. Control
11.1 The employer shall adopt the relevant technical and/or administrative control measures, and monitor them, through the programme established for that purpose, when the values set out in Table 17 of this Standard are obtained as a result of comparing the upper confidence limit (LSC) with the exposure limit value (VLE) of the chemical contaminants of the working environment.
11.2 The technical control measure(s) shall be determined according to the nature of the production processes, technological aspects, and their feasibility and viability.
11.3 The technical control measures to be adopted may include, among others, the following: a) Modification of work procedures to minimise the generation of contaminants of the working environment or the exposure of occupationally exposed personnel; b) Preventive and corrective maintenance of installations, processes, machinery and equipment; c) Modification, adaptation or replacement of installations, processes, machinery and equipment with others that generate lower emissions of contaminants of the working environment; d) Conditioning, isolation or physical redistribution of installations, processes, machinery and equipment or areas to prevent the dispersion of contaminants of the working environment; e) Use of general ventilation systems; f) Use of local exhaust ventilation systems to prevent the dispersion of contaminants into the working environment; g) Provision of containers for waste collection, and/or h) Replacement of the chemical substances in the working environment with others whose effects are less harmful.
11.4 Chemical contaminants of the working environment shall be sampled again once the technical control measure(s) have been implemented, to verify whether their concentration has decreased below the exposure limit value (VLE).
11.5 Administrative control measures shall be applied immediately, until the technical control measure(s) referred to in item 11.3 of this Standard are implemented.
11.6 Administrative control measures shall be adopted in order not to expose occupationally exposed personnel to concentrations higher than the exposure limit values set out in Appendix I of this Standard, including, among others, the following: a) Limiting the duration and frequency of exposure of occupationally exposed personnel to contaminant chemical substances, by means of: 1) Rescheduling activities; 2) Redefining exposure times and frequency; 3) Rotating personnel, and 4) Isolating them in a contaminant-free atmosphere; b) Providing the required personal protective equipment; c) Restricting access to the areas or, as applicable, providing personal protective equipment to workers not involved in the handling of the chemical substances, to prevent their exposure to chemical contaminants of the working environment, and d) A respiratory protection programme, containing the following elements: 1) The results of the recognition and exposure evaluation information for the sampled area; 2) Medical evaluations of occupationally exposed personnel who need to use respirators; 3) The criteria for selecting filters, cartridges and canisters in accordance with NOM-116-STPS-2009 and/or the NMX standards on respirators, or those replacing them; 4) The procedure for checking the fit and seal test of respirators; 5) Instructions for normal use and emergency use of respirators; 6) Instructions for checking the quality, quantity and flow of the air that shall be supplied to occupationally exposed personnel, where self-contained breathing apparatus (SCBA) is used; 7) Instructions for maintenance, cleaning, disinfection, care, storage, inspection, repair, replacement and final disposal of respirators, and 8) Training and information for occupationally exposed personnel who need to use respiratory protective equipment, taking into account the limitations on its use.
11.7 The respiratory protection programme shall be monitored to review its correct implementation.
11.8 Where carcinogenic chemical substances, confirmed (A1) or suspected in humans (A2), are handled at the workplace, strict control shall be maintained to keep the upper confidence limit (LSC) below the action level (NA). Where the upper confidence limit (LSC) cannot be kept below the action level (NA), the relevant control measures shall be implemented, including, among others: a) Providing high-efficiency respiratory personal protective equipment, or positive-pressure or negative-pressure air purifiers, as applicable; b) Using local exhaust ventilation systems to capture and prevent the dispersion of contaminants into the working environment, and/or c) Isolating the area, department or process involving the emission of chemical contaminants of the working environment. If, following the application of the measures described above, the upper confidence limit (LSC) remains above the action level (NA), the carcinogenic chemical substances shall be replaced with others whose harmful effects are lower.
11.9 Where the concentration of a chemical contaminant exceeds the peak exposure limit value (VLE-P) as a result of a spill, leak or dispersion emergency, at least the following measures shall be applied immediately: a) Evacuation of personnel from the contaminated area; b) Provision of first aid to personnel requiring it; c) Entry of emergency response teams with protective equipment appropriate to the type of risk present; d) Immediate ventilation of the contaminated work area; e) Evaluation of the conditions of the working environment until the emergency is brought under control, and f) Monitoring of the health of personnel from the contaminated area.
11.10 The record of monitoring of the technical and/or administrative control measures, by job or work area, referred to in items 11.3 and 11.6 of this Standard, shall contain: a) The name of the area, department or process that is the subject of the measurement; b) The contaminant agent that is the subject of the measurement; c) The control measure(s) adopted and the person(s) responsible for their implementation and monitoring; d) The concentration measured in the working environment (CMA-PPT or CT); e) The exposure limit value (VLE) corresponding to the substance evaluated, in accordance with Appendix I of this Standard, and f) The result of the comparison between the upper confidence limit (LSC) and the exposure limit value (VLE) of the substance, as applicable.
12. Health surveillance
12.1 Health surveillance of occupationally exposed personnel shall be carried out through a programme that assesses their state of health, identifies their susceptibility to chemical contaminants of the working environment and detects early alterations to their health.
12.2 The programme for the health surveillance of occupationally exposed personnel shall consider, at least, the following: a) The occupational medical history, comprising: 1) The worker's identification details; 2) Hereditary and family history (AHF); 3) Non-pathological personal history (APNP); 4) Pathological personal history (APP); 5) The occupational history, including previous and current exposures to the risk; 6) Current conditions, as applicable; 7) A review of systems, and 8) The physical examination, with emphasis on the acuity of the senses and the ability to express oneself so as to convey, quickly and accurately, spoken or written communications or any signal; b) The administration of pre-employment medical examinations to identify organic alterations that could be aggravated by exposure to chemical substances; c) The performance of specific medical examinations, based on the activity of the exposed workers and the biological exposure index, IBE, subject to annual clinical follow-up or to evidence of signs or symptoms indicating alteration of workers' health. Medical examinations shall be carried out in accordance with the official Mexican standards issued in this respect by the Ministry of Health and/or the Ministry of Labour and Social Welfare, and, in the absence thereof, as indicated by the physician of the company, private institution, or social security or health institution, and d) The technical and/or administrative control measures, referred to in items 11.3 and 11.6 of this Standard, which shall be adopted in accordance with the results of the evaluation of chemical contaminants of the working environment and of the medical examinations performed.
12.3 Health surveillance of occupationally exposed personnel shall be conducted by a physician with knowledge and experience in occupational medicine and/or in the biological effects of chemical substances.
12.4 The medical examinations performed and their records, as well as the technical and/or administrative control measures adopted, shall be included in a clinical file that shall be kept for a minimum period of five years, counted from the date of the last examination.
13. Training
13.1 The training and instruction provided to occupationally exposed personnel shall address, at least, the following topics: a) The properties of the chemical substance(s) handled at the workplace; b) The effects that exposure to the chemical substance(s) may cause; c) The health hazards from exposure to the chemical substance(s) in the work area; d) The importance of their participation in the recognition and evaluation of chemical contaminants of the working environment; e) How to work safely with the chemical substance(s); f) The control of the chemical substance(s) at the job and/or work area; g) The respiratory protection programme, and h) The content of the hazard and risk communication system used by the company for signage and the safety data sheet.
13.2 Training and instruction shall be provided to occupationally exposed personnel at least every twelve months.
14. Verification units
14.1 The employer may choose to engage an accredited and approved verification unit, in accordance with the provisions of the Federal Law on Metrology and Standardisation, to assess conformity with this Standard.
14.2 Verification units shall verify compliance with this Standard, on the basis of the provisions of Chapter 16 thereof, for which purpose they shall issue the corresponding assessment report.
14.3 The assessment report issued by a verification unit shall contain the following: a) Data on the workplace verified: 1) The name, business name or company name; 2) The Federal Taxpayers Registry; 3) The full address; 4) The telephone number, and 5) Its main activity; b) Data on the verification unit: 1) The name, business name or company name; 2) The accreditation number; 3) The approval number granted by the Ministry, and 4) Its full address, and c) Data on the assessment report: 1) The code and name of the Standard; 2) The name of the verifier evaluated and approved; 3) The date of verification; 4) The assessment report number; 5) The validity of the assessment report; 6) The place of issue of the assessment report; 7) The date of issue of the assessment report, and 8) The registration number of the assessment report issued by the Ministry when the respective report is submitted.
14.4 The validity of assessment reports issued by verification units shall be two years, provided that the conditions on which their issuance was based are maintained.
15. Testing laboratories
15.1 The employer shall engage an accredited and approved testing laboratory, in accordance with the provisions of the Federal Law on Metrology and Standardisation, to carry out the evaluation of chemical contaminants of the working environment required by this Standard.
15.2 The testing laboratory shall deliver its result report to the employer, in accordance with Chapter 10 of this Standard.
15.3 The result report issued by the testing laboratory shall contain the following: a) Data on the workplace evaluated: 1) The name, business name or company name; 2) The Federal Taxpayers Registry; 3) The full address; 4) The telephone number, and 5) Its main activity; b) Data on the testing laboratory: 1) The business name or company name; 2) The accreditation number; 3) The approval number granted by the Ministry, and 4) Its full address, and c) Data on the result report: 1) The code of the Standard, as well as the code and name of the procedure or method for the sampling and analytical determination of chemical contaminants of the working environment; 2) The name of the signatory evaluated and approved; 3) The chemical contaminant(s) evaluated; 4) The equipment used and its serial number, for sampling and analytical determination; 5) The sampling date(s); 6) The result report number; 7) The validity of the result report; 8) The place of issue of the result report; 9) The date of issue of the result report, and 10) The registration number of the result report issued by the Ministry when the respective report is submitted.
15.4 The validity of the result reports shall depend on the correlation between the upper confidence limit (LSC) and the exposure limit value (VLE), in accordance with the sampling and evaluation periods contained in Table 18 and on the basis of the following: Table 18 Validity of the Laboratory Result Report Upper Confidence Limit Sampling and Evaluation Period
VLE < LSC - At least once every 3 months
0.75 VLE < LSC ≤ VLE Once every 6 months
0.50 VLE < LSC ≤ 0.75 VLE Once every 12 months
0.25 VLE < LSC ≤ 0.50 VLE Once every 18 months
- LSC ≤ 0.25 VLE Once every 24 months
a) At least once every 3 months, where the upper confidence limit (LSC) is greater than the exposure limit value (VLE); b) Once every 6 months, where the upper confidence limit (LSC) is less than or equal to the exposure limit value (VLE), but greater than 75 per cent of the exposure limit value (VLE); c) Once every 12 months, where the upper confidence limit (LSC) is less than or equal to 75 per cent of the exposure limit value (VLE), but greater than 50 per cent of the exposure limit value (VLE); d) Once every 18 months, where the upper confidence limit (LSC) is less than or equal to 50 per cent of the exposure limit value (VLE), but greater than 25 per cent of the exposure limit value (VLE), or e) Once every 24 months, where the upper confidence limit (LSC) is less than or equal to 25 per cent of the exposure limit value (VLE).
15.5 The validity of the result reports referred to in the preceding item shall cease to have effect where other chemical substances are introduced and/or the installations, processes, machinery and equipment handling them are modified.
16. Conformity assessment procedure
16.1 This conformity assessment procedure applies both to inspection visits carried out by the labour authority and to verification visits carried out by verification units.
16.2 The current assessment report shall be available to the labour authority when so requested.
16.3 The aspects to be verified during the conformity assessment of this Standard shall be carried out, as applicable, by means of physical verification, documentary review, records or interviews, in accordance with the following: Type of
Provision Acceptance Criterion Observations Risk
verification
6.1 and 8.1 Documentary The employer complies when it presents documentary evidence that: It has the updated study of chemical contaminants of the working environment, and The study of chemical contaminants of the working environment includes the following: The updated list of all chemical contaminants of the working environment present at the workplace, and Information on the chemical contaminants of the working environment in existence, comprising at least: o The quantity handled per working day, expressed in: Grams or millilitres; Kilograms or litres, or Tonnes or cubic metres; o The physical state of the chemical
contaminants of the
working environment, in accordance with Table 1, and o Its toxicological information, on: The route(s) of entry into the body, and The Health Risk Grade or the Health Hazard Category, in accordance with the hazard and risk communication system used at the workplace. 6.1, 8.2, 8.3 Documentary The employer complies when it presents documentary evidence and 8.4 that: The study is supplemented with the safety data sheets of all chemical substances handled at the workplace, identifying those included in Appendix I of this Standard from those that are not; The study of chemical contaminants of the working environment is updated when: The chemical substances handled at the workplace are replaced or others are introduced, or The installations, processes, machinery and equipment handling chemical substances are modified, and The study of chemical contaminants of the working environment is kept for at least five years.
6.2, 9.1 and Documentary The employer complies when it presents evidence Serious
9.2 documentary evidence that: It has the recognition of chemical contaminants of the working environment; The recognition of chemical contaminants of the working environment is carried out by the employer or by a testing laboratory, and The recognition of chemical contaminants of the working environment comprises the identification of: The workplace where it is carried out; The chemical substance(s) or mixtures handled at the workplace, when they involve risks to the health of workers owing to their properties, concentration, level and duration of exposure or action;
The emitting sources and
characteristics of the area, process and job; The chemical substance(s) or mixtures to be sampled; The homogeneous exposure groups to chemical contaminants of the working environment;
The occupationally exposed
personnel to be considered for sampling, and The administrative and/or technical controls that may exist at the workplace, as applicable.
6.2 and 9.3 Documentary The employer complies when it presents evidence This provision documentary evidence that: applies where
the following criteria: In accordance with item 9.4 of this Standard, where prior result reports on
the contaminants of the
working environment prepared by a testing laboratory are available, or In accordance with item 9.5 of this Standard, where no prior result reports on the contaminants of the working environment prepared by a testing laboratory are available.
6.2, 9.3 a) and Documentary The employer complies when it presents evidence This provision Serious
| The identification of the chemical substance(s) | that the |
| or mixtures to be sampled that | recognition |
| are handled at the workplace, | has been |
| when they involve risks to the health of | carried out by the |
| workers, is determined on the basis of | employer. |
9.4 documentary evidence that, where prior applies where the
respective time-weighted average (VLE-PPT) or short-time (VLE-CT) exposure limit value is available and the result is placed in the ranges indicated in Table 2, and The chemical substances with Very High, High and Moderate priority are sampled.
The quantity of substance handled per day in the area, process or job, in accordance with the categories set out in Table 3; The risk classification, as indicated in Table 4, and based on the following: The Health Risk Grade of the chemical substance, considering its route of entry into the body (oral, dermal and/or inhalation) and the Lethal Concentration 50 (CL50), selected in accordance with the provisions of Table 5, or The Health Hazard Category of the chemical substance, determined in accordance with the hazard statement code of the Globally Harmonised System for the Classification and Communication of Hazards of Chemical Substances, in accordance with the provisions of Table 6, and The volatility of solid chemical substances or of those in a liquid or gaseous state. Where the safety data sheet does not contain this information on the substance, it is obtained as follows: In the case of solid chemical substances, the generation of dust is taken into account, based on particle size, in accordance with Table 7; In the case of chemical substances in a liquid state, their boiling point and the process operating temperature are considered, in accordance with Table 8, and All gases are considered to have high volatility.
| prior result reports on the | that the |
| contaminants of the working environment, that have | recognition |
| been prepared by a testing laboratory: | has been |
| The concentration measured in | carried out by the |
| the working environment (CMA) of the | employer. |
| chemical contaminants, is compared with its |
| 6.2, 9.3 b), Documentary | The employer complies when it presents evidence | This provision Serious |
| 9.5, 9.6, 9.7 | documentary evidence that, where there are no | applies where |
| and 9.8 | prior result reports on chemical contaminants of the working environment prepared by a testing laboratory, it has available for each chemical substance the following information: | that the recognition has been carried out by the employer. |
6.2 and 9.9 Documentary The employer complies when it presents evidence This provision Serious documentary evidence that the determination of the applies where
process or job; Assigns to each chemical substance in Table 9 the weighting values for the quantity handled, the risk classification and its volatility, indicated in Table 10; Calculates the sum of the three weighting values of each chemical substance in Table 9; Indicates in Table 9 the sampling priority (Very Low, Low, Moderate, High or Very High) of the chemical substances, according to the sum of the weighting values, using Table 11, and Considers for sampling the chemical substances with Very High, High and Moderate priority.
| priority of chemical substances | that the |
| contaminants of the working environment to be | recognition |
| sampled, is carried out as follows: | has been |
| Lists in Table 9 the chemical | carried out by the |
| substances handled in the area, | employer. |
6.2 and 9.10 Documentary The employer complies when it presents evidence This provision documentary evidence that the selection of personnel applies where
that worker is considered for sampling, and Where two or more workers are exposed to the same chemical substance(s), with similar concentrations, the same exposure time during their working days and who carry out similar work, determines the homogeneous exposure groups, considering that they share: The same area, process or job, and The same route of entry of the chemical substance into the body.
| occupationally exposed for the sampling | that the |
| of chemical substances is carried out in | recognition |
| accordance with the following: | has been |
| Where in the area, process or job of | carried out by the |
| work there is only one worker, | employer. |
6.2 and 9.11 Documentary The employer complies when it presents evidence This provision Serious documentary evidence that the determination of the applies where
exposure time from Table 12, and records it for each substance in Table 13; Assigns to each chemical substance the weighting values recorded for the route(s) of entry, number of occupationally exposed personnel and exposure time, and records the result in Table 13; Adds up, for each chemical substance present in the area, process or job, the weighting values recorded for the route(s) of entry, number of occupationally exposed personnel and exposure time, and records the result in the column identified as “Total”, of Table 13; Identifies in Table 14 the sampling priority of the homogeneous exposure groups, considering the result of the sum of the weighting values obtained in Table 13, and Considers for sampling the homogeneous exposure groups that have a Very High, High and Moderate priority.
| homogeneous exposure groups, is done | that the |
| on the basis of the following: | recognition |
| Selects the weighting values | has been |
| for the route(s) of entry, number of | carried out by the |
| occupationally exposed personnel, and | employer. |
6.2 and 9.12 Documentary The employer complies when it presents evidence This provision Serious documentary evidence that the number of personnel applies where
For Very High priority, is obtained based on the number of personnel that
makes up the homogeneous exposure
group, in accordance with Table 15, or; For High and Moderate priority, is obtained based on the number of personnel making up the homogeneous exposure group, in accordance with Table 16.
| occupationally exposed personnel to be considered for | that the |
| sampling of the homogeneous exposure | recognition |
| groups identified with Very | has been |
| High, High and Moderate priority, is defined in accordance with the | carried out by the |
| following: | employer. |
6.2 and 9.13 Documentary The employer complies when it presents evidence This provision Serious documentary evidence that the recognition report of the applies where
employer. The Federal Taxpayers Registry; The area, process and job that is the subject of the recognition; Its main activity, and Its address; Information on the chemical substance(s) or mixtures handled at the workplace, comprising: The chemical, trade or common name of the substance and its CAS number;
The chemical substances that
make up the mixtures, where applicable, when they contain a quantity equal to or greater than 1% by volume; The following physical and chemical properties: o Boiling temperature; o Molecular weight;
o Physical state of the chemical
substance, and o Volatility of solid substances or of those in a liquid or gaseous state; The route(s) of entry of the chemical substance(s) into the body: oral, dermal and respiratory; The duration and frequency of the
exposure of occupationally exposed
personnel to chemical contaminants of the working environment; The Health Risk Grade or the Health Hazard Category, and The exposure limit values; The identification of the emitting sources and characteristics of the area, process and job: The identification of the sources emitting the contaminant; The physical location of the emitting sources by contaminant agent; The location of the areas, processes and jobs where there is a risk of exposure; The condition of the place: open or enclosed; Whether or not there are general or local air extraction and/or injection systems; The characteristics of the process: o Continuous, or o Intermittent, and The conditions of the process as to whether or not it involves: o Generation of the contaminant by combustion;
o Increase or decrease in
temperature; o Increase or decrease in pressure, and/or o Generation of humidity; The determination of the priority of the chemical substance(s) or mixtures to be sampled: The criterion used to determine
the chemical substance(s) or
mixtures contaminating the working environment to be sampled, based on: o The concentration measured in the
working environment (CMA) from
prior result reports prepared by a testing laboratory, and o The classification of the quantity of substance handled in the area or job; risk classification, and its volatility, and The sampling priority of the chemical substances, where applicable, based on:
o The quantity of substance
handled; o The risk classification, based on the Health Risk Grade or the Health Hazard Category, and o The determination of the volatility of chemical substances; The identification of the homogeneous exposure groups to chemical contaminants of the working environment: The area, process and job where the occupationally exposed personnel or homogeneous exposure groups are located; The jobs involved; The number of exposed workers; The activities carried out; The duration and frequency of exposure, and The personal protective equipment available; The determination of the priority of the homogeneous exposure groups, based on: The route(s) of entry into the body;
The number of occupationally exposed
personnel, and The exposure time; The occupationally exposed personnel to be considered for sampling, and
The description of the administrative
and/or technical controls that, as applicable, may exist at the workplace.
| recognition report of the working environment contains: | that the |
| The identification of the workplace: | recognition |
| The name, business name or company | has been |
| name; | carried out by the |
6.2 and 9.14 Documentary The employer complies when it presents documentary evidence that the recognition report is signed by the person who prepared it and, where applicable, by the person who validated it, and is kept for at least five years.
6.3 Physical The employer complies when, on carrying out a Serious walk-through of the workplace, it is confirmed that caution, mandatory action and prohibition signs are posted, as appropriate, at the entrance to areas where there is exposure to chemical contaminants of the working environment, to prevent risks to the health of workers, especially those not involved in handling the chemical substances, in accordance with NOM- 026-STPS-2008, or those replacing it. 6.4, 10.1.1, Documentary The employer complies when it presents evidence The employer shall Serious
10.1.2, documentary evidence that: have the 10.4.4, Has the evaluation on the report of
10.1.2, documentary evidence that: have the 10.4.4, Has the evaluation on the report of
10.5.1 and concentration of the chemical agents results that
10.5.2 contaminants of the working environment, shall provide the
testing laboratory carried out by a testing laboratory, and
has the report of contaminants prepared by it
or by the
same laboratory; The validity and The testing laboratory validates the veracity of the
recognition of the chemical agents information contaminants of the working environment, contained in the when it has been carried out by the employer, evaluation report will be in accordance with item 9.1 of the responsibility this Standard; The concentrations of the agents of the testing chemical contaminants of the working laboratory. environment are evaluated when the chemical substances handled at the workplace are replaced or others are introduced; the installations, processes, machinery and equipment handling them are modified, or the validity of the result reports ends; The evaluation report contains the aspects specified in item
evaluation report; shall contain
The evaluation of the concentration of the the
chemical contaminants of the information that
working environment is carried out by a establishes item
testing laboratory, on the basis of the 10.5.1
recognition of such agents of this Standard.| same laboratory; | The validity | and |
| The testing laboratory validates the | veracity of | the |
10.5.1 of this Standard, and The evaluation report is signed by the person who prepared it and is kept for at least five years.
6.5 Documentary The employer complies when it presents documentary evidence Serious that it carries out biological monitoring for chemical exposure of occupationally exposed personnel and complies with the provisions of NOM-047- SSA1-2011, or those replacing it.
6.6, 11.1 and Documentary The employer complies when it presents evidence Serious
11.2 documentary evidence that: Implements control actions, so as not to
expose workers to
concentrations higher than the exposure limit values set out in Appendix I of this Standard; Adopts the relevant technical and/or administrative control measures, through the programme established for that purpose, when the values set out in Table 17 of this Standard are obtained as a result of comparing the upper confidence limit (LSC) with the exposure limit value (VLE) of the chemical contaminants of the working environment, and Determines the technical control measure(s) according to the nature of the
production processes, technological
aspects, and their feasibility and viability.
6.6 and 11.1 Records The employer complies when it presents evidence Serious that it has records of the monitoring of the control measures adopted when chemical contaminants of the working environment exceed the exposure limit values set out in Appendix I of this Standard.
6.6 and 11.3 Documentary The employer complies when it presents evidence Serious documentary evidence that the technical control measures to be adopted include, among others, the following: Modification of work procedures to minimise the generation of contaminants of the working environment or the exposure of occupationally exposed personnel; Preventive and corrective maintenance of installations, processes, machinery and equipment; Modification, adaptation or replacement of installations, processes, machinery and equipment with others that generate lower emissions of contaminants of the working environment; Conditioning, isolation or physical redistribution of installations, processes, machinery and equipment or areas to prevent the dispersion of contaminants of the working environment; Use of general ventilation systems; Use of local exhaust ventilation systems to prevent the dispersion of contaminants into the working environment; Provision of containers for waste collection, and/or Replacement of the chemical substances in the working environment with others whose effects are less harmful.
6.6, 11.4 and Documentary The employer complies when it presents evidence Serious
11.5 documentary evidence that: Chemical contaminants of the
working environment are sampled
again once the technical control measure(s) have been implemented, in order
to verify whether their
concentration has decreased below the exposure limit value (VLE), and Administrative control measures are applied immediately, until the technical control measure(s) referred to in item 11.3 of this Standard are implemented.
6.6 and 11.6 Documentary The employer complies when it presents evidence Serious
documentary evidence that the
administrative control measures are adopted for the
purpose of not exposing occupationally exposed personnel to
concentrations higher than the exposure limit values set out in Appendix I of this Standard, including, among others, the following: Limiting the duration and frequency
of exposure of occupationally exposed personnel to
contaminant chemical substances, by means of: Rescheduling activities; Redefining exposure times and frequency; Rotating personnel, and Isolating them in a contaminant-free atmosphere; Providing the required personal protective equipment; Restricting access to the areas or, as applicable, providing personal protective equipment to workers not involved in the handling of the chemical substances, to prevent their exposure to chemical contaminants of the working environment, and A respiratory protection programme, containing the following elements: The results of the recognition and exposure evaluation information for the sampled area;
Medical evaluations of
occupationally exposed personnel who need to use respirators; The criteria for selecting filters, cartridges and canisters in accordance with NOM-116-STPS-2009 and/or the NMX standards on respirators, or those replacing them; The procedure for checking the fit and seal test of respirators; Instructions for normal use and emergency use of respirators; Instructions for checking the quality, quantity and flow of the air that shall be supplied to occupationally exposed personnel, where self-contained breathing apparatus (SCBA) is used; Instructions for maintenance,
cleaning, disinfection, care, storage, inspection,
repair, replacement and final disposal of respirators, and Training and information for occupationally exposed personnel who need to use respiratory protective equipment, taking into account the limitations on its use.
| purpose of not | exposing the | personnel |
| occupationally | exposed | to |
| of exposure | of the | personnel |
| occupationally | exposed | to the |
cleaning, disinfection, care,
storage, inspection,6.6 and 11.7 Records The employer complies when it presents evidence Serious that it has records of the monitoring of the respiratory protection programme to review its correct implementation.
6.6 and 11.8 Documentary The employer complies when it presents evidence Serious documentary evidence that: Strict control is maintained, where carcinogenic chemical substances, confirmed (A1) or suspected in humans (A2), are handled at the workplace, so as to keep the upper confidence limit (LSC) below the action level (NA); The relevant control measures are implemented, where the upper confidence limit (LSC) cannot be kept below the action level (NA), including, among others: Providing high-efficiency respiratory personal protective equipment, or positive-pressure or negative-pressure air purifiers, as applicable; Using local exhaust ventilation systems to capture and prevent the dispersion of contaminants into the working environment, and/or Isolating the area, department or process involving the emission of chemical contaminants of the working environment, and The carcinogenic chemical substances are replaced with others whose harmful effects are lower, if, following the application of the measures described above, the upper confidence limit (LSC) remains above the action level (NA).
6.6 and 11.9 a) Documentary The employer complies when it presents evidence Serious to e) documentary evidence that, where the concentration of a chemical contaminant exceeds the peak exposure limit value (VLE-P) as a result of a spill, leak or dispersion emergency, at least the following measures are applied immediately: Evacuation of personnel from the contaminated area; Provision of first aid to personnel requiring it; Entry of emergency response teams with protective equipment appropriate to the type of risk present; Immediate ventilation of the contaminated work area, and Evaluation of the conditions of the working environment until the emergency is brought under control.
6.6 and 11.9 f) Records The employer complies when it presents evidence Serious that it has records of the monitoring of the health of personnel from the contaminated area, as a result of a spill, leak or dispersion emergency.
6.6 and 11.10 Records The employer complies when it presents evidence Serious that it has records of the monitoring of the technical and/or administrative control measures, by job or work area, referred to in items
11.3 and 11.6 of this Standard, and that they contain: The name of the area, department or process that is the subject of the measurement; The contaminant agent that is the subject of the measurement; The control measure(s) adopted and the person(s) responsible for their implementation and monitoring; The concentration measured in the working environment (CMA-PPT or CT); The exposure limit value (VLE) corresponding to the substance evaluated, in accordance with Appendix I of this Standard, and The result of the comparison between the upper confidence limit (LSC) and the exposure limit value
(VLE) of the substance, as
applicable.
6.7 Interview The employer complies when, on interviewing
occupationally exposed personnel,
selected in accordance with the sampling criterion set out in Table 19 “Sample size by number of occupationally exposed workers”, it is confirmed that it provides them with personal protective equipment specific to the risk, in accordance with NOM-017-STPS-2008, or those replacing it.
6.8 and 12.1 Documentary The employer complies when it presents evidence Serious documentary evidence that: It carries out medical examinations of occupationally exposed personnel as part of their health surveillance, and keeps the results on file, and Health surveillance of occupationally exposed personnel is carried out through a programme that assesses their state of health, identifies their susceptibility to chemical contaminants of the working environment and detects early alterations to their health.
6.8 and 12.2 Documentary The employer complies when it presents documentary evidence that the programme for the
health surveillance of
occupationally exposed personnel considers, at least, the following: The occupational medical history, comprising: The worker's identification details; Hereditary and family history (AHF); Non-pathological personal history (APNP);
Pathological personal
history (APP);
The occupational history with
previous and current exposures to the risk; Current conditions, as applicable; A review of systems, and The physical examination, with emphasis on the acuity of the senses and the ability to express oneself so as to convey, in
a quick and accurate manner,
spoken or written communications or any signal; The administration of pre-employment medical examinations to identify organic alterations that could be aggravated by exposure to chemical substances;
alteration of workers' health, Mexican standards issued in this and respect The technical and/or control measures the Ministry of
company, private institution, or social security or health institution. 6.8, 12.3 and Documentary The employer complies when it presents evidence
| The performance of specific medical | The medical |
| examinations, based on the activity of | examinations shall |
| the exposed workers and the | be carried out |
| biological exposure index, IBE, subject to | in accordance with |
| annual clinical follow-up or evidence | indicated by the |
| of signs or symptoms indicating | official |
| and/or administrative, referred to in | Health and/or the |
| items 11.3 and 11.6 of this Standard, | Ministry of |
| which are adopted in accordance with the | Labour and |
| results of the evaluation of chemical | Social Welfare, |
| contaminants of the working | and, in the absence thereof, |
| environment and of the medical examinations | as indicated by the |
| performed. | physician of the |
12.4 documentary evidence that: Health surveillance of occupationally exposed personnel is conducted by a physician with knowledge and experience in occupational medicine and/or in the biological effects of chemical substances, and The medical examinations performed and their records, as well as the technical and/or administrative control measures adopted, are included in a clinical file that is kept for a minimum period of five years, counted from the date of the last examination.
6.9 Documentary The employer complies when it presents documentary evidence that it informs workers about the health risks from exposure to chemical contaminants of the working environment.
6.10 and 13 Documentary The employer complies when it presents documentary evidence that:
Provides training and instruction to
occupationally exposed personnel on the handling of chemical substances and the type of control applied to prevent contamination of the working environment, and The training and instruction provided to occupationally exposed personnel considers, at least, the following topics: The properties of the chemical substance(s) handled at the workplace; The effects that may be caused by
exposure to the chemical
substance(s); The health hazards from
exposure to the chemical
substance(s) in the work area; The importance of their participation in the recognition and evaluation of chemical contaminants of the working environment; How to work safely with the chemical substance(s); The control of the chemical substance(s) at the job and/or work area;
The respiratory protection
programme, and
The content of the
hazard and risk communication system used by the company for signage and the safety data sheet.
6.10 and 13.2 Records The employer complies when it presents evidence that it has records of the training and instruction provided to occupationally exposed personnel at least every twelve months.
6.11 Records The employer complies when it presents evidence Serious that it has records of the
recognition, evaluation and control
carried out and the medical examinations performed.
6.12 Documentary The employer complies when it presents evidence Serious documentary evidence that it informs occupationally exposed personnel of the results of the annual medical examinations performed on them.
6.13 Physical The employer complies when, on carrying out a Serious walk-through of the workplace, it is confirmed that minors aged 14 to 16 and women who are pregnant or breastfeeding are not exposed to chemical contaminants of the working environment.
16.4 For the selection of the occupationally exposed personnel to be interviewed, the sampling criterion set out in Table 19 shall apply. Table 19 Sample Size by Number of Occupationally Exposed Workers Number of Occupationally Exposed Workers Number of Workers to be Interviewed 1-15 1 16-50 2 51-105 3 1 for every 35 workers up to More than 105 a maximum of 15
16.5 Compliance with this Standard may be demonstrated by: a) The assessment report of a verification unit accredited and approved under the terms of the Federal Law on Metrology and Standardisation, and b) The result report of a testing laboratory accredited and approved under the terms of the Federal Law on Metrology and Standardisation.
16.6 The employer may use the Module for the Recognition, Evaluation and Control of Chemical Contaminant Agents, available on the electronic services portal of the Ministry of
Labour and Social Welfare, at the following electronic link:
http://ercsq.stps.gob.mx/ercsq/Login/LoginCT.aspx, as support for compliance with the obligations of Chapters 9, 10 and 11 of this Standard.
16.7 Documentary evidence and administrative records referred to in this Standard may be presented in printed form or on magnetic media, and shall be kept for at least two years.
17. Update of Appendix I
17.1 The Ministry shall review and, where applicable, update, every two years, the information contained in Appendix I, Exposure limit values for chemical contaminants of the working environment, in accordance with internationally recognised scientific references. For such purposes, the provisions of the Federal Law on Metrology and Standardisation shall apply.
18. Enforcement
18.1 Enforcement of compliance with this Standard is the responsibility of the Ministry.
19. Bibliography
19.1 Federal Law on Metrology and Standardisation. Last amendment published in the Official Gazette of the Federation of 9 April 2012.
19.2 NOM-008-SCFI-2002, General system of units of measurement. Published in the Official Gazette of the Federation of 27 November 2002.
19.3 NMX-Z-12-2-1987, Sampling for inspection by attributes - Part 2: Sampling methods, tables and graphs. Declaration of validity published in the Official Gazette of the Federation of 28 October 1987.
19.4 Globally Harmonized System of Classification and Labelling of Chemicals (GHS). Fourth revised edition. United Nations, New York and Geneva, 2011.
19.5 Workplace Exposure Standards for Airborne Contaminants. Australia. Publisher: Safe Work Australia, December 2011.
19.6 Occupational Exposure Limits for Chemical Agents in Spain 2013. Spain, Publisher: Ministry of Employment and Social Security / National Institute of Safety and Hygiene at Work.
19.7 Threshold Limit Values. For Chemical Substances and Physical Agents and Biological Exposure Indices. USA, Publisher: American Conference of Governmental Industrial Hygienists, 2012.
19.8 Mary Eide, Michael Simmons and Warren Hendricks, Validation Guidelines for Air Sampling Methods utilising Chromatographic Analysis. USA, Publisher: OSHA, May 2010.
19.9 Mary E. Eide, Phil J. Giles, Michael K. Simmons and Warren D. Hendricks, Evaluation Guidelines for Air Sampling Methods utilising Spectroscopic Analysis. USA, Publisher: OSHA, October 2010.
19.10 Nelson A. Leidel, Kenneth A. Busch and Jeremiah R. Lynch, Exposure Sampling Strategy Manual. USA, Publisher: National Institute for Occupational Safety and Health, 1977.
19.11 OSHA Technical Manual, OTM. USA, Occupational Safety and Health Administration, 20 January 1999.
19.12 Guidance on the interpretation of workplace exposure standards for airborne contaminants. Australia. Publisher: Safe Work Australia, April 2012.
19.13 NIOSH Pocket Guide to Chemical Hazards. USA, Publisher: National Institute for Occupational Safety and Health/Centers for Disease Control and Prevention.
19.14 NIOSH Manual of Analytical Methods/4th edition. USA, Publisher: National Institute for Occupational Safety and Health/Centers for Disease Control and Prevention.
19.15 Module for the Recognition, Evaluation and Control of Chemical Contaminant Agents. Mexico, Ministry of Labour and Social Welfare. Online.
19.16 International Chemical Control Toolkit. Occupational safety, health and environment programme of the International Labour Organization. Online.
19.17 COSHH Essentials/Easy steps to control health risks from chemicals. United Kingdom, Health and Safety Executive. Online.
19.18 Toxnet/Hazardous Substances Data Bank, HSDB. USA, United States National Library of Medicine. Online.
19.19 Fundación Mapfre, Manual de Higiene Industrial. Fourth edition. Spain, 1996.
19.20 Barbara A. Plog, and Patricia J. Quinlan, Fundamentals of Industrial Hygiene. 5th edition. USA, Publisher: National Safety Council.
19.21 R.R. Langner, S.K. Norwood, G.E. Socha and H.R. Hoyle, Two methods for establishing industrial hygiene priorities. American Industrial Hygiene Association Journal. USA, Vol. 40, No. 12, 1979.
19.22 Christopher L. Holzner, Richard B. Hirsh and Janet B. Perper, Managing Workplace Exposure Information. American Industrial Hygiene Association Journal. USA, Vol. 54, No. 1, 1993.
19.23 Keith Tait, A Commentary on the AIHA Position Statement and White Paper on a Generic Exposure Assessment Standard. American Industrial Hygiene Association. USA, November 1994.
19.24 Charles Steer and Gavin Irving, Workplace Exposure Standards - How do we adjust for extended work shifts? AIOH2009 Conference, 5 - 9 December 2009, Canberra, ACT, Australia.
7. 2-Methoxyethyl acetate Haematological effect; effect on 118.13 110-49-6 SKIN, IBE 0.1 ppm
8. 2-Pentyl acetate Upper respiratory tract irritation 130.20 626-38-0 50 ppm 100 ppm
9. 3-Pentyl acetate Upper respiratory tract irritation 130.20 620-11-1 50 ppm 100 ppm
10. Benzyl acetate Upper respiratory tract irritation 150.18 140-11-4 A4 10 ppm
12. Isobutyl acetate Upper respiratory tract irritation 116.16 110-19-0 150 ppm
13. Isopentyl acetate Upper respiratory tract irritation 130.20 123-92-2 50 ppm 100 ppm
14. Isopropyl acetate Upper respiratory tract irritation 102.13 108-21-4 100 ppm 200 ppm
15. Methyl acetate Headache; upper respiratory tract and eye irritation; optic nerve damage 74.08 79-20-9 200 ppm 250 ppm
16. n-Amyl acetate Upper respiratory tract irritation 130.20 628-63-7 50 ppm 100 ppm
17. n-Butyl acetate Upper respiratory tract irritation 116.16 123-86-4 150 ppm 200 ppm
18. n-Propyl acetate Upper respiratory tract irritation 102.13 109-60-4 200 ppm 250 ppm
19. sec-Butyl acetate Upper respiratory tract irritation 116.16 105-46-4 200 ppm
20. sec-Hexyl acetate Upper respiratory tract irritation 144.21 108-84-9 50 ppm
21. tert-Amyl acetate Upper respiratory tract irritation 130.20 625-16-1 50 ppm 100 ppm
23. Vinyl acetate Upper respiratory tract irritation 86.09 108-05-4 A3 10 ppm 15 ppm
26. Acetone Upper respiratory tract irritation 58.05 67-64-1 A4, IBE 500 ppm 750 ppm
27. Acetonitrile Upper respiratory tract irritation 41.05 75-05-8 A4, SKIN 20 ppm
28. 2,2-Dichloropropionic acid Upper respiratory tract irritation 143.00 75-99-0 A4 5 mg/m3 (I)
29. 2-Chloropropionic acid Reproductive organ damage 108.53 598-78-7 SKIN 0.1 ppm
34. Adipic acid Upper respiratory tract irritation 146.14 124-04-9 5 mg/m3
35. Boric acid Upper respiratory tract irritation 61.80 10043-35-3 A4 2 mg/m3 (I) 6 mg/m3 (I)
36. Chloroacetic acid Upper respiratory tract irritation 94.50 79-11-8 A4, SKIN 0.5 ppm (IFV)
37. Dichloroacetic acid Upper respiratory tract irritation 128.95 79-43-6 A3, SKIN 0.5 ppm
38. Formic acid Upper respiratory tract irritation 46.02 64-18-6 5 ppm 10 ppm
39. Phosphoric acid Upper respiratory tract irritation 98.00 7664-38-2 1 mg/m3 3 mg/m3
42. Oxalic acid Upper respiratory tract irritation 90.04 144-62-7 1 mg/m3 2 mg/m3
43. Picric acid Eye irritation; dermatitis; 229.11 88-89-1 0.1 mg/m3
44. Propionic acid Upper respiratory tract irritation 74.08 79-09-4 10 ppm
53. n-Butyl acrylate Upper respiratory tract irritation 128.17 141-32-2 A4, SEN 2 ppm
54. Acrylonitrile Central nervous system damage; 53.05 107-13-1 A3, SKIN 2 ppm
55. Acrolein Upper respiratory tract irritation 56.06 107-02-8 A4, SKIN, P 0.1 ppm
56. Adiponitrile Upper respiratory tract irritation 108.10 111-69-3 SKIN 2 ppm
60. Furfuryl alcohol Upper respiratory tract irritation 98.10 98-00-0 SKIN 10 ppm 15 ppm
61. Isoamyl alcohol Upper respiratory tract irritation 88.15 123-51-3 100 ppm 125 ppm
62. Isooctyl alcohol Upper respiratory tract irritation 130.23 26952-21-6 SKIN 50 ppm
63. Propargyl alcohol Eye irritation; kidney damage and 56.06 107-19-7 SKIN 1 ppm
64. Aldrin Central nervous system damage; 364.93 309-00-2 A3, SKIN 0.05 mg/m3 (IFV)
65. Raw untreated cotton, dust Byssinosis; bronchitis; pulmonary function various A4 0.1 mg/m3 (T)
68. tert-Amyl methyl ether, TAME Central nervous system damage; 102.20 994-05-8 20 ppm
73. Acetic anhydride Upper respiratory tract irritation 102.09 108-24-7 A4 1 ppm 3 ppm
74. Phthalic anhydride Upper respiratory tract irritation 148.11 85-44-9 A4, SEN 1 ppm
86. Arsine Damage to nervous system 77.95 7784-42-1 0.005 ppm
92. Barium and soluble compounds Eye, skin and 137.30 7440-39-3 A4 0.5 mg/m3
93. Benzene Leukaemia 78.11 71-43-2 A1, SKIN, IBE 0.5 ppm 2.5 ppm
104. Sodium borate, anhydrous Upper respiratory tract irritation 201.22 1330-43-4 A4 2 mg/m3 (I) 6 mg/m3 (I)
105. Sodium borate, decahydrate Upper respiratory tract irritation 381.37 1303-96-4 A4 2 mg/m3 (I) 6 mg/m3 (I)
106. Coal tar pitch volatiles, as Skin cancer; pneumoconiosis various 65996-93-2 A1, IBEP 0.2 mg/m3
109. Bromochloromethane Central nervous system damage; 129.39 74-97-5 200 ppm
110. Bromoform Upper respiratory tract irritation 252.73 75-25-2 A3 0.5 ppm
111. 1-Bromopropane Liver and embryo/foetal damage; 122.99 106-94-5 10 ppm
112. Allyl bromide Upper respiratory tract irritation 120.99 106-95-6 A4, SKIN 0.1 ppm 0.2 ppm
113. Ethyl bromide Liver damage; damage to nervous 108.98 74-96-4 A3, SKIN 5 ppm
114. Hydrogen bromide Upper respiratory tract irritation 80.92 10035-10-6 P 2 ppm
115. Methyl bromide Upper respiratory tract irritation 94.95 74-83-9 A4, SKIN 1 ppm
131. p-tert-Butyltoluene Upper respiratory tract irritation 148.18 98-51-1 1 ppm
132. 2-Butoxyethanol Upper respiratory tract irritation 118.17 111-76-2 A3, IBE 20 ppm
144. Coal, dusts Lung damage; pulmonary fibrosis various A4 0.9 mg/m3 (R)
149. Cellulose Upper respiratory tract irritation various 9004-34-6 10 mg/m3
150. Portland cement Pulmonary function; symptoms various 65997-15-1 A4 1 mg/m3 (R, E)
154. Ethyl cyanoacrylate Upper respiratory tract irritation 125.12 7085-85-0 0.2 ppm
155. Methyl 2-cyanoacrylate Upper respiratory tract irritation 111.10 137-05-3 0.2 ppm
156. Cyanogen Upper respiratory tract irritation 52.04 460-19-5 10 ppm
157. Acetone cyanohydrin, as Cn Upper respiratory tract irritation 85.10 75-86-5 SKIN, P 5 mg/m3
158. Calcium cyanide Upper respiratory tract irritation 92.12 592-01-8 SKIN, P 5 mg/m3
159. Hydrogen cyanide Upper respiratory tract irritation 27.03 74-90-8 SKIN, P 4.7 ppm
160. Potassium cyanide Upper respiratory tract irritation 65.11 151-50-8 SKIN, P 5 mg/m3
161. Sodium cyanide Upper respiratory tract irritation 49.00 143-33-9 SKIN, P 5 mg/m3
166. Cyclohexanone Upper respiratory tract irritation 98.14 108-94-1 A3, SKIN 20 ppm 50 ppm
167. Cyclohexene Upper respiratory tract irritation 82.14 110-83-8 300 ppm
168. Cyclohexylamine Upper respiratory tract irritation 99.17 108-91-8 A4 10 ppm
172. Cyclopentane Upper respiratory tract irritation 70.13 287-92-3 600 ppm
173. Cyhexatin Upper respiratory tract irritation 385.16 13121-70-5 A4 5 mg/m3
174. Zirconium and compounds, as Zr Eye irritation 91.22 7440-67-7 A4 5 mg/m3 10 mg/m3
175. Citral Effect on body weight; 152.24 5392-40-5 A4, SKIN, SEN 5 ppm (IFV)
176. Clopidol Upper respiratory tract irritation 192.06 2971-90-6 A4 10 mg/m3
179. 1-Chloro-1-nitropropane Eye irritation; oedema 123.54 600-25-9 2 ppm
183. 2-Chloroacetophenone Upper respiratory tract irritation 154.59 532-27-4 A4 0.05 ppm
184. Chloroacetone Upper respiratory tract irritation 92.53 78-95-5 SKIN, P 1 ppm
187. Chlorodiphenyl, 42% chlorine Liver damage; eye irritation; 266.50 53469-21-9 SKIN 1 mg/m3
188. Chlorodiphenyl, 54% chlorine Upper respiratory tract irritation 328.40 11097-69-1 SKIN, A3 0.5 mg/m3
189. Chlorodifluoromethane Central nervous system damage; 86.47 75-45-6 A4 1000 ppm
190. o-Chlorostyrene Central nervous system damage; 138.60 2039-87-4 50 ppm 75 ppm
191. Chloroform Liver damage; damage to 119.38 67-66-3 A3 10 ppm
196. β-Chloroprene Upper respiratory tract irritation 88.54 126-99-8 SKIN 10 ppm
197. o-Chlorotoluene Upper respiratory tract irritation 126.59 95-49-8 50 ppm
200. Allyl chloride Upper respiratory tract irritation 76.50 107-05-1 A3, SKIN 1 ppm 2 ppm
201. Benzyl chloride Upper respiratory tract irritation 126.58 100-44-7 A3 1 ppm
202. Benzoyl chloride Upper respiratory tract irritation 140.57 98-88-4 A4, P 0.5 ppm
203. Cyanogen chloride Pulmonary oedema; irritation of the 61.48 506-77-4 P 0.3 ppm
204. Zinc chloride, fume Upper respiratory tract irritation 136.29 7646-85-7 1 mg/m3 2 mg/m3
205. Chloroacetyl chloride Upper respiratory tract irritation 112.95 79-04-9 SKIN 0.05 ppm 0.15 ppm
206. Chromyl chloride Upper respiratory tract irritation 154.92 14977-61-8 0.025 ppm
207. Dimethylcarbamoyl chloride Nasal cancer; irritation of the tract 107.54 79-44-7 A2, SKIN 0.005 ppm
210. Methyl chloride Liver and kidney damage: damage to 50.49 74-87-3 A4, SKIN 50 ppm 100 ppm
211. Polyvinyl chloride, PVC Pneumoconiosis; irritation of the various 9002-86-2 A4 1 mg/m3 (R)
212. Thionyl chloride Upper respiratory tract irritation 118.98 7719-09-7 P 0.2 ppm
219. Copper, dusts and mists, as Cu Gastrointestinal irritation; fever 63.55 7440-50-8 1 mg/m3
221. Cresol Upper respiratory tract irritation 108.14 1319-77-3 A4, SKIN 20 mg/m3 (IFV)
222. m-Cresol Upper respiratory tract irritation 108.14 108-39-4 A4, SKIN 20 mg/m3 (IFV)
223. o-Cresol Upper respiratory tract irritation 108.14 95-48-7 A4, SKIN 20 mg/m3 (IFV)
224. p-Cresol Upper respiratory tract irritation 108.14 106-44-5 A4, SKIN 20 mg/m3 (IFV)
231. Lead chromate, as Pb Reproductive organ damage 323.22 7758-97-6 A2, IBE 0.05 mg/m3
242. 2,4-D Upper respiratory tract irritation 221.04 94-75-7 A4 10 mg/m3
243. Decaborane Convulsion; cognitive decline 122.31 17702-41-9 SKIN 0.05 ppm 0.15 ppm
246. Diacetone alcohol Upper respiratory tract irritation 116.16 123-42-2 50 ppm
249. Diborane Upper respiratory tract irritation 27.69 19287-45-7 0.1 ppm
250. Diquat dibromide Upper respiratory tract irritation 344.05 85-00-7 A4, SKIN 0.5 mg/m3 (I)
251. Ethylene dibromide Liver, kidney and heart damage; 187.88 106-93-4 A3, SKIN
252. 2-N-Dibutylaminoethanol Upper respiratory tract irritation 173.29 102-81-8 SKIN, IBEA 0.5 ppm
253. Dicyclopentadiene Upper respiratory tract irritation 132.21 77-73-6 5 ppm
254. Dichloroethyl ether Upper respiratory tract irritation 143.02 111-44-4 A4, SKIN 5 ppm 10 ppm
255. 1,2-Dichloropropane Upper respiratory tract irritation 112.99 78-87-5 A4, SEN 10 ppm
256. 1,1-Dichloro-1-nitroethane Upper respiratory tract irritation 143.96 594-72-9 2 ppm
257. 1,4-Dichloro-2-butene Upper respiratory tract irritation 124.99 764-41-0 A2, SKIN 0.005 ppm
258. 1,3-Dichloro-5,5-dimethylhydantoin Upper respiratory tract irritation 197.03 118-52-5 0.2 mg/m3 0.4 mg/m3
259. Dichloroacetylene Nausea; damage to nervous system 94.93 7572-29-4 A3, P 0.1 ppm
260. o-Dichlorobenzene Upper respiratory tract irritation 147.01 95-50-1 A4 20 ppm 50 ppm
261. p-Dichlorobenzene Eye irritation; kidney damage 147.01 106-46-7 A3 10 ppm
262. 3,3'-Dichlorobenzidine Bladder cancer; irritation of 253.13 91-94-1 A3, SKIN
268. cis-1,2-Dichloroethylene Central nervous system damage; 96.94 156-59-2 200 ppm
269. trans-1,2-Dichloroethylene Central nervous system damage; 96.94 156-60-5 200 ppm
279. Diethylamine Upper respiratory tract irritation 73.14 109-89-7 A4, SKIN 5 ppm 15 ppm
280. 2-Diethylaminoethanol Upper respiratory tract irritation 117.19 100-37-8 SKIN 2 ppm
281. Diethylenetriamine Upper respiratory tract irritation 103.17 111-40-0 SKIN 1 ppm
282. Diphenylamine Liver and kidney damage; effect 169.24 122-39-4 A4 10 mg/m3
283. Difluorodibromomethane Upper respiratory tract irritation 209.83 75-61-6 100 ppm
284. Oxygen difluoride Headache; oedema 54.00 7783-41-7 P 0.05 ppm
285. Diglycidyl ether, DGE Eye and skin irritation; damage to 130.14 2238-07-5 A4 0.01 ppm
286. Diisobutyl ketone Upper respiratory tract irritation 142.23 108-83-8 25 ppm
287. 1,6-Hexamethylene diisocyanate Upper respiratory tract irritation 168.22 822-06-0 0.005 ppm
288. 4,4'-Diisocyanate of Respiratory sensitiser 250.26 101-68-8 0.005 ppm
293. N,N-Dimethylacetamide Embryo/foetal damage; damage to 87.12 127-19-5 A4, SKIN, IBE 10 ppm
294. Dimethylamine Upper respiratory tract irritation 45.08 124-40-3 A4 5 ppm 15 ppm
298. 2,3-Dimethylbutane Central nervous system damage; 86.17 79-29-8 500 ppm 1000 ppm
299. Dimethylethoxysilane Upper respiratory tract irritation 104.20 14857-34-2 0.5 ppm 1.5 ppm
303. 2,3-Dimethylpentane Central nervous system damage; 100.20 565-59-3 400 ppm 500 ppm
308. 1,2-Dinitrobenzene Methaemoglobinaemia; damage to 168.11 528-29-0 SKIN, IBEM 0.15 ppm
309. 1,3-Dinitrobenzene Methaemoglobinaemia; damage to 168.11 99-65-0 SKIN, IBEM 0.15 ppm
310. 1,4-Dinitrobenzene Methaemoglobinaemia; eye damage 168.11 100-25-4 SKIN, IBEM 0.15 ppm
320. Nitrogen dioxide Upper respiratory tract irritation 46.01 10102-44-0 A4 0.2 ppm
321. Titanium dioxide Upper respiratory tract irritation 79.90 13463-67-7 A4 10 mg/m3
322. Vinyl cyclohexene dioxide Reproductive organ damage 140.18 106-87-6 A3, SKIN 0.1 ppm
330. Low-sulphur diesel fuel No. 4 Dermatitis various 68476-31-3 A3, SKIN 100 mg/m3 (IFV)
331. Stoddard solvent Eye, skin and kidney damage; nausea; 140.00 8052-41-3 100 ppm
335. Carbon disulphide Damage to nervous system 76.14 75-15-0 A4, SKIN, IBE 1 ppm
336. Dimethyl disulphide Upper respiratory tract irritation 94.20 624-92-0 SKIN 0.5 ppm
337. Diuron Upper respiratory tract irritation 233.10 330-54-1 A4 10 mg/m3
338. Divinylbenzene Upper respiratory tract irritation 130.19 1321-74-0 10 ppm
339. Dodecyl mercaptan Upper respiratory tract irritation 202.40 112-55-0 SEN 0.1 ppm
340. Endosulfan Upper respiratory tract irritation 406.95 115-29-7 A4, SKIN 0.1 mg/m3 (IFV)
342. Enflurane Central nervous system damage; 184.50 13838-16-9 A4 75 ppm
343. Epichlorohydrin Upper respiratory tract irritation 92.53 106-89-8 A3, SKIN 0.5 ppm
348. Stearates Upper respiratory tract irritation various A4 10 mg/m3
349. Styrene Peripheral neuropathy; irritation 104.16 100-42-5 A4, IBE 20 ppm 40 ppm
352. Ethanol Upper respiratory tract irritation 46.07 64-17-5 A3 1000 ppm
355. Isopropyl ether Upper respiratory tract irritation 102.17 108-20-3 250 ppm 310 ppm
358. Ethyl ether Central nervous system damage; 74.12 60-29-7 400 ppm 500 ppm
359. Ethyl mercaptan Upper respiratory tract irritation 62.13 75-08-1 0.5 ppm
361. Ethylamine Eye and skin irritation; damage to 45.08 75-04-7 SKIN 5 ppm 15 ppm
362. Ethylbenzene Upper respiratory tract irritation 106.16 100-41-4 A3, IBE 20 ppm
363. Ethylene chlorohydrin Central nervous system damage; 80.52 107-07-3 A4, SKIN, P 1 ppm
366. Ethyleneimine Upper respiratory tract irritation 43.08 151-56-4 A3, SKIN 0.05 ppm 0.1 ppm
369. N-Ethylmorpholine Upper respiratory tract irritation 115.18 100-74-3 SKIN 5 ppm
376. Phenyl ether - Diphenyl, vapour mixture Nausea; eye, nose and irritation of 166.00 8004-13-5 7 mg/m3
377. Phenyl ether, vapour Upper respiratory tract irritation 170.20 101-84-8 1 ppm 2 ppm
378. Phenylphosphine Dermatitis; haematological effect; 110.10 638-21-1 P 0.05 ppm
381. Phenyl mercaptan Central nervous system damage; 110.18 108-98-5 SKIN 0.1 ppm
382. O-Ethyl phenylphosphonothioate and of Cholinesterase inhibitor 323.31 2104-64-5 A4, SKIN, IBEA 0.1 mg/m3 (I)
385. Phenothiazine Photosensitiser of eyes; 199.26 92-84-2 SKIN 5 mg/m3
389. Ferrovanadium, dusts Upper respiratory tract irritation 106.8 12604-58-9 1 mg/m3 3 mg/m3
396. Fluorine Upper respiratory tract irritation 38.00 7782-41-4 1 ppm 2 ppm
397. Sodium fluoroacetate Central nervous system damage; 100.02 62-74-8 SKIN 0.05 mg/m3
398. Carbonyl fluoride Upper respiratory tract irritation 66.01 353-50-4 2 ppm 5 ppm
399. Hydrogen fluoride, as F Upper respiratory tract irritation 20.01 7664-39-3 SKIN, IBE, P 0.5 ppm 2 ppm
400. Perchloryl fluoride Upper respiratory tract irritation 102.46 7616-94-6 3 ppm 6 ppm
408. Formamide Eye and skin irritation; damage to 45.04 75-12-7 SKIN 10 ppm
410. Methyl formate Upper respiratory tract irritation 60.05 107-31-3 100 ppm 150 ppm
411. Dibutylphenyl phosphate Cholinesterase inhibitor; 286.26 2528-36-1 SKIN, IBEA 0.3 ppm
412. Dibutyl phosphate Upper respiratory tract irritation 210.21 107-66-4 SKIN 5 mg/m3 (IFV)
413. Tributyl phosphate Upper respiratory tract irritation 266.32 126-73-8 IBEA 0.2 ppm
417. Trimethyl phosphite Eye irritation; inhibitor of the 124.08 121-45-9 2 ppm
418. Hexamethylphosphoramide Respiratory tract cancer 179.20 680-31-9 A3, SKIN
419. Yellow phosphorus Upper respiratory tract irritation 123.92 12185-10-3 0.1 mg/m3
420. Phosgene Upper respiratory tract irritation 98.92 75-44-5 0.1 ppm
421. Di-2-ethylhexyl phthalate, DEHP Upper respiratory tract irritation 390.54 117-81-7 A3 5 mg/m3
422. Dibutyl phthalate Testicular damage; irritation of the 278.34 84-74-2 5 mg/m3
423. Diethyl phthalate Upper respiratory tract irritation 222.23 84-66-2 A4 5 mg/m3
424. Dimethyl phthalate Upper respiratory tract irritation 194.19 131-11-3 5 mg/m3
425. m-Phthalodinitrile Upper respiratory tract irritation 128.14 626-17-5 5 mg/m3 (IFV)
426. o-Phthalodinitrile Convulsion; effect on the weight of the 128.14 91-15-6 1 mg/m3 (IFV)
427. Furfural Upper respiratory tract irritation 96.08 98-01-1 A3, SKIN, IBE 2 ppm
428. Liquefied petroleum gas, LPG Nervous system depression various 68476-85-7 1000 ppm
429. Natural gas Cardiac sensitiser; damage to various 8006-14-2 1000 ppm
430. Petrol Upper respiratory tract irritation various 86290-81-5 A3 300 ppm 500 ppm
431. Glycerine, mists Upper respiratory tract irritation 92.09 56-81-5 - 10 mg/m3 -
432. Glycidol Upper respiratory tract irritation 74.08 556-52-5 A3 2 ppm
3. Acetaldehyde Upper respiratory tract irritation 44.05 75-07-0 A3, P 25 ppm
6. 2-Methylbutyl acetate Upper respiratory tract irritation 130. 20 624-41-9 50 ppm 100 ppm
11. Ethyl acetate Upper respiratory tract irritation 88.10 141-78-6 400 ppm
22. tert-Butyl acetate Upper respiratory tract irritation 116.16 540-88-5 200 ppm
51. Ethyl acrylate Upper respiratory tract irritation 100.11 140-88-5 A4 5 ppm 15 ppm
52. Methyl acrylate Upper respiratory tract irritation 86.09 96-33-3 A4, SKIN, SEN 2 ppm
59. Allyl alcohol Upper respiratory tract irritation 58.08 107-18-6 A4, SKIN 0.5 ppm
75. Hexahydrophthalic anhydride Respiratory sensitiser; 154.17 85-42-7 SEN, P 0.005 mg/m3 (IFV)
96. Benzo(a)anthracene Skin cancer 228.30 56-55-3 A2, IBEP
97. Benzo(a)pyrene Cancer 252.30 50-32-8 A2, IBEP
119. n-Butanol Upper respiratory tract irritation 74.12 71-36-3 20 ppm
120. sec-Butanol Upper respiratory tract irritation 74.12 78-92-2 100 ppm
148. Catechol Upper respiratory tract irritation 110.11 120-80-9 A3, SKIN 5 ppm
151. Ketene Upper respiratory tract irritation 42.04 463-51-4 0.5 ppm 1.5 ppm
302. 2,2-Dimethylpentane Central nervous system damage; 100.20 590-35-2 400 ppm 500 ppm
304. 2,4-Dimethylpentane Central nervous system damage; 100.20 108-08-7 400 ppm 500 ppm
341. Endrin Liver damage; damage to nervous system 380.93 72-20-8 A4, SKIN 0.1 mg/m3
360. Ethyl tert-butyl ether, ETBE Pulmonary function; damage 102.18 637-92-3 - 5 ppm
409. Ethyl formate Upper respiratory tract irritation 74.08 109-94-4 A4 100 ppm
No. Chemical Substance Health Alteration / Effect PM CAS No. Notation
PPT CT or P1. Poorly and lightly refined Upper respiratory tract irritation various A2
mineral oil, mists,2. Highly and very highly refined Upper respiratory tract irritation various 8012-95-1 A4 5 mg/m3
pure mineral oil, mists, except| 4. | 2-Butoxyethyl acetate | Haemolysis | 160.20 | 112-07-2 | A3 | 20 ppm |
| 5. | 2-Ethoxyethyl acetate | Reproductive organ damage | 132.16 | 111-15-9 | SKIN, IBE | 2 ppm |
24. Acetylene Asphyxia 26.02 74-86-2 25. Acetophenone Upper respiratory tract irritation 120.15 98-86-2 10 ppm
30. 2-Ethylhexanoic acid Teratogenic effect 144.24 149-57-5 5 mg/m3 (IFV) 31. Acetic acid Upper respiratory tract irritation 60.00 64-19-7 10 ppm 15 ppm
32. Acetylsalicylic acid Eye and skin irritation 180.15 50-78-2 5 mg/m3 33. Acrylic acid Upper respiratory tract irritation 72.06 79-10-7 A4, SKIN 2 ppm
40. Methacrylic acid Eye and skin irritation 86.09 79-41-4 20 ppm 41. Nitric acid Upper respiratory tract irritation 63.02 7697-37-2 2 ppm 4 ppm
45. Sulphuric acid Pulmonary function 98.08 7664-93-9 A2 (M) 0.2 mg/m3 (T) 46. Terephthalic acid Respiratory tract irritation 166.13 100-21-0 10 mg/m3
| 47. | Thioglycolic acid | Eye and skin irritation | 92.12 | 68-11-1 | SKIN | 1 ppm |
| 48. | Trichloroacetic acid | Upper respiratory tract irritation | 163.39 | 76-03-9 | A3 | 1 ppm |
49. Acrylamide Central nervous system damage 71.08 79-06-1 A3, SKIN 0.03 mg/m3 (IFV) 50. 2-Hydroxypropyl acrylate Upper respiratory tract irritation 130.14 999-61-1 SKIN, SEN 0.5 ppm
57. Alachlor Haemosiderosis 269.80 15972-60-8 A3, SEN 1 mg/m3 (IFV) 58. Synthetic camphor Upper respiratory tract irritation 152.23 76-22-2 A4 2 ppm 3 ppm
| 66. | Starch | Dermatitis | various | 9005-25-8 | A4 | 10 mg/m3 |
| 67. | Aluminium, metal and insoluble compounds | Pneumoconiosis; lower respiratory tract irritation; | 26.98 various | 7429-90-5 | A4 | 1 mg/m3 (R) |
69. 4-Aminodiphenyl Bladder and liver cancer 169.23 92-67-1 A1, SKIN 70. 2-Aminopyridine Headache; nausea; damage to 94.12 504-29-0 0.5 ppm
71. Amitrole Thyroid effect 84.08 61-82-5 A3 0.2 mg/m3 72. Ammonia Eye damage; irritation of the tract 17.03 7664-41-7 25 ppm 35 ppm
76. Maleic anhydride Respiratory sensitiser 98.06 108-31-6 A4, SEN 0.01 mg/m3 (IFV)
77. Trimellitic anhydride Respiratory sensitiser 192.12 552-30-7 SKIN, SEN 0.0005 mg/m3 (IFV) 0.002 mg/m3 (IFV)
78. Aniline Methaemoglobinaemia 93.12 62-53-3 A3, SKIN, IBE 2 ppm
79. o-Anisidine Methaemoglobinaemia 123.15 90-04-0 A3, SKIN, IBEM 0.5 mg/m3
80. p-Anisidine Methaemoglobinaemia 123.15 104-94-9 A4, SKIN, IBEM 0.5 mg/m3
81. Antimony and compounds, as Upper respiratory tract irritation 121.75 7440-36-0 0.5 mg/m3
Sb and skin various82. Argon Asphyxia 39.95 7440-37-1 83. Calcium arsenate Lung cancer; hepatic damage 398.07 7778-44-1 A1 1 mg/m3
| 84. | Arsenic and inorganic compounds, as As | Lung cancer | 74.92 various | 7440-38-2 | A1, IBE | 0.01 mg/m3 |
| 85. | Gallium arsenide | Upper respiratory tract irritation | 144.64 | 1303-00-0 | A3 | 0.0003 mg/m3 (R) |
| 87. | Asbestos, all forms, including Chrysotile | Pneumoconiosis; lung cancer; mesothelioma | various | 1332-21-4 | A1 | 0.1 f/cm3 (F) |
| 88. | Petroleum asphalt fumes, as benzene-soluble aerosols | Upper respiratory tract irritation and eyes | various | 8052-42-4 | A4, IBEP | 0.5 mg/m3(I) |
| 89. | Atrazine and symmetrical atrazines | Convulsion | 215.69 | 1912-24-9 | A4 | 5 mg/m3 |
| 90. | Sodium azide | Cardiac damage; lung damage | 65.02 | 26628-22-8 | A4, P | 0.29 mg/m3 |
| 91. | Sodium azide, as vapour of | Cardiac damage; lung damage | 65.02 | 26628-22-8 | A4, P | 0.11 ppm |
94. Benzidine Bladder cancer 184.23 92-87-5 A1, SKIN 95. Benomyl Upper respiratory tract irritation 290.32 17804-35-2 A3, SEN 1 mg/m3 (I)
98. Benzo(b)fluoranthene Cancer 252.30 205-99-2 A2, IBEP 99. Benzotrichloride Eye, skin and respiratory tract irritation 195.50 98-07-7 A2, SKIN, P 0.1 ppm
100. Beryllium and compounds, as Be Sensitiser; berylliosis; 9.01 7440-41-7 A1, SKIN, SEN 0.00005 mg/m3 (I)
chronic beryllium disease various| 101. | Biphenyl | Pulmonary function | 154.20 | 92-52-4 | 0.2 ppm | |
| 102. | bis(Chloromethyl) ether | Lung cancer | 114.96 | 542-88-1 | A1 | 0.001 ppm |
| 103. | Sodium bisulphite | Upper respiratory tract irritation | 104.07 | 7631-90-5 | A4 | 5 mg/m3 |
107. Bromacil Thyroid effect 261.11 314-40-9 A3 10 mg/m3 108. Bromine Upper respiratory tract irritation 159.81 7726-95-6 0.1 ppm 0.2 ppm
| 116. | Vinyl bromide | Liver cancer | 106.96 | 593-60-2 | A2 | 0.5 ppm |
| 117. | 1,3-Butadiene | Cancer | 54.09 | 106-99-0 | A2 | 2 ppm |
| 118. | Butane | Central nervous system damage; | various | 106-97-8 | 1000 ppm |
121. tert-Butanol Central nervous system damage 74.12 75-65-0 A4 100 ppm 122. 1-Butene Effect on body weight 56.11 106-98-9 250 ppm 123. 2-Butene Effect on body weight 56.11 107-01-7 250 ppm 124. cis-2-Butene Effect on body weight 56.11 590-18-1 250 ppm
125. trans-2-Butene Effect on body weight 56.11 624-64-6 250 ppm 126. n-Butylamine Headache; irritation of the 73.14 109-73-9 SKIN, P 5 ppm
127. Butylene Effect on body weight 56.11 25167-67-3 250 ppm 128. o-sec-Butylphenol Upper respiratory tract irritation 150.22 89-72-5 SKIN 5 ppm
129. n-Butyl glycidyl ether, BGE Reproductive system damage 130.21 2426-08-6 SKIN, SEN 3 ppm 130. n-Butyl mercaptan Upper respiratory tract irritation 90.19 109-79-5 0.5 ppm
133. Cadmium Kidney damage 112.40 7440-43-9 A2, IBE 0.01 mg/m3 134. Cadmium and compounds, as Cd Kidney damage various 7440-43-9 A2, IBE 0.002 mg/m3 (R) 135. Chlorinated camphene Convulsion; liver damage 414.00 8001-35-2 A3, SKIN 0.5 mg/m3 1 mg/m3 136. Kaolin Pneumoconiosis 258.16 1332-58-7 A4 2 mg/m3 (R,E) 137. Caprolactam Upper respiratory tract irritation 113.16 105-60-2 A5 10 mg/m3 40 mg/m3
| 138. | Captafol | Skin irritation | 349.06 | 2425-06-1 | A4, SKIN | 0.1 mg/m3 |
| 139. | Captan | Skin irritation | 300.60 | 133-06-2 | A3, SEN | 5 mg/m3 (I) |
| 140. | Carbaryl | Reproductive organ damage | 201.20 | 63-25-2 | A4, SKIN, IBEA | 0.5 mg/m3 (IFV) |
141. Carbofuran Cholinesterase inhibitor 221.30 1563-66-2 A4, IBEA 0.1 mg/m3 (IFV) 142. Coal, dusts Pneumoconiosis; skin irritation various 2 mg/m3 143. Coal, dusts Lung damage; pulmonary fibrosis various A4 0.4 mg/m3 (R)
| 145. | Fibrous silicon carbide | Cancer; mesothelioma | 40.10 | 409-21-2 | A2, F | 0.1 f/cc(F) |
| 146. | Non-fibrous silicon carbide | Upper respiratory tract irritation | 40.10 | 409-21-2 | 10 mg/m3 (I, E) 3 mg/m3 (R, E) | |
| 147. | 3-Carene | Upper respiratory tract irritation | 136.00 | 13466-78-9 | A4, SEN | 20 ppm |
152. Cyanamide Eye and skin irritation 42.04 420-04-2 2 mg/m3 153. Calcium cyanamide Upper respiratory tract irritation 80.11 156-62-7 A4 0.5 mg/m3
162. Cyclohexane Central nervous system damage 84.16 110-82-7 100 ppm
163. cis-1,2-Cyclohexanedicarboxylic Respiratory sensitiser; 154.17 13149-00-3 SEN, P 0.005 mg/m3 (IFV)
anhydride upper respiratory tract irritation164. trans-1,2- Respiratory sensitiser; 154.17 14166-21-3 SEN, P 0.005 mg/m3 (IFV)
Cyclohexanedicarboxylic upper respiratory tract irritation
anhydride eyes and skin
165. Cyclohexanol Eye irritation, damage to system 100.16 108-93-0 SKIN 50 ppm| 169. | Cyclonite | Liver damage | 222.26 | 121-82-4 | A4, SKIN | 0.5 mg/m3 |
| 170. | Cyclopentadienyl manganese tricarbonyl, as Mn | Skin irritation; central nervous system damage | 204.10 | 12079-65-1 | SKIN | 0.1 mg/m3 |
| 171. | Cyclopentadiene | Upper respiratory tract irritation | 66.10 | 542-92-7 | 75 ppm |
177. Chlordane Liver damage 409.80 57-74-9 A3, SKIN 0.5 mg/m3 178. Chlorine Upper respiratory tract irritation 70.91 7782-50-5 A4 0.5 ppm
180. 2-Chloro-1-propanol Liver damage 94.54 78-89-7 A4, SKIN 1 ppm 181. 1-Chloro-2-propanol Liver damage 94.54 127-00-4 A4, SKIN 1 ppm 182. Chloroacetaldehyde Upper respiratory tract irritation 78.50 107-20-0 P 1 ppm
185. Chlorobenzene Liver damage 112.56 108-90-7 A3, IBE 5 ppm 15 ppm 186. o-Chlorobenzylidene malononitrile Upper respiratory tract irritation 188.62 2698-41-1 A4, SKIN, P 0.05 ppm
| 192. | Chloromethyl methyl ether | Lung cancer | 80.50 | 107-30-2 | A2 | |
| 193. | p-Chloronitrobenzene | Methaemoglobinaemia | 157.56 | 100-00-5 | A3, SKIN, IBEM | 0.1 ppm |
| 194. | Chloropentafluoroethane | Cardiac sensitiser | 154.47 | 76-15-3 | 1000 ppm | |
| 195. | Chloropicrin | Eye irritation; oedema | 164.39 | 76-06-2 | A4 | 0.1 ppm |
198. Chlorpyrifos Cholinesterase inhibitor 350.57 2921-88-2 A4, SKIN, IBEA 0.1 mg/m3 (IFV) 199. Ammonium chloride, fume Upper respiratory tract irritation 53.50 12125-02-9 10 mg/m3 20 mg/m3
208. Ethyl chloride Liver damage 64.52 75-00-3 A3, SKIN 100 ppm 209. Hydrogen chloride Upper respiratory tract irritation 36.47 7647-01-0 A4, P 2 ppm
| 213. | Vinylidene chloride | Liver and kidney damage | 96.95 | 75-35-4 | A4 | 5 ppm |
| 214. | Vinyl chloride | Lung cancer; damage to | 62.50 | 75-01-4 | A1 | 1 ppm |
215. Cobalt carbonyl, as Co Pulmonary oedema; spleen damage 341.94 10210-68-1 0.1 mg/m3
216. Cobalt hydrocarbonyl, as Co Pulmonary oedema; lung damage 171.98 16842-03-8 0.1 mg/m3
217. Cobalt and compounds Asthma; pulmonary function; effect 58.93 7440-48-4 A3, IBE 0.02 mg/m3
inorganic, as Co on the myocardium various
218. Copper fume, as Cu Gastrointestinal irritation; fever 63.55 7440-50-8 0.2 mg/m3220. Rosin, thermal decomposition Dermatitis; asthma; skin various 8050-09-7 SEN
products of sensitiser| 225. | Chrysene | Cancer | 228.30 | 218-01-9 | A3, IBEP | |
| 226. | Calcium chromate, as Cr | Lung cancer | 156.09 | 13765-19-0 | A2 | 0.001 mg/m3 |
| 227. | Zinc chromate | Nasal cancer | various | 13530-65-9 | A1 | 0.01 mg/m3 |
| 228. | Zinc yellow chromate | Nasal cancer | 183.39 | 37300-23-5 | A1 | 0.01 mg/m3 |
| 229. | Strontium chromate, as Cr | Cancer | 203.61 | 7789-06-2 | A2 | 0.0005 mg/m3 |
| 230. | Lead chromate, as Cr | Reproductive organ damage | 323.22 | 7758-97-6 | A2 | 0.012 mg/m3 |
232. Potassium zinc chromate Nasal cancer 418.76 11103-86-9 A1 0.01 mg/m3
233. tert-Butyl chromate, as Respiratory tract irritation 230.22 1189-85-1 SKIN, P 0.1 mg/m3
CrO3 lower and skin
234. Chromite ore process Lung cancer 223.83 1308-31-2 A1 0.05 mg/m3| 235. | Chromium, metal and Cr III compounds | Upper respiratory tract irritation and skin | various | 7440-47-3 | A4 | 0.5 mg/m3 |
| 236. | Chromium, Cr VI compounds | Lung cancer | various | 7440-47-3 | A1 | 0.01 mg/m3 |
237. Chromium, Cr VI compounds Respiratory tract irritation various 7440-47-3 A1, IBE 0.05 mg/m3
soluble in water upper; cancer
238. Crotonaldehyde Upper respiratory tract irritation 70.09 4170-30-3 A3, SKIN, P 0.3 ppm| 239. | Crufomate | Cholinesterase inhibitor | 291.71 | 299-86-5 | A4, IBEA | 5 mg/m3 |
| 240. | Coumaphos | Cholinesterase inhibitor | 362.80 | 56-72-4 | A4, SKIN, IBEA | 0.05 mg/m3 (IFV) |
| 241. | Cumene | Upper respiratory tract irritation | 120.19 | 98-82-8 | 50 ppm |
244. Demeton Cholinesterase inhibitor 258.34 8065-48-3 SKIN, IBEA 0.05 mg/m 245. Diacetyl Lung damage (bronchiolitis 86.10 431-03-8 A4 0.01 ppm 0.02 ppm
| 247. | Diazinon | Cholinesterase inhibitor | 304.36 | 333-41-5 | A4, SKIN, IBEA | 0.01 mg/m3 (IFV) |
| 248. | Diazomethane | Upper respiratory tract irritation | 42.04 | 334-88-3 | A2 | 0.2 ppm |
| 263. | Dichlorodiphenyltrichloroethane, DDT | Liver damage | 354.50 | 50-29-3 | A3 | 1 mg/m3 |
| 264. | Dichlorodifluoromethane | Cardiac sensitiser | 120.91 | 75-71-8 | A4 | 1000 ppm |
| 265. | 1,1-Dichloroethane | Upper respiratory tract irritation | 98.97 | 75-34-3 | A4 | 100 ppm |
266. 1,2-Dichloroethane Liver damage; nausea 98.96 107-06-2 A4 10 ppm 267. 1,2-Dichloroethylene Central nervous system damage; 96.95 540-59-0 200 ppm
270. Dichlorofluoromethane Liver damage 102.92 75-43-4 10 ppm 271. Dichloromethane Carboxyhaemoglobinaemia; damage to 84.93 75-09-2 A3, IBE 50 ppm
| 272. | 1,3-Dichloropropene | Kidney damage | 110.98 | 542-75-6 | A3, SKIN | 1 ppm |
| 273. | Dichlorotetrafluoroethane | Pulmonary function | 170.93 | 76-14-2 | A4 | 1000 ppm |
| 274. | Dichlorvos | Cholinesterase inhibitor | 220.98 | 62-73-7 | A4, SKIN, SEN, | 0.1 mg/m3 (IFV) |
| 275. | Dicrotophos | Cholinesterase inhibitor | 237.21 | 141-66-2 | A4, SKIN, IBEA | 0.05 mg/m3 (IFV) |
| 276. | Dieldrin | Liver damage; effect on system | 380.93 | 60-57-1 | A3, SKIN | 0.1 mg/m3 (IFV) |
277. Diethanolamine Liver and kidney damage 105.14 111-42-2 A3, SKIN 2 mg/m3 278. Diethyl ketone Upper respiratory tract irritation 86.13 96-22-0 200 ppm 300 ppm
289. Isophorone diisocyanate Respiratory sensitiser 222.30 4098-71-9 0.005 ppm 290. 2,4-Toluene diisocyanate Respiratory sensitiser 174.15 584-84-9 A4, SEN 0.005 ppm 0.02 ppm 291. 2,6-Toluene diisocyanate Respiratory sensitiser 174.15 91-08-7 A4, SEN 0.005 ppm 0.02 ppm 292. Diisopropylamine Upper respiratory tract irritation 101.19 108-18-9 SKIN 5 ppm
| 295. | bis(2-Dimethylaminoethyl) ether, DMAEE | Upper respiratory tract irritation, eyes and skin | 160.26 | 3033-62-3 | SKIN | 0.05 ppm | 0.15 ppm |
| 296. | N,N-Dimethylaniline | Methaemoglobinaemia | 121.18 | 121-69-7 | A4, SKIN, IBEM | 5 ppm | 10 ppm |
| 297. | 2,2-Dimethylbutane | Central nervous system damage; | 86.17 | 75-83-2 | 500 ppm | 1000 ppm |
| 300. | N,N-Dimethylformamide | Liver damage | 73.09 | 68-12-2 | A4, SKIN, IBE | 10 ppm |
| 301. | N,N-Dimethylhydrazine | Upper respiratory tract irritation | 60.12 | 57-14-7 | A3, SKIN | 0.01 ppm |
| 305. | 2,2-Dimethylpropane | Peripheral neuropathy | 72.15 | 463-82-1 | 600 ppm | |
| 306. | Ethylene glycol dinitrate, EGDN | Vasodilatation; headache | 152.06 | 628-96-6 | SKIN | 0.05 ppm |
| 307. | Propylene glycol dinitrate | Headache; damage to system | 166.09 | 6423-43-4 | SKIN, IBEM | 0.05 ppm |
| 311. | Dinitrobenzene, mixture of isomers | Methaemoglobinaemia; eye damage | 168.11 | 25154-54-5 | SKIN, IBEM | 0.15 ppm |
| 312. | 4,6-Dinitro-o-cresol | Metabolic disorders | 198.13 | 534-52-1 | SKIN | 0.2 mg/m3 |
| 313. | 3,5-Dinitro-o-toluamide | Liver damage | 225.16 | 148-01-6 | A4 | 1 mg/m3 |
| 314. | Dinitrotoluene | Cardiac damage; effect on system | 182.15 | 25321-14-6 | A3, SKIN, IBEM | 0.2 mg/m3 |
315. 1,4-Dioxane Liver damage 88.10 123-91-1 A3, SKIN 20 ppm 316. Dioxathion Cholinesterase inhibitor 456.54 78-34-2 A4, SKIN, IBEA 0.1 mg/m3 (IFV) 317. Sulphur dioxide Pulmonary function; irritation of the 64.07 7446-09-5 A4 0.25 ppm
| 318. | Carbon dioxide | Asphyxia | 44.01 | 124-38-9 | 5 000 ppm | 30 000 ppm |
| 319. | Chlorine dioxide | Upper respiratory tract irritation | 67.46 | 10049-04-4 | 0.1 ppm | 0.3 ppm |
| 323. | 1,3-Dioxolane | Haematological effect | 74.08 | 646-06-0 | 20 ppm |
| 324. | Dipropyl ketone | Upper respiratory tract irritation | 114.80 | 123-19-3 | 50 ppm |
| 325. | Diquat | Lower respiratory tract irritation; cataracts | 184.24 | 2764-72-9 | A4, SKIN | 0.5 mg/m3 (I) 0.1 mg/m3 (R) |
| 326. | Diesel fuel | Dermatitis | various | 68334-30-5 | A3, SKIN | 100 mg/m3 (IFV) |
| 327. | Marine diesel fuel | Dermatitis | various | 77650-28-3 | A3, SKIN | 100 mg/m3 (IFV) |
| 328. | Diesel fuel No. 2 | Dermatitis | various | 68476-34-6 | A3, SKIN | 100 mg/m3 (IFV) |
| 329. | Diesel fuel No. 2 | Dermatitis | various | 68476-30-2 | A3, SKIN | 100 mg/m3 (IFV) |
| 332. | Disulfiram | Vasodilatation; nausea | 296.54 | 97-77-8 | A4 | 2 mg/m3 |
| 333. | Disulfoton | Cholinesterase inhibitor | 274.38 | 298-04-4 | A4, SKIN, IBEA | 0.05 mg/m3 (IFV) |
| 334. | Allyl propyl disulphide | Upper respiratory tract irritation | 148.16 | 2179-59-1 | SEN | 0.5 ppm |
344. Heptachlor epoxide Liver damage 389.40 1024-57-3 A3, SKIN 0.05 mg/m3
345. Tin, organic compounds, Respiratory tract irritation various A4, SKIN 0.1 mg/m3 0.2 mg/m3
as Sn upper and eyes; headache;| 346. | Tin, metal | Pneumoconiosis (or stannosis) | 118.69 | 7440-31-5 | 2 mg/m3 |
| 347. | Tin, oxide and inorganic compounds, as Sn, except | Pneumoconiosis (or stannosis) | 150.71 various | 18282-10-5 | 2 mg/m3 |
| 350. | Strychnine | Central nervous system damage | 334.40 | 57-24-9 | 0.15 mg/m3 |
| 351. | Ethane | Cardiac sensitiser; damage to | various | 74-84-0 | 1000 ppm |
353. Ethanolamine Eye and skin irritation 61.08 141-43-5 3 ppm 6 ppm 354. Allyl glycidyl ether, AGE Upper respiratory tract irritation 114.14 106-92-3 A4 1 ppm
356. Ethyl amyl ketone Neurotoxicity 128.21 541-85-5 10 ppm 357. Ethyl butyl ketone Central nervous system damage; 114.19 106-35-4 50 ppm 75 ppm
364. Ethylenediamine Liver and kidney damage; asthma 60.10 107-15-3 A4, SKIN 10 ppm 365. Ethylene glycol Upper respiratory tract irritation 62.07 107-21-1 A4, P 100 mg/m3 (H)
367. Ethylene Asphyxia 28.05 74-85-1 A4 200 ppm 368. Ethylidene norbornene Upper respiratory tract irritation 120.19 16219-75-3 P 5 ppm
| 370. | Ethion | Cholinesterase inhibitor | 384.48 | 563-12-2 | A4, SKIN, IBEA | 0.05 mg/m3 (IFV) |
| 371. | 2-Ethoxyethanol | Reproductive organ damage | 90.12 | 110-80-5 | SKIN, IBE | 2 ppm |
| 372. | Fenamiphos | Cholinesterase inhibitor | 303.40 | 22224-92-6 | A4, SKIN, IBEA | 0.05 mg/m3 (IFV) |
| 373. | m-Phenylenediamine | Skin irritation; liver damage | 108.05 | 108-45-2 | A4 | 0.1 mg/m3 |
| 374. | o-Phenylenediamine | Anaemia | 108.05 | 95-54-5 | A3 | 0.1 mg/m3 |
| 375. | p-Phenylenediamine | Skin sensitiser; irritation | 108.05 | 106-50-3 | A4 | 0.1 mg/m3 |
| 379. | Phenyl glycidyl ether, PGE | Testicular damage | 150.17 | 122-60-1 | A3, SKIN, SEN | 0.1 ppm |
| 380. | Phenylhydrazine | Upper respiratory tract irritation | 108.14 | 100-63-0 | A3, SKIN | 0.1 ppm |
383. N-Phenyl-β-naphthylamine Cancer 219.29 135-88-6 A4 384. Phenol Upper respiratory tract irritation 94.11 108-95-2 A4, SKIN, IBE 5 ppm
| 386. | Fensulfothion | Cholinesterase inhibitor | 308.35 | 115-90-2 | A4, SKIN, IBEA | 0.01 mg/m3 (IFV) |
| 387. | Fenthion | Cholinesterase inhibitor | 278.34 | 55-38-9 | A4, SKIN, IBEA | 0.05 mg/m3 (IFV) |
| 388. | Ferbam | Central nervous system damage; | 416.50 | 14484-64-1 | A4 | 5 mg/m3 (I) |
| 390. | Synthetic vitreous fibres, refractory ceramic fibre | Pulmonary fibrosis; pulmonary function | various | A2 | 0.2 f/cm3 (F) |
| 391. | Synthetic vitreous fibres, glass wool fibre | Upper respiratory tract irritation | various | A3 | 1 f/cm3 (F) |
| 392. | Synthetic vitreous fibres, mineral wool fibre | Upper respiratory tract irritation | various | A3 | 1 f/cm3 (F) |
| 393. | Synthetic vitreous fibres, slag wool fibre | Upper respiratory tract irritation | various | A3 | 1 f/cm3 (F) |
| 394. | Synthetic vitreous fibres, special purpose glass fibre | Upper respiratory tract irritation | various | A3 | 0.5 f/cm3 |
| 395. | Synthetic vitreous fibres, glass fibre filament | Upper respiratory tract irritation | various | A4 | 1 f/cm3 (F) 5 mg/m3 (I) |
401. Sulphuryl fluoride Central nervous system damage 102.07 2699-79-8 5 ppm 10 ppm 402. Vinylidene fluoride Liver damage 64.04 75-38-7 A4 500 ppm 403. Vinyl fluoride Liver cancer; liver damage 46.05 75-02-5 A2 1 ppm 404. Fluorides, as F Bone damage; fluorosis various A4, IBE 2.5 mg/m3 405. Fonofos Cholinesterase inhibitor 246.32 944-22-9 A4, SKIN, IBEA 0.1 mg/m3 (IFV) 406. Phorate Cholinesterase inhibitor 260.40 298-02-2 A4, SKIN, IBEA 0.05 mg/m3 (IFV) 407. Formaldehyde Upper respiratory tract irritation 30.03 50-00-0 A2, SEN, P 0.3 ppm
414. Triphenyl phosphate Cholinesterase inhibitor 326.28 115-86-6 A4 3 mg/m3 415. Tri-o-cresyl phosphate Cholinesterase inhibitor 368.37 78-30-8 A4, SKIN, IBEA 0.1 mg/m3 416. Phosphine Upper respiratory tract irritation 34.00 7803-51-2 0.3 ppm 1 ppm
20. Concordance with international standards
This Standard does not concord with any international standard, as no such reference existed at the time it was drawn up.
TRANSITIONAL PROVISIONS
FIRST. This Official Mexican Standard shall enter into force two years after its publication in the Official Gazette of the Federation. SECOND. During the period established in the First Transitional Provision, employers shall comply with Official Mexican Standard NOM-010-STPS-1999, Safety and hygiene conditions at workplaces where chemical substances capable of generating contamination of the working environment are handled, transported, processed or stored, or shall make the adaptations necessary to observe the provisions of this Official Mexican Standard NOM-010-STPS-2014, Chemical Contaminants of the Working Environment - Recognition, Evaluation and Control. In the latter case, the labour authority shall provide, at the request of interested employers, advice and guidance to implement compliance, without employers becoming liable to penalties for non-compliance with the standard in force, provided that this does not result from an inspection visit. THIRD. Result reports issued by testing laboratories accredited and approved in accordance with the Federal Law on Metrology and Standardisation shall have the validity corresponding to the reference value defined in accordance with item 8.6 of NOM-010-STPS-1999, Safety and hygiene conditions at workplaces where chemical substances capable of generating contamination of the working environment are handled, transported, processed or stored. Once that validity period ends, workplaces may choose to carry out sampling of chemical contaminants of the working environment in accordance with the criteria set out in item 9.3 of this Standard. FOURTH. Testing laboratories accredited and approved in accordance with the Federal Law on Metrology and Standardisation may continue using the procedures of Appendix II, Procedures for the determination of chemical substances in the working environment, of Official Mexican Standard NOM-010-STPS-1999, Safety and hygiene conditions at workplaces where chemical substances capable of generating contamination of the working environment are handled, transported, processed or stored, until NOM-010-STPS-2014, Chemical Contaminants of the Working Environment - Recognition, Evaluation and Control, enters into force. FIFTH. Testing laboratories accredited and approved on the basis of the Federal Law on Metrology and Standardisation may proceed to arrange the corresponding update of the accreditation of analytical techniques and the approval of sampling and analytical determination procedures or methods recognised by labour authorities or by international organisations recognised or regulated by other countries, as from the date of publication of this Standard in the Official Gazette of the Federation. SIXTH. As from the date this Official Mexican Standard enters into force, Official Mexican Standard NOM-010-STPS-1999, Safety and hygiene conditions at workplaces where chemical substances capable of generating contamination of the working environment are handled, transported, processed or stored, published in the Official Gazette of the Federation of 13 March 2000, together with its clarification and correction notice of 21 August 2000, shall cease to have effect. Mexico City, Federal District, on the twenty-fifth day of the month of April two thousand and fourteen.- The Secretary of Labour and Social Welfare, Jesús Alfonso Navarrete Prida.- Signature.
Appendix I
Exposure limit values for chemical contaminants of the working environment I.1 Concentrations measured in the working environment (CMA) shall be kept below the exposure limit values (VLE) set out in Table I.1 of this Appendix. For chemical substances that are handled at the workplace and are not listed in Table I.1, the recognition of the working environment shall be carried out and training shall be provided to workers, in accordance with Chapters 9 and 13, respectively, of this Standard, and their concentrations in the working environment shall be kept in accordance with the exposure limit values used by labour authorities or recognised international organisations. I.2 Table I.1 contains the names of the chemical substances; their health alterations or effects; the molecular weight; their CAS number; the notations relating to the carcinogen classification, biological exposure indices, other abbreviations and notes, as well as the exposure limit values (VLE), in their three expressions: time-weighted average exposure, short-time or peak (PPT and CT or PICO). The description of the notations is given at the end of the table. I.3 The time-weighted average exposure limit values (VLE-PPT) in Table I.1 are indicated for normal temperature and pressure conditions (TPN), and for a working day of 8 hours and 40 hours a week. I.4 The time-weighted average, short-time or peak exposure limit values (PPT and CT or PICO), as well as the other information contained in Table I.1, do not constitute defined lines of separation between safe and hazardous concentration. They are guidelines or recommendations to prevent risks to the health of occupationally exposed personnel. TABLE I.1 Exposure Limit Values for Chemical Contaminants of the Working Environment VLE (L) except metalworking fluids, metalworking fluids upper and eyes, male upper reproductive organ upper upper upper upper and eyes upper and eyes upper upper and eyes; central nervous system damage, respiratory tract upper and eyes; optic nerve damage upper upper and eyes upper and eyes upper and eyes upper and eyes upper upper and eyes upper, eyes and skin; central nervous system damage (D) upper; central nervous system damage; pregnancy loss upper and eyes; central nervous system damage; lower haematological effect upper and eyes, male upper and eyes; pulmonary function upper upper; autonomic nervous system damage upper upper upper and eyes; testicular damage upper, eyes and skin upper, eyes and skin upper and eyes; dental erosion upper, eyes and skin skin sensitiser upper, eyes and skin upper, eyes and skin upper and eyes upper and eyes upper, eyes and gastrointestinal; central nervous system damage; skin sensitiser upper, eyes and skin; eye damage upper, eyes and skin lower respiratory tract irritation upper and eyes; pulmonary oedema; pulmonary emphysema upper and lower upper and eyes; anosmia upper and eyes upper and eyes upper and eyes upper liver liver and kidney damage pulmonary neurotoxicity embryo/foetal damage (L) central nervous system; respiratory dizziness upper upper and eyes upper, eyes and skin upper respiratory tract irritation, eyes and skin (D) and central nervous system; systemic effect, lower, peripheral; vascular system damage; liver and kidney damage related, hydrazoic acid, muscular (L) upper; testicular damage and male reproduction; embryo/foetal damage (L) (L) (L) upper respiratory (berylliosis) upper, eyes and skin upper upper benzene-soluble aerosol upper and lower; lung damage liver damage upper and eyes; liver damage neurotoxicity upper and eyes central nervous upper upper and skin cardiac sensitiser upper and eyes upper; central nervous system damage, respiratory tract upper and eyes upper, eyes and skin upper upper and eyes; nausea upper and eyes upper male; cholinesterase inhibitor; embryo damage Anthracite, bituminous or lignite upper and skin; pulmonary damage and a central nervous system upper and eyes; dermatitis upper respiratory; asthma upper; pulmonary oedema upper and eyes upper and skin upper and eyes lower and eyes upper; headache; cyanosis/hypoxia upper; headache; nausea; thyroid effect upper; headache; nausea; thyroid effect upper; headache; nausea; thyroid effect upper; headache; nausea; thyroid effect upper, eyes and skin central nervous upper and eyes upper and eyes upper and eyes upper and eyes upper, eyes and skin; central nervous system damage upper; effect on weight; kidney damage various upper respiratory tract irritation; eye damage upper upper and eyes pulmonary upper and eyes upper, eyes and skin upper and eyes upper; skin sensitiser, chloracne upper; liver damage, chloracne asphyxia; cardiac sensitiser peripheral neuropathy embryo/foetus; central nervous system damage (L) pulmonary upper and eyes upper, eyes and skin upper and eyes upper and eyes; liver and kidney damage upper, eyes and skin upper and eyes respiratory tract upper, eyes and skin upper and lower upper upper and skin upper respiratory upper central nervous system; testicular damage; teratogenic effect respiratory tract lower; changes in pulmonary function upper liver of metal fume, metal fume (L) welding core upper upper upper upper (L) male; teratogenic effect; vasoconstriction male; teratogenic effect; vasoconstriction chromium, as insoluble Cr upper and eyes upper, eyes and skin; central nervous system damage upper and skin 3 (IFV) obliterative, similar disease) upper and eyes upper and eyes upper; headache, lower; cataracts 0.1 mg/m3 (R) effect on the reproductive system upper and eyes upper and lower, and eyes upper and eyes; nausea upper; effect on body weight upper upper and eyes upper peripheral upper and eyes; liver damage (L) eyes upper and eyes; liver and kidney damage eye irritation eye irritation eye irritation central nervous system IBEA reproductive; central nervous system damage upper; central nervous system damage upper and eyes upper; convulsions upper and eyes haematological upper; liver damage; central nervous system damage pulmonary; upper respiratory tract irritation male reproductive organ upper and eyes upper; respiratory sensitiser methylenediphenyl, MDI upper; eye damage liver upper; gastrointestinal damage upper respiratory tract irritation and eyes upper respiratory tract irritation and eyes upper and eyes; headache upper; nasal cancer upper respiratory tract irritation upper respiratory tract irritation upper respiratory tract irritation central nervous eyes eyes eyes reproductive respiratory tract lower lower; bronchitis lower lower female and male upper Diesel fuel, off-road, sulphur central nervous system damage upper and eyes peripheral upper; central nervous system damage upper upper upper lower; liver and kidney damage central nervous; headache cardiac damage upper; male reproductive organ damage nausea; effects on the central nervous system and immune system tin hydride upper, eyes and skin of the respiratory tract upper; central nervous system damage central nervous system upper upper, eyes and skin; dermatitis upper and eyes eye and skin irritation upper respiratory tract irritation upper; central nervous system damage testicular, eyes upper; kidney damage; nephropathy; cochlear damage liver and kidney damage upper and eyes upper; liver and kidney damage upper and eyes upper; eye damage male; embryo/foetal damage of the respiratory tract upper skin upper and eyes; nausea testicular damage upper and skin; anaemia eye and skin irritation O-4-nitrophenyl, EPN (L) upper; lung damage; central nervous system damage skin irritation effect on body weight; spleen damage upper and lower, and eyes continuous upper, eyes and skin cardiac damage; nausea lower, bone damage upper and lower, skin and eyes; fluorosis upper and lower; methaemoglobinaemia; fluorosis upper and eyes liver and kidney upper upper and lower, and eyes upper respiratory tract irritation upper, bladder and eyes upper and eyes; nausea; headache upper and gastrointestinal; headache; central nervous system damage cholinesterase upper upper and lower; gastrointestinal irritation; liver damage upper; pulmonary oedema; pulmonary emphysema lower respiratory tract upper and eyes upper upper and eyes upper and eyes body upper and eyes central; cardiac sensitiser central nervous system upper and eyes; central nervous system damage upper upper, eyes and skin
0.1 mg/m3 (IFV)
433. Glyoxal Respiratory tract irritation 58.04 107-22-2 A4, SEN
upper; metaplasia of the larynx
434. Glutaraldehyde, activated or Respiratory tract irritation 100.11 111-30-8 A4, SEN, P 0.05 ppm unactivated upper, eyes and skin; damage to
central nervous system 10 mg/m3
435. Synthetic graphite Pneumoconiosis various
2 mg/m3 (R)
436. Graphite, all forms, except Pneumoconiosis 12.00 7782-42-5
graphite fibres 4 mg/m3
437. Oat, barley and wheat grain, Bronchitis; irritation of the respiratory tract, various, dusts upper; function
pulmonary
434. Glutaraldehyde, activated or Respiratory tract irritation 100.11 111-30-8 A4, SEN, P 0.05 ppm
unactivated upper, eyes and skin; damage to437. Oat, barley and wheat grain, Bronchitis; irritation of the tract various
dusts respiratory, upper; function0.5 mg/m3
438. Hafnium and compounds, as Hf Respiratory tract irritation 178.49 7440-58-6 upper and eyes; damage to liver various
50 ppm
439. Halothane Central nervous system damage; 197.39 151-67-7 A4
damage to liver; vasodilatation
438. Hafnium and compounds, as Hf Respiratory tract irritation 178.49 7440-58-6
upper and eyes; liver damage various0.5 mg/m3 (I)
440. Flour, dusts Asthma; irritation of the respiratory tract, various, SEN
upper respiratory; bronchitis (D)
441. Helium Asphyxia 4.00 7440-59-7
0.05 mg/m3
442. Heptachlor Damage to liver 373.32 76-44-8 A3, SKIN 443. Heptane Central nervous system damage; 100.20 142-82-5 400 ppm 500 ppm
upper respiratory tract irritation
444. Hexachlorobenzene Porphyria effect; damage to skin; 284.78 118-74-1 A3, SKIN 0.002 mg/m3
damage to central nervous system
445. Hexachlorobutadiene Damage to kidney 260.76 87-68-3 A3, SKIN 0.02 ppm 446. Hexachlorocyclopentadiene Respiratory tract irritation 272.75 77-47-4 A4 0.01 ppm
upper
Se
453. Tellurium hexafluoride, as Te Respiratory tract irritation 241.61 7783-80-4 0.02 ppm
lower
454. n-Hexane Central nervous system damage; 86.18 110-54-3 SKIN, IBE 50 ppm
peripheral neuropathy; eye irritation
455. 1,6-Hexanediamine Respiratory tract irritation 116.21 124-09-4 0.5 ppm
upper and skin
456. 1-Hexene Central nervous system damage 84.16 592-41-6 50 ppm
457. Hexylene glycol Respiratory tract irritation 118.17 107-41-5 P 25 ppm
upper and eyes
458. Hydrazine Cancer of the respiratory tract 32.05 302-01-2 A3, SKIN 0.01 ppm
upper (D)
upper, eyes and skin
462. Caesium hydroxide Respiratory tract irritation 149.92 21351-79-1 2 mg/m3
upper, eyes and skin
463. Potassium hydroxide Respiratory tract irritation 56.10 1310-58-3 P 2 mg/m3
upper, eyes and skin
464. Sodium hydroxide Respiratory tract irritation 40.01 1310-73-2 P 2 mg/m3
upper, eyes and skin
465. Butylated hydroxytoluene, BHT Respiratory tract irritation 220.34 128-37-0 A4 2 mg/m3 (IFV)
upper
466. Antimony hydride Respiratory tract irritation 124.78 7803-52-3 0.1 ppm
lower; haemolysis; damage to kidney
467. Lithium hydride Respiratory tract irritation 7.95 7580-67-8 0.025 mg/m3
upper, eyes and skin
468. Iron dicyclopentadienyl, as Damage to liver 186.03 102-54-5 10 mg/m3
Fe
cardiac sensitiser
473. Isobutanol Irritation of eyes and skin 74.12 78-83-1 50 ppm 474. Isobutene Respiratory tract irritation 56.11 115-11-7 A4 250 ppm
upper; effect on body weight
475. Methyl isocyanate Respiratory tract irritation 57.05 624-83-9 SKIN 0.02 ppm
upper
476. Triglycidyl isocyanurate Damage to reproductive organ 297.25 2451-62-9 0.05 mg/m3
male
477. Isophorone Respiratory tract irritation 138.21 78-59-1 A3, P 5 ppm
upper and eyes; damage to central nervous system; fatigue; malaise
478. Isopentane Peripheral neuropathy 72.15 78-78-4 600 ppm 479. Isopropyl glycidyl ether, IGE Respiratory tract irritation 116.18 4016-14-2 50 ppm 75 ppm
upper and eyes; dermatitis
480. Isopropylamine Respiratory tract irritation 59.08 75-31-0 5 ppm 10 ppm
upper; damage to eyes
various
484. n-Butyl lactate Respiratory tract irritation 146.19 138-22-7 5 ppm
upper; headache
485. Natural rubber latex, as Respiratory sensitiser various 9006-04-6 SEN, SKIN 0.0001 mg/m3 (I)
inhalable allergenic proteins
486. Lindane Central nervous system damage 290.85 58-89-9 A3, SKIN 0.5 mg/m3
and liver
487. Western red cedar wood, Asthma various A4, SEN 0.5 mg/m3 (I)
dusts
488. Oak and beech wood, dusts Pulmonary function various A1 489. Birch, mahogany, walnut, Pulmonary function various A2
teak wood, dusts
490. Madera, all the other dusts of Pulmonary function various A4
wood
491. Woods, except red cedar, Pulmonary function various 1 mg/m3 (I)
dusts
except alkyl compounds
497. Methacrylonitrile Irritation of eyes and skin; damage to 67.09 126-98-7 A4, SKIN 1 ppm
central nervous system
498. Sodium metabisulphite Respiratory tract irritation 190.13 7681-57-4 A4 5 mg/m3
upper
499. Methyl methacrylate Respiratory tract irritation 100.13 80-62-6 A4, SEN 50 ppm 100 ppm
upper and eyes; effect on body weight; pulmonaryy oedema
500. Methane Cardiac sensitiser; damage to various 74-82-8 1000 ppm
central nervous system
501. Methanol Headache; damage to eyes; 32.04 67-56-1 SKIN, IBE 200 ppm 250 ppm
nausea; dizziness
502. Methylacetylene Central nervous system damage 40.07 74-99-7 1000 ppm 503. Azinphos-methyl Cholinesterase inhibitor 317.34 86-50-0 A4, SKIN, SEN, 0.2 mg/m3 (IFV)
IBEA
504. -Methylstyrene Respiratory tract irritation 118.18 98-83-9 A3 10 ppm
upper; damage to kidney; damage to reproductive organ reproductive female
505. Methyl ethyl ketone, MEK Respiratory tract irritation 72.10 78-93-3 IBE 200 ppm 300 ppm
upper; damage to central and peripheral nervous system
506. Methylhydrazine Respiratory tract irritation 46.07 60-34-4 A3, SKIN 0.01 ppm
upper and eyes; lung cancer; damage to liver
507. Methyl isoamyl ketone Respiratory tract irritation 114.20 110-12-3 20 ppm
upper and eyes; damage to liver and kidney; damage to central nervous system
508. Methyl isobutyl ketone Respiratory tract irritation 100.16 108-10-1 A3, IBE 20 ppm 75 ppm
upper; dizziness; headache
509. Methyl isopropyl ketone Damage to embryo/foetus; toxicity 86.14 563-80-4 20 ppm
neonatal
510. Methyl mercaptan Damage to liver 48.11 74-93-1 0.5 ppm 511. 1-Methylnaphthalene Respiratory tract irritation 142.20 90-12-0 A4, SKIN 0.5 ppm
lower; damage to lung
512. Methyl n-amyl ketone Irritation of eyes and skin 114.18 110-43-0 50 ppm 513. Methyl n-butyl ketone Peripheral neuropathy; damage 100.16 591-78-6 SKIN, IBE 5 ppm 10 ppm
testicular
514. Methyl parathion Cholinesterase inhibitor 263.20 298-00-0 A4, SKIN, IBEA 0.2 mg/m3 (IFV) 515. Methyl propyl ketone Pulmonary function; irritation of 86.17 107-87-9 150 ppm
eyes
516. Metsulfuron-methyl Haematological effect 364.38 74222-97-2 A4 5 mg/m3 517. Methyl tert-butyl ether, MTBE Respiratory tract irritation 88.17 1634-04-4 A3 50 ppm
upper; damage to kidney
518. Methyl vinyl ketone Respiratory tract irritation 70.10 78-94-4 SKIN, SEN, P 0.2 ppm
upper and eyes; damage to central nervous system
519. (Methyl-2-methoxyethoxy) propanol Respiratory tract irritation 148.20 34590-94-8 SKIN 100 ppm 150 ppm
upper and eyes; damage to central nervous system
520. 4-Methyl-2-pentanol Respiratory tract irritation 102.18 108-11-2 SKIN 25 ppm 40 ppm
upper and eyes; damage to central nervous system
521. Methylacetylene-propadiene, Central nervous system damage 40.07 59355-75-8 1000 ppm 1250 ppm
mixture
522. Methylal Central nervous system damage; 76.10 109-87-5 1000 ppm
eye irritation
523. Methylamine Respiratory tract irritation 31.06 74-89-5 5 ppm 15 ppm
upper, eyes and skin
524. N-Methylaniline Methaemoglobinaemia; damage to 107.15 100-61-8 SKIN, IBEM 0.5 ppm
central nervous system
525. Methylcyclohexane Respiratory tract irritation 98.19 108-87-2 400 ppm
upper; damage to central nervous system; damage to liver and kidney
526. Methylcyclohexanol Respiratory tract irritation 114.19 25639-42-3 50 ppm
upper and eyes
527. o-Methylcyclohexanone Respiratory tract irritation 112.17 583-60-8 SKIN 50 ppm 75 ppm
upper and eyes; damage to central nervous system
IBEA
531. Methylenebis(4-cyclohexyl isocyanate) Respiratory tract irritation 262.35 5124-30-1 0.005 ppm
lower; respiratory sensitiser
upper respiratory tract irritation
535. 3-Methylhexane Central nervous system damage; 100.20 589-34-4 400 ppm 500 ppm
upper respiratory tract irritation
536. 2-Methylnaphthalene Respiratory tract irritation 142.20 91-57-6 A4, SKIN 0.5 ppm
lower; damage to lung
537. 2-Methylpentane Central nervous system damage; 86.17 107-83-5 500 ppm 1000 ppm
upper respiratory tract irritation and eyes
538. 3-Methylpentane Central nervous system damage; 86.17 96-14-0 500 ppm 1000 ppm
upper respiratory tract irritation and eyes
539. Methomyl Cholinesterase inhibitor 162.20 16752-77-5 A4, IBEA 2.5 mg/m3 540. 1-Methoxy-2-propanol Irritation of eyes; damage to system 90.12 107-98-2 100 ppm 150 ppm
central nervous
541. Methoxychlor Central nervous system damage; 345.65 72-43-5 A4 10 mg/m3
damage to liver
542. 2-Methoxyethanol Haematological effect; effect on the 76.09 109-86-4 SKIN, IBE 0.1 ppm
reproductive system
543. 4-Methoxyphenol Irritation of eyes; damage to skin 124.15 150-76-5 5 mg/m3 544. Metribuzin Damage to liver; effect 214.28 21087-64-9 A4 5 mg/m3
haematological
upper, eyes and skin
upper respiratory
554. Naphthalene Haematological effect; irritation of the 128.19 91-20-3 A4, SKIN 10 ppm 15 ppm
respiratory tract upper and eyes; damage to eyes (L)
555. ß-Naphthylamine Bladder cancer 143.18 91-59-8 A1 556. α-Naphthylthiourea, ANTU Thyroid effect; nausea 202.27 86-88-4 A4, SKIN 0.3 mg/m3
557. Naled Cholinesterase inhibitor 380.79 300-76-5 A4, SKIN, SEN, 0.1 mg/m3 (IFV)
IBEA
558. Carbon black Bronchitis 12.00 1333-86-4 A3 3 mg/m3 (I)
(D)
559. Neon Asphyxia 20.18 7440-01-9 560. Nicotine Central nervous system damage 162.23 54-11-5 SKIN 0.5 mg/m3
and gastrointestinal; cardiac damage
561. Nickel, inorganic compounds, Lung cancer various A1 0.2 mg/m3 (I)
insoluble, as Ni
562. Nickel, inorganic compounds, Damage to lung; nasal cancer various A4 0.1 mg/m3 (I)
soluble, as Ni
methaemoglobinaemia
569. p-Nitroaniline Damage to liver; eye irritation; 138.12 100-01-6 A4, SKIN, IBEM 3 mg/m3
methaemoglobinaemia
570. Nitrobenzene Methaemoglobinaemia 123.11 98-95-3 A3, SKIN, IBE 1 ppm
(L)
571. 4-Nitrodiphenyl Bladder cancer 199.20 92-93-3 A2, SKIN 572. Nitroethane Respiratory tract irritation 75.07 79-24-3 100 ppm
upper; damage to central nervous system and damage to liver (D)
respiratory tract upper; damage to lung
576. 5-Nitro-o-toluidine Damage to liver 152.16 99-55-8 A3 1 mg/m3 (I) 577. 1-Nitropropane Respiratory tract irritation 89.09 108-03-2 A4 25 ppm
upper and eyes; damage to liver
578. 2-Nitropropane Liver cancer; damage to liver 89.09 79-46-9 A3 10 ppm
(L)
579. N-Nitrosodimethylamine Liver cancer and kidney; damage to 74.08 62-75-9 A3, SKIN
liver
upper
586. p,p'-Oxybis(benzenesulfonyl Teratogenic effect 358.40 80-51-3 0.1 mg/m3 (I)
hydrazine)
587. Phosphorus oxychloride Respiratory tract irritation 153.35 10025-87-3 0.1 ppm
upper
588. Aluminium oxide Respiratory tract irritation, 101.96 1344-28-1 10 mg/m3
eyes and skin
589. Boron oxide Irritation of eyes and tract 69.64 1303-86-2 10 mg/m3
upper respiratory
590. Cadmium oxide, as Cd Lung and prostate cancer; 128.41 1306-19-0 A1 0.01 mg/m3 (I) irritation of the respiratory tract; 0.002 mg/m3 (R)
damage to kidney
591. Calcium oxide Respiratory tract irritation 56.08 1305-78-8 2 mg/m3
upper
haematological effect; damage to embryo/foetus
595. Ethylene oxide Cancer; damage to nervous system 44.05 75-21-8 A2 1 ppm
central
596. Iron oxide Pneumoconiosis 159.70 1309-37-1 A4 5 mg/m3 (R)
597. Magnesium oxide Irritation of eyes and a system 40.32 1309-48-4 A4 10 mg/m3 (I)
respiratory
598. Mesityl oxide Respiratory tract irritation 98.14 141-79-7 15 ppm 25 ppm
upper and eyes; damage to central nervous system
599. Nitrogen oxide Respiratory tract irritation 30.01 10102-43-9 IBEM 25 ppm
upper; hypoxia/cyanosis; forms nitrosyl haemoglobin
600. Propylene oxide Respiratory tract irritation 58.08 75-56-9 A3, SEN 2 ppm
upper and eyes
601. Ozone Pulmonary function 48.00 10028-15-6 P 0.1 ppm 602. Ozone, heavy workload, Pulmonary function 48.00 10028-15-6 A4 0.20 ppm
moderate or light (≤ 2 hours)
442. Heptachlor Liver damage 373.32 76-44-8 A3, SKIN 443. Heptane Central nervous system damage; 100.20 142-82-5 400 ppm 500 ppm
| 445. | Hexachlorobutadiene | Kidney damage | 260.76 | 87-68-3 | A3, SKIN | 0.02 ppm |
| 446. | Hexachlorocyclopentadiene | Upper respiratory tract irritation | 272.75 | 77-47-4 | A4 | 0.01 ppm |
447. Hexachloroethane Liver and kidney damage 236.74 67-72-1 A3, SKIN 1 ppm 448. Hexachloronaphthalene Liver damage; chloracne 334.74 1335-87-1 SKIN 0.2 mg/m3 449. Hexafluoroacetone Testicular and kidney damage 166.02 684-16-2 SKIN 0.1 ppm 450. Hexafluoropropylene Kidney damage 150.02 116-15-4 0.1 ppm 451. Sulphur hexafluoride Asphyxia 146.07 2551-62-4 1000 ppm 452. Selenium hexafluoride, as Pulmonary oedema 192.96 7783-79-1 0.05 ppm
459. Hydrogen Asphyxia 1.01 1333-74-0 460. Hydroquinone Eye irritation; eye damage 110.11 123-31-9 A3, SEN 1 mg/m3 461. Calcium hydroxide Upper respiratory tract irritation 74.10 1305-62-0 5 mg/m3
| 469. | Iron, soluble salts, as Fe | Upper respiratory tract irritation and skin | 55.84 various | 7439-89-6 | 1 mg/m3 |
| 470. | Indene | Liver damage | 116.15 | 95-13-6 | 5 ppm |
| 471. | Indium and compounds, as In | Pulmonary oedema; pneumonitis; dental erosion; malaise | 114.82 various | 7440-74-6 | 0.1 mg/m3 |
| 472. | Isobutane | Central nervous system damage; | 58.12 | 75-28-5 | 1000 ppm |
473. Isobutanol Eye and skin irritation 74.12 78-83-1 50 ppm 474. Isobutene Upper respiratory tract irritation 56.11 115-11-7 A4 250 ppm
478. Isopentane Peripheral neuropathy 72.15 78-78-4 600 ppm 479. Isopropyl glycidyl ether, IGE Upper respiratory tract irritation 116.18 4016-14-2 50 ppm 75 ppm
| 481. | N-Isopropylaniline | Methaemoglobinaemia | 135.21 | 768-52-5 | SKIN, IBEM | 2 ppm |
| 482. | 2-Isopropoxyethanol | Haematological effect | 104.15 | 109-59-1 | SKIN | 5 ppm |
| 483. | Yttrium and compounds, as Y | Pulmonary fibrosis | 88.91 | 7440-65-5 | 1 mg/m3 |
| 488. | Oak and beech wood, dusts | Pulmonary function | various | A1 |
| 489. | Birch, mahogany, walnut, | Pulmonary function | various | A2 |
492. Malathion Cholinesterase inhibitor 330.36 121-75-5 A4, SKIN, IBEA 1 mg/m3 (IFV)
493. Manganese and compounds Central nervous system damage 54.94 7439-96-5 0.2 mg/m3
inorganic, as Mn various
494. Mercury, as Hg, compounds Central nervous system damage various 7439-97-6 SKIN 0.01 mg/m3 0.03 mg/m3
alkyl and peripheral; kidney damage
495. Mercury, as Hg, elemental and Central nervous system damage; various 7439-97-6 A4, SKIN, IBE 0.025 mg/m3
inorganic forms kidney damage
496. Mercury, as Hg, all Central nervous system damage; various 7439-97-6 SKIN 0.1 mg/m3
forms of aryl compounds kidney damage502. Methylacetylene Central nervous system damage 40.07 74-99-7 1000 ppm 503. Azinphos-methyl Cholinesterase inhibitor 317.34 86-50-0 A4, SKIN, SEN, 0.2 mg/m3 (IFV)
510. Methyl mercaptan Liver damage 48.11 74-93-1 0.5 ppm 511. 1-Methylnaphthalene Upper respiratory tract irritation 142.20 90-12-0 A4, SKIN 0.5 ppm
512. Methyl n-amyl ketone Eye and skin irritation 114.18 110-43-0 50 ppm 513. Methyl n-butyl ketone Peripheral neuropathy; damage 100.16 591-78-6 SKIN, IBE 5 ppm 10 ppm
514. Methyl parathion Cholinesterase inhibitor 263.20 298-00-0 A4, SKIN, IBEA 0.2 mg/m3 (IFV) 515. Methyl propyl ketone Pulmonary function; irritation of 86.17 107-87-9 150 ppm
| 516. | Metsulfuron-methyl | Haematological effect | 364.38 | 74222-97-2 | A4 | 5 mg/m3 |
| 517. | Methyl tert-butyl ether, MTBE | Upper respiratory tract irritation | 88.17 | 1634-04-4 | A3 | 50 ppm |
| 528. | 2-Methylcyclopentadienyl manganese tricarbonyl, as Mn | Central nervous system damage; lung, liver and kidney damage | 218.10 | 12108-13-3 | SKIN | 0.2 mg/m3 |
| 529. | Methyldemeton | Cholinesterase inhibitor | 230.30 | 8022-00-2 | SKIN, IBEA | 0.05 mg/m3 (IFV) |
| 530. | S-Methyldemeton | Cholinesterase inhibitor | 230.30 | 919-86-8 | A4, SKIN, SEN, | 0.05 mg/m3 (IFV) |
532. 4,4'-Methylenedianiline Liver damage 198.26 101-77-9 A3, SKIN 0.1 ppm
533. 4,4'-Methylene bis(2-chloroaniline), Bladder cancer; 267.17 101-14-4 A2, SKIN, IBE 0.01 ppm
MBOCA methaemoglobinaemia
534. 2-Methylhexane Central nervous system damage; 100.20 591-76-4 400 ppm 500 ppm539. Methomyl Cholinesterase inhibitor 162.20 16752-77-5 A4, IBEA 2.5 mg/m3 540. 1-Methoxy-2-propanol Eye irritation; damage to system 90.12 107-98-2 100 ppm 150 ppm
543. 4-Methoxyphenol Eye irritation; skin damage 124.15 150-76-5 5 mg/m3 544. Metribuzin Liver damage; effect 214.28 21087-64-9 A4 5 mg/m3
545. Mevinphos Cholinesterase inhibitor 224.16 7786-34-7 A4, SKIN, IBEA 0.01 mg/m3 (IFV)
546. Mica Pneumoconiosis 797.00 12001-26-2 3 mg/m3 (R)
547. Molybdenum, soluble compounds, Respiratory tract irritation 95.95 7439-98-7 A3 0.5 mg/m3 (R)
as Mo lower various
548. Molybdenum, metal and Respiratory tract irritation 95.95 7439-98-7 10 mg/m3 (I)
insoluble compounds, as Mo lower various 3 mg/m3 (R)
549. Sulphur monochloride Upper respiratory tract irritation 135.03 10025-67-9 P 1 ppm| 550. | Monocrotophos | Cholinesterase inhibitor | 223.16 | 6923-22-4 | A4, SKIN, IBEA | 0.05 mg/m3 (IFV) |
| 551. | Diquat dibromide monohydrate | Lower respiratory tract irritation; cataracts | 362.06 | 6385-62-2 | A4, SKIN | 0.5 mg/m3 (I) 0.1 mg/m3 (R) |
| 552. | Carbon monoxide | Carboxyhaemoglobinaemia | 28.01 | 630-08-0 | IBE | 25 ppm |
| 553. | Morpholine | Eye damage; irritation of the tract | 87.12 | 110-91-8 | A4, SKIN | 20 ppm |
555. ß-Naphthylamine Bladder cancer 143.18 91-59-8 A1 556. α-Naphthylthiourea, ANTU Thyroid effect; nausea 202.27 86-88-4 A4, SKIN 0.3 mg/m3
559. Neon Asphyxia 20.18 7440-01-9 560. Nicotine Central nervous system damage 162.23 54-11-5 SKIN 0.5 mg/m3
563. Nickel, elemental, as Ni Dermatitis; pneumoconiosis 58.71 7440-02-0 A5 1.5 mg/m3 (I) 564. Nickel carbonyl, as Ni Chemical pneumonitis 170.73 13463-39-3 0.05 ppm 565. Nickel subsulphide, as Ni Lung cancer 240.19 12035-72-2 A1 0.1 mg/m3 (I) 566. Nitrapyrin Liver damage 230.93 1929-82-4 A4 10 mg/m3 20 mg/m3 567. n-Propyl nitrate Nausea; headache 105.09 627-13-4 IBEM 25 ppm 40 ppm 568. Isobutyl nitrite Vasodilatation; 103.12 542-56-3 A3, IBEM, P 1 ppm (IFV)
571. 4-Nitrodiphenyl Bladder cancer 199.20 92-93-3 A2, SKIN 572. Nitroethane Upper respiratory tract irritation 75.07 79-24-3 100 ppm
| 573. | Nitrogen | Asphyxia | 14.01 | 7727-37-9 | ||
| 574. | Nitroglycerin, NG | Vasodilatation | 227.09 | 55-63-0 | SKIN | 0.05 ppm |
| 575. | Nitromethane | Thyroid effect; irritation of the | 61.04 | 75-52-5 | A3 | 20 ppm |
| 576. | 5-Nitro-o-toluidine | Liver damage | 152.16 | 99-55-8 | A3 | 1 mg/m3 (I) |
| 577. | 1-Nitropropane | Upper respiratory tract irritation | 89.09 | 108-03-2 | A4 | 25 ppm |
580. 2-Nitrotoluene Methaemoglobinaemia 137.13 88-72-2 SKIN, IBEM 2 ppm 581. 3-Nitrotoluene Methaemoglobinaemia 137.13 99-08-1 SKIN, IBEM 2 ppm 582. 4-Nitrotoluene Methaemoglobinaemia 137.13 99-99-0 SKIN, IBEM 2 ppm 583. Nonane Central nervous system damage 128.26 111-84-2 200 ppm 584. Octachloronaphthalene Liver damage 403.74 2234-13-1 SKIN 0.1 mg/m3 0.3 mg/m3 585. Octane, all isomers Upper respiratory tract irritation 114.22 111-65-9 300 ppm
590. Cadmium oxide, as Cd Lung and prostate cancer; 128.41 1306-19-0 A1 0.01 mg/m3 (I)
respiratory tract irritation; 0.002 mg/m3 (R)592. Zinc oxide Metal fume fever 81.37 1314-13-2 2 mg/m3 (R) 10 mg/m3 (R) 593. o-Chlorinated diphenyl oxide Chloracne; liver damage 377.00 31242-93-0 0.5 mg/m3 594. Dinitrogen oxide Central nervous system damage; 44.02 10024-97-2 A4 50 ppm
601. Ozone Pulmonary function 48.00 10028-15-6 P 0.1 ppm 602. Ozone, heavy workload, Pulmonary function 48.00 10028-15-6 A4 0.20 ppm
| 603. | Ozone, light workload | Pulmonary function | 48.00 | 10028-15-6 | A4 | 0.10 ppm |
| 604. | Ozone, moderate workload | Pulmonary function | 48.00 | 10028-15-6 | A4 | 0.08 ppm |
| 605. | Ozone, heavy workload | Pulmonary function | 48.00 | 10028-15-6 | A4 | 0.05 ppm |
| 606. | Paraquat, as the cation | Lung damage | 257.18 | 4685-14-7 | 0.5 mg/m3 |
0.1 mg/m3 (R)
607. Paraffin, fumes Respiratory tract irritation various 8002-74-2 2 mg/m3
upper; nausea
608. Parathion Cholinesterase inhibitor 291.27 56-38-2 A4, SKIN, IBE 0.05 mg/m3 (IFV)
(X)
609. Insoluble or poorly various 10 mg/m3 (I) soluble particles not otherwise 3 mg/m3 (R)
specified
610. Pentaborane Central nervous system damage 63.17 19624-22-7 0.005 ppm 0.015 ppm
and convulsion
upper and eyes; damage to central nervous system and cardiaco
upper and eyes
616. Pentaerythritol Respiratory tract irritation 136.15 115-77-5 10 mg/m3
upper and eyes
617. Sulphur pentafluoride Respiratory tract irritation 254.11 5714-22-7 P 0.01 ppm
upper; damage to lung
618. Bromine pentafluoride Respiratory tract irritation 174.92 7789-30-2 0.1 ppm
upper, eyes and skin
619. Pentane Peripheral neuropathy 72.15 109-66-0 600 ppm 620. 2,4-Pentanedione Neurotoxicity; damage to system 100.12 123-54-6 SKIN 20 ppm
central nervous
621. Phosphorus pentasulphide Respiratory tract irritation 222.29 1314-80-3 1 mg/m3 3 mg/m3
upper
622. Vanadium pentoxide, as V Respiratory tract irritation 181.88 1314-62-1 A3 0.05 mg/m3 (I)
upper and lower
623. Perchloromethyl mercaptan Respiratory tract irritation 185.87 594-42-3 0.1 ppm
upper and eyes
624. Perfluoroisobutylene Respiratory tract irritation 200.04 382-21-8 P 0.01 ppm
upper; haematological effect
upper and skin
628. Hydrogen peroxide Respiratory tract irritation 34.02 7722-84-1 A3 1 ppm
upper, eyes and skin
629. Methyl ethyl ketone peroxide Irritation of eyes and skin; damage to 176.24 1338-23-4 P 0.2 ppm
liver and kidney
upper and skin; pulmonaryy damage and a central nervous system
634. β-Pinene Respiratory tract irritation 136.00 127-91-3 A4, SEN 20 ppm
upper and skin; pulmonaryy damage and a central nervous system
635. Piperacina and salts, as Respiratory sensitiser; asthma 86.14 110-85-0 A4, SEN 0.03 ppm (IFV)
piperacina
636. Pyrethrum Damage to liver; irritation of the various 8003-34-7 A4 5 mg/m3
respiratory tract lower
637. Pyridine Irritation of skin; damage to liver and 79.10 110-86-1 A3 1 ppm
kidney
640. Plata and compounds solubles, Argyria various 7440-22-4 0.01 mg/m3
as Ag
641. Platinum, metal Asthma; irritation of the tract 195.09 7440-06-4 1 mg/m3
upper respiratory
642. Platinum and soluble salts, as Pt Asthma; irritation of the respiratory tract, various, 0.002 mg/m3
upper respiratory
central nervous system
645. 2-Propanol Respiratory tract irritation 60.09 67-63-0 A4, IBE 200 ppm 400 ppm
upper and eyes; damage to central nervous system
646. n-Propanol Respiratory tract irritation 60.09 71-23-8 A4 100 ppm
upper and eyes (L)
647. 1,3-Propane sultone Cancer 122.14 1120-71-4 A3 648. Propyleneimine Respiratory tract irritation 57.09 75-55-8 A3, SKIN 0.2 ppm 0.4 ppm
upper; damage to kidney
649. Propylene Asphyxia; irritation of the tract 42.08 115-07-1 A4 500 ppm
upper respiratory
650. β-Propiolactone Skin cancer; irritation of the 72.06 57-57-8 A3 0.5 ppm
respiratory tract upper
651. Propionaldehyde Respiratory tract irritation 58.10 123-38-6 20 ppm
upper
652. Propoxur Cholinesterase inhibitor 209.24 114-26-1 A3, IBEA 0.5 mg/m3 653. Kerosene Respiratory tract irritation various 8008-20-6 A3, SKIN 200 mg/m3 (p)
upper and skin; damage to central nervous system
654. Hydrodesulphurised kerosene Respiratory tract irritation various 64742-81-0 A3, SKIN 200 mg/m3 (p)
upper and skin; damage to central nervous system
655. Quinone Irritation of eyes; damage to skin 108.09 106-51-4 0.1 ppm 656. Resorcinol Irritation of eyes and skin 110.11 108-46-3 A4 10 ppm 20 ppm
3
657. Rodio, soluble compounds, Asthma various 7440-16-6 A4 0.01 mg/m
as Rh
658. Rodio, metal and compounds Metal = irritation of the tract 102.91 7440-16-6 A4 1 mg/m3 insolubles, as Rh upper respiratory; various
Insoluble = lower respiratory tract irritation
659. Ronnel Cholinesterase inhibitor 321.57 299-84-3 A4, IBEA 5 mg/m3 (IFV) 660. Rotenone Respiratory tract irritation 391.41 83-79-4 A4 5 mg/m3
upper and eyes; damage to central nervous system
upper and eyes; nausea
664. Sesone Irritation gastrointestinal 309.13 136-78-7 A4 10 mg/m3
upper and eyes; damage to kidney
667. Methyl silicate Respiratory tract irritation 152.22 681-84-5 1 ppm
upper; damage to eyes
668. Silica, crystalline α-quartz Pulmonary fibrosis; cancer of 60.09 14808-60-7 A2 0.025 mg/m3 (R)
lung
669. Silica, cristobalite Pulmonary fibrosis; cancer of 60. 09 14464-46-1 A2 0.025 mg/m3 (R)
lung
670. Silica, tripoli Pulmonary fibrosis; cancer of 60. 09 1317-95-9 A2 0.025 mg/m3 (R)
lung
671. Subtilisins Respiratory tract irritation various 1395-21-7 P 0.00006 mg/m3
upper, lower and skin; asthma
upper and eyes
upper
683. Hydrogen sulphide Respiratory tract irritation 34.08 7783-06-4 1 ppm 5 ppm
upper; damage to central nervous system
684. Sulprofos Cholinesterase inhibitor 322.43 35400-43-2 A4, SKIN, IBEA 0.1 mg/m3 (IFV) 685. 2,4,5-T Damage to nervous system 255.49 93-76-5 A4 10 mg/m3
peripheral
686. Talc with asbestos fibres Pneumoconiosis; cancer of various A1 0.1 f/cm3 (F)
lung; mesotelioma
687. Talc without asbestos fibres Pulmonary function; fibrosis various 14807-96-6 A4 2 mg/m3 (R,E)
pulmonary
Bi2Te3
690. Bismuth telluride, undoped, Damage to lung 800.83 1304-82-1 A4 10 mg/m3
as Bi2Te3
693. Terbufos Cholinesterase inhibitor 288.45 13071-79-9 A4, SKIN, IBEA 0.01 mg/m3 (IFV) 694. Terphenyls Respiratory tract irritation 230.31 26140-60-3 P 5 mg/m3
upper and eyes
695. Hydrogenated terphenyls, Damage to liver 241.00 61788-32-7 0.5 ppm
unirradiated
upper and eyes; pulmonaryy oedema; damage to liver
698. Carbon tetrabromide Irritation of eyes, tract 331.65 558-13-4 0.1 ppm 0.3 ppm
upper respiratory and skin, damage to liver
liver and kidney
707. Sulphur tetrafluoride Respiratory tract irritation 108.07 7783-60-0 P 0.1 ppm
upper and eyes; damage to lung
708. Tetrahydrofuran Respiratory tract irritation 72.10 109-99-9 A3, SKIN 50 ppm 100 ppm
upper; damage to central nervous system; damage to kidney
709. Germanium tetrahydride Haematological effect 76.63 7782-65-2 0.2 ppm 710. Silicon tetrahydride Respiratory tract irritation 32.12 7803-62-5 5 ppm
upper and skin
711. Tetrakis(hydroxymethyl) chloride of Effect on body weight; 190.56 124-64-1 A4 2 mg/m3 phosphonium central nervous system;
hepatic
712. Tetrakis(hydroxymethyl) sulphate of Effect on body weight; 406.26 55566-30-8 A4, SEN 2 mg/m3 phosphonium central nervous system;
hepatic
713. Tetramethylsuccinonitrile Headache; nausea; 136.20 3333-52-6 SKIN 0.5 ppm
convulsion
714. Tetramethyl lead, as Pb Central nervous system damage 267.33 75-74-1 SKIN 0.15 mg/m3 715. Tetranitromethane Respiratory tract irritation 196.04 509-14-8 A3 0.005 ppm
upper and eyes; cancer respiratory tract upper
716. Tetryl Respiratory tract irritation 287.15 479-45-8 1.5 mg/m3
upper
717. Osmium tetroxide, as Os Respiratory tract irritation 254.20 20816-12-0 0.0002 ppm 0.0006 ppm
upper, eyes and skin
718. 4,4'-Thiobis(6-tert-butyl-m-cresol) Respiratory tract irritation 358.52 96-69-5 A4 10 mg/m3
upper
719. Thiram Effect on body weight and 240.44 137-26-8 A4, SEN 0.05 mg/m3 (IFV)
haematological
720. o-Tolidine Irritation of eyes and vejiga; damage to 212.28 119-93-7 A3, SKIN -
kidney; cancer of vejiga; methaemoglobinaemia
721. Toluene Visual damage; damage to reproductive organ 92.13 108-88-3 A4, IBE 20 ppm
reproductive female; pregnancy loss
722. m-Toluidine Irritation of eyes and vejiga; damage to 107.15 108-44-1 A4, SKIN, IBEM 2 ppm
kidney; methaemoglobinaemia
723. o-Toluidine Irritation of eyes and vejiga; damage to 107.15 95-53-4 A3, SKIN, IBEM 2 ppm
kidney; methaemoglobinaemia
724. p-Toluidine Methaemoglobinaemia 107.15 106-49-0 A3, SKIN, IBEM 2 ppm 725. Boron tribromide Respiratory tract irritation 250.57 10294-33-4 P 1 ppm
upper
upper and eyes
729. 1,1,1-Trichloroethane Damage to liver; damage to system 133.42 71-55-6 A4, IBE 350 ppm 450 ppm
central nervous
730. 1,1,2-Trichloroethane Central nervous system damage 133.41 79-00-5 A3, SKIN 10 ppm
and liver
731. Trichloroethylene Central nervous system damage; 131.40 79-01-6 A2, IBE 10 ppm 25 ppm
cognitive decline; renal toxicity
732. Trichlorofluoromethane Cardiac sensitiser 137.38 75-69-4 A4, P 1000 ppm
3
733. Trichloronaphthalene Damage to liver; chloracne 231.51 1321-65-9 SKIN 5 mg/m 734. 1,2,3-Trichloropropane Damage to liver and kidney; irritation 147.43 96-18-4 A3, SKIN 10 ppm
of the respiratory tract upper and eyes
735. Phosphorus trichloride Respiratory tract irritation 137.35 7719-12-2 0.2 ppm 0.5 ppm
upper, eyes and skin
and cardiaco
739. Boron trifluoride Respiratory tract irritation 67.82 7637-07-2 P 1 ppm
lower, neumoconiosis
740. Chlorine trifluoride Respiratory tract irritation 92.46 7790-91-2 P 0.1 ppm
upper and eyes; damage to lung
741. Nitrogen trifluoride Damage to liver and kidney; 71.00 7783-54-2 IBEM 10 ppm
methaemoglobinaemia
upper
744. 2,4,6-Trinitrotoluene, TNT Damage to liver; 227.13 118-96-7 SKIN, IBEM 0.1 mg/m3
methaemoglobinaemia; catarata
745. Antimony trioxide, as Sb Lung cancer; 291.50 1309-64-4 A2 (L)
neumoconiosis
746. Arsenic trioxide, as As Skin cancer and lung 197.84 1327-53-3 A1 0.01
mg/m3
central nervous system
upper, eyes and skin
752. 4-Vinylcyclohexene Damage to reproductive organ 108.18 100-40-3 A3 0.1 ppm
female and male
753. Vinyltoluene Respiratory tract irritation 118.18 25013-15-4 A4 50 ppm 100 ppm
upper and eyes
gastrointestinal
757. Xylene, mixture Respiratory tract irritation 106.16 1330-20-7 A4, IBE 100 ppm 150 ppm
upper and eyes; damage to central nervous system
758. m-Xylene Respiratory tract irritation 106.16 108-38-3 A4, IBE 100 ppm 150 ppm
upper and eyes; damage to central nervous system
759. o-Xylene Respiratory tract irritation 106.16 95-47-6 A4, IBE 100 ppm 150 ppm
upper and eyes; damage to central nervous system
760. p-Xylene Respiratory tract irritation 106.16 106-42-3 A4, IBE 100 ppm 150 ppm
upper and eyes; damage to central nervous system
761. Xylidine, mixture of isomers Damage to liver; 121.18 1300-73-8 A3, SKIN, IBEM 0.5 ppm (IFV)
methaemoglobinaemia
762. Iodine Respiratory tract irritation 126.91 7553-56-2 A4 0.01 ppm (IFV) 0.1 ppm (V)
upper; hipotiroidismo
763. Iodoform Central nervous system damage 393.78 75-47-8 0.6 ppm 764. Methyl iodide Damage to eyes; damage to system 141.95 74-88-4 SKIN 2 ppm
central nervous I.1.1 Notations, abbreviations and notes to Table I.1: A1, A2, A3, A4 and A5: refer to the classification of chemical substances as carcinogens and indicate five levels: A1 Confirmed human carcinogen The agent is carcinogenic to humans, based on evidence from epidemiological studies. A2 Suspected human carcinogen Studies accepted as adequate in quality but which are conflicting and insufficient to classify the agent as confirmed in exposed humans, or the agent is carcinogenic in experimental animals, at doses, by routes of exposure, at histological sites or by mechanisms considered relevant to the exposure of occupationally exposed personnel. A2 is used mainly when the evidence of carcinogenicity in humans is limited and there is sufficient evidence of carcinogenicity in experimental animals with relevance to humans. A3 Confirmed animal carcinogen with unknown relevance to humans The agent is carcinogenic in experimental animals at relatively high doses, by routes of administration, at sites or histological types, or by mechanisms that are not considered relevant to occupationally exposed personnel. Available epidemiological studies do not confirm an increased risk of cancer in exposed humans. The evidence suggests that the agent is not likely to cause cancer in humans except under uncommon and unlikely routes or levels of exposure. A4 Not classified as a human carcinogen An agent which may be carcinogenic to humans but cannot be conclusively assessed owing to a lack of data. In vitro or animal studies do not provide indications of carcinogenicity sufficient to classify the agent in one of the other categories. A5 Not suspected as a human carcinogen The agent is not suspected of being a human carcinogen, based on epidemiological studies in humans. These studies have sufficient follow-up, reliable exposure histories, sufficiently high doses and statistical tests with sufficient power, to conclude that exposure to the agent does not carry a significant risk of cancer to humans. The evidence suggests that the absence of carcinogenicity in experimental animals may be taken into account, provided it is supported by other relevant data. IBE Biological Exposure Index recommended for the chemical substance. IBEA Biological Exposure Index for pesticides that inhibit acetylcholinesterase. IBEM Biological Exposure Index for methaemoglobin inducers. IBEP Biological Exposure Index for polycyclic aromatic hydrocarbons. P Where this notation appears, the value in the CT or P column refers to the peak exposure limit value (VLE-P); where it does not appear, it refers to the short-time exposure limit value (VLE-CT). SKIN The capacity of the chemical substance to be absorbed through the skin, mucous membranes or eyes in significant amounts, increasing the risk from exposure to that environmental contaminant. SEN The potential of a chemical substance to produce respiratory or dermal sensitisation. (D) Simple asphyxiant: an exposure limit value (VLE) cannot be recommended for each simple asphyxiant because the limiting factor is the available oxygen. The minimum oxygen content shall be 18% by volume under normal atmospheric pressure, equivalent to an oxygen partial pressure of 17.99 kPa (35 torr). Oxygen-deficient atmospheres do not provide adequate warning, since most simple asphyxiants are odourless. Several simple asphyxiants present an explosion hazard. This factor shall be taken into account when limiting the concentration of the asphyxiant. (IFV) Inhalable fraction and vapour. Numerous chemical agents are usually present in the working environment in the form of particulate matter, and their limit value is expressed in mg/m 3, even though it has an equivalent in ppm. However, owing to their physico-chemical properties or conditions of use, these agents may also be present in vapour form, so that the two phases, particulate matter and vapour, present simultaneously in the environment, contribute to the exposure. The IFV notation indicates that a chemical agent has a vapour pressure high enough to be present in the environment in both forms: particulate matter and vapour. In these cases, account is taken of the ratio between the concentration in vapour-saturated air and the VLE-PPT, assigning the notation when the quotient is between 0.1 and 10. In addition to the foregoing, the industrial hygienist shall also consider the possible presence of both phases for the correct evaluation of exposure in operations, for example, spraying, in processes involving temperature changes that could affect the physical state of the chemical agent, or when a significant fraction of the vapour may dissolve or adsorb onto the particles of another chemical substance, in the same way as water-soluble compounds in environments with high humidity. (See C. Perez and S. C. Soderholm. Some chemicals requiring special consideration when deciding whether to sample the particle, vapor, or both phases of an atmosphere. Appl. Occup. Environ. Hyg. 6 (10), 859-864. 1991). (E) This value is for particulate matter containing less than 1% crystalline silica and no asbestos. (F) Fibres. (H) Aerosol only. (I) Inhalable fraction. (K) Shall not exceed 2 mg/m3 of respirable particle mass. (L) Exposure by all routes shall be controlled to as low a level as possible. (p) Application restricted to conditions where exposure to aerosols is negligible. (R) Respirable fraction. (T) Thoracic fraction. (V) Vapour and aerosol. (X) Particulate matter for which there is no toxicological evidence on which to establish an exposure limit value (VLE). Nevertheless, it is advisable to keep exposures below the indicated exposure limit value (VLE). Such exposure limit value (VLE) is only applicable to particulate matter meeting the following conditions: It lacks a specific exposure limit value (VLE); It is insoluble or poorly soluble in water or, preferably, in lung fluid, if that information is available, and It has low toxicity, that is, it is not cytotoxic, genotoxic, or does not otherwise chemically react with lung tissue; and does not emit ionising radiation, cause sensitisation or any other toxic effect other than that which may result from its accumulation in the lung. Appendix II Hazard code of chemical substances and its description The alphanumeric code of the Harmonised System for the Classification and Communication of Hazards of Chemical Products consists of a letter and three numbers: a) The letter "H" means "hazard statement"; b) The first digit designates the type of hazard to which the statement is assigned, which is for the following hazards: "2" physical, and "3" for health, and c) The following two numbers correspond to the consecutive numbering of the hazards according to the intrinsic properties of the substance or mixture. Health Hazard Code and Description H304. May be fatal if swallowed and enters airways. H330. Fatal if inhaled. H331. Toxic if inhaled. H332. Harmful if inhaled. H333. May be harmful if inhaled. H305. May be harmful if swallowed and enters airways. H334. May cause allergy or asthma symptoms or breathing difficulties if inhaled. H335. May cause respiratory irritation. H336. May cause drowsiness or dizziness. H340. May cause genetic defects (state route of exposure if it is conclusively proven that no other routes of exposure cause the hazard). H341. Suspected of causing genetic defects (state route of exposure if it is conclusively proven that no other routes of exposure cause the hazard). H350. May cause cancer (state route of exposure if it is conclusively proven that no other routes of exposure cause the hazard). H351. Suspected of causing cancer (state route of exposure if it is conclusively proven that no other routes of exposure cause the hazard). H360. May damage fertility or the unborn child (state specific effect if known) (state route of exposure if it is conclusively proven that no other routes of exposure cause the hazard). H361. Suspected of damaging fertility or the unborn child (state specific effect if known) (state route of exposure if it is conclusively proven that no other routes of exposure cause the hazard). H370. Causes damage to organs (or state all organs affected, if known) (state route of exposure if it is conclusively proven that no other routes of exposure cause the hazard). H371. May cause damage to organs (or state all organs affected, if known) (state route of exposure if it is conclusively proven that no other routes of exposure cause the hazard). H372. Causes damage to organs (state all organs affected, if known) through prolonged or repeated exposure (state route of exposure if it is conclusively proven that no other routes of exposure cause the hazard). H373. May cause damage to organs (state all organs affected, if known) through prolonged or repeated exposure (state route of exposure if it is conclusively proven that no other routes of exposure cause the hazard). (H300 + H330). Fatal if swallowed or if inhaled. (H301 + H331). Toxic if swallowed or if inhaled. (H302 + H332). Harmful in contact or if inhaled. (H310 +H330). Fatal in contact with skin or if inhaled. (H311 + H331). Toxic in contact with skin or if inhaled. (H312 + H332). Harmful in contact with skin or if inhaled. (H303 + H333). May be harmful if swallowed or if inhaled. (H313 + H333). May be harmful in contact with skin or if inhaled. (H303 + H313 + H333). May be harmful if swallowed, in contact with skin or if inhaled. (H300 + H310 + H330). Fatal if swallowed, in contact with skin. (H301 + H311 + H331). Toxic if swallowed, in contact with skin or if inhaled. (H302 + H312 + H332). Harmful if swallowed, in contact with skin or if inhaled. Guide A (Non-mandatory) Example for calculating exposure limit values for contaminant mixtures in the working environment The content of this guide is a supplement for a better understanding of this Standard and is not mandatory. The equations for calculating additive effects, independent effects and synergistic effects are set out in item 10.4.1, subparagraphs f), g) and h), of this Standard. A.I Additive effect Where two or more chemical substances that act on the same organ, apparatus or system of the body are present, their additive effect shall mainly be taken into account. In this case, the sum of the ratio of each of the concentrations measured in the working environment (CMA) to its exposure limit value (VLE) must be less than or equal to 1, to be in compliance. Example: In a work environment, the air was found to contain 400 ppm of acetone (VLE-PPT 500 ppm); 150 ppm of sec-butyl acetate (VLE-PPT 200 ppm), and 100 ppm of methyl ethyl ketone (VLE-PPT 200 ppm). Therefore, the time-weighted average exposure limit value (VLE-PPT) of the mixture is exceeded. A.2 Special case of the additive effect The special case of the additive effect occurs when the source of the contaminant is a liquid mixture and it is assumed that the proportion of its components in the working environment is similar to that of the original mixture. To assess compliance with the exposure limit value (VLE) of the mixture, field sampling instruments shall be calibrated in the laboratory to have a specific response to this air-vapour mixture, quantitatively and qualitatively, and also at fractional concentrations of this mixture. Example: ½ of the VLE; 1/10 of the VLE; 2 times the VLE; 10 times the exposure limit value (VLE). Example: A liquid mixture is available containing: 50% heptane with VLE-PPT = 400 ppm; 30% methyl chloroform with VLE-PPT = 350 ppm, and 20% tetrachloroethylene with VLE-PPT = 25 ppm. Conversion formula 1 ppm = (24.45 / PM ) mg / m 3. For: Heptane PM = 100.20 mg / m3 = (100.20 / 24.45) 400 ppm = 1639.26 mg / m3 (1 mg / m3 = 0.244 ppm) Methyl chloroform PM = 133.42 mg / m3 = (133.42 / 24.45) 350 ppm = 1909.89 mg / m3 (1 mg / m3 = 0.183 ppm) Tetrachloroethylene PM = 165.8 mg / m3= (165.8 / 24.45) 25 ppm = 169.52 mg / m3 (1 mg / m3 = 0.1474 ppm) It is assumed that the mixture evaporates completely. Of this mixture, the: 50% or (626.5664) (0.5) = 313.2832 mg/m3 is heptane; 30% or (626.5664) (0.3) = 187.9699 mg/m3 is methyl chloroform, and 20% or (626.5664) (0.2) = 125.3133 mg/m3 is tetrachloroethylene. These values are converted to ppm as follows: Heptane (313.2832 mg/m3) (0.244) = 76.441 ppm; Methyl chloroform (187.9699 mg/m3) (0.183) = 34.398 ppm, and Tetrachloroethylene (125.3133 mg/m3) (0.1474) = 18.045 ppm. VLE-PPT of the mixture = 76.441 + 34.398 + 18.045 = 128.884 ppm. A.3 Independent effects Where the main effects of the different contaminants present in the working environment are independent, exceptions to this rule may be made, as occurs when the different components of the mixture produce purely local effects on different organs of the body. In such cases, the exposure limit value (VLE) is exceeded when at least one result of the same series has a value greater than unity. Example: A mixture of contaminants contains 0.045 mg/m 3 of lead (VLE-PPT = 0.05 mg/m3) and 0.198 mg/m3 of sulphuric (VLE-PPT = 0.2 mg/m3). Therefore, the time-weighted average exposure limit value (VLE-PPT) is not exceeded. A.4 Synergistic effects With some combinations of contaminants of the working environment, synergistic or potentiating effects may occur. In such cases, for the time being, they shall be determined individually. These potentiating or synergistic contaminants are not necessarily harmful in themselves. It is also possible to potentiate the effects of exposure to such contaminants by routes of entry other than inhalation, for example, the ingestion of alcohol and the inhalation of a narcotic such as trichloroethylene. The synergistic effect typically occurs at high concentrations and is less likely at low concentrations. Examples of processes typically associated with two or more harmful environmental contaminants are welding, blasting with explosives, painting, lacquering, certain smelting operations, and exhaust fumes from diesel and petrol engines, among others. ______________________________
609. Insoluble or poorly various 10 mg/m3 (I)
soluble particles not otherwise specified 3 mg/m3 (R)611. Iron pentacarbonyl, as Pulmonary oedema; damage to system 195.90 13463-40-6 0.1 ppm 0.2 ppm
Fe nervous, central
612. Pentachlorophenol Upper respiratory tract irritation 266.35 87-86-5 A3, SKIN, IBE 0.5 mg/m3| 613. | Pentachloronaphthalene | Liver damage; chloracne | 300.40 | 1321-64-8 | SKIN | 0.5 mg/m3 |
| 614. | Pentachloronitrobenzene | Liver damage | 295.36 | 82-68-8 | A4 | 0.5 mg/m3 |
| 615. | Phosphorus pentachloride | Upper respiratory tract irritation | 208.24 | 10026-13-8 | 0.1 ppm |
619. Pentane Peripheral neuropathy 72.15 109-66-0 600 ppm 620. 2,4-Pentanedione Neurotoxicity; damage to system 100.12 123-54-6 SKIN 20 ppm
| 625. | Perfluorobutyl ethylene | Haematological effect | 246.10 | 19430-93-4 | 100 ppm | |
| 626. | Ammonium perfluorooctanoate | Liver damage | 431.00 | 3825-26-1 | A3, SKIN | 0.01 mg/m3 |
| 627. | Dibenzoyl peroxide | Upper respiratory tract irritation | 242.22 | 94-36-0 | A4 | 5 mg/m3 |
630. Persulphates, as S2O8 Skin irritation various 0.1 mg/m3 631. Picloram Liver and kidney damage 241.48 1918-02-1 A4 10 mg/m3 632. Pindone Coagulation 230.25 83-26-1 0.1 mg/m3 633. α-Pinene Upper respiratory tract irritation 136.00 80-56-8 A4, SEN 20 ppm
638. Tetraethyl pyrophosphate, TEPP Cholinesterase inhibitor 290.20 107-49-3 SKIN, IBEA 0.01 mg/m3 (IFV)
639. Silver and compounds, metal, Argyria 107.87 7440-22-4 0.1 mg/m3
dusts and fumes various643. Lead and inorganic compounds, Central nervous system damage 207.20 7439-92-1 A3, IBE 0.05 mg/m3
as Pb and peripheral; haematological effect various
644. Propane Cardiac sensitiser; damage to 44.10 74-98-6 1000 ppm647. 1,3-Propane sultone Cancer 122.14 1120-71-4 A3 648. Propyleneimine Upper respiratory tract irritation 57.09 75-55-8 A3, SKIN 0.2 ppm 0.4 ppm
| 652. | Propoxur | Cholinesterase inhibitor | 209.24 | 114-26-1 | A3, IBEA | 0.5 mg/m3 |
| 653. | Kerosene | Upper respiratory tract irritation | various | 8008-20-6 | A3, SKIN | 200 mg/m3 (p) |
655. Quinone Eye irritation; skin damage 108.09 106-51-4 0.1 ppm 656. Resorcinol Eye and skin irritation 110.11 108-46-3 A4 10 ppm 20 ppm
658. Rhodium, metal and Metal = irritation of the tract 102.91 7440-16-6 A4 1 mg/m3
insoluble compounds, as Rh respiratory, upper; various| 659. | Ronnel | Cholinesterase inhibitor | 321.57 | 299-84-3 | A4, IBEA | 5 mg/m3 (IFV) |
| 660. | Rotenone | Upper respiratory tract irritation | 391.41 | 83-79-4 | A4 | 5 mg/m3 |
661. Sucrose Dental erosion 342.30 57-50-1 A4 10 mg/m3
662. Selenium and compounds, as Se Respiratory tract irritation 78.96 7782-49-2 0.2 mg/m3
upper and eyes various
663. Hydrogen selenide, as Se Upper respiratory tract irritation 80.98 7783-07-5 0.05 ppm665. Calcium silicate, without fibres Respiratory tract irritation 116.16 1344-95-2 A4 10 mg/m3 (E)
synthetic upper
666. Ethyl silicate Upper respiratory tract irritation 208.30 78-10-4 10 ppm672. Subtilisins, as pure Respiratory tract irritation 28.00 9014-01-1 P 0.00006 mg/m3
crystalline enzyme, 100% upper, lower and skin; asthma
673. Ammonium sulphamate Upper respiratory tract irritation 114.13 7773-06-0 10 mg/m3674. Calcium sulphate dihydrate Nasal symptoms 172.20 10101-41-4 10 mg/m3 (I) 675. Calcium sulphate hydrate Nasal symptoms 172.20 13397-24-5 10 mg/m3 (I) 676. Barium sulphate Pneumoconiosis 233.43 7727-43-7 10 mg/m3 677. Calcium sulphate, anhydrous Nasal symptoms 136.14 7778-18-9 10 mg/m3 (I) 678. Calcium sulphate hemihydrate Nasal symptoms 145.16 10034-76-1 10 mg/m3 (I) 679. Dimethyl sulphate Eye and skin irritation 126.10 77-78-1 A3, SKIN 0.1 ppm 680. Sulfotep Cholinesterase inhibitor 322.30 3689-24-5 A4, SKIN, IBEA 0.1 mg/m3 (IFV) 681. Carbonyl sulphide Central nervous system damage 60.08 463-58-1 5 ppm 682. Dimethyl sulphide Upper respiratory tract irritation 62.14 75-18-3 10 ppm
| 684. | Sulprofos | Cholinesterase inhibitor | 322.43 | 35400-43-2 | A4, SKIN, IBEA | 0.1 mg/m3 (IFV) |
| 685. | 2,4,5-T | Damage to nervous system | 255.49 | 93-76-5 | A4 | 10 mg/m3 |
| 688. | Thallium and compounds, as Tl | Gastrointestinal damage; peripheral neuropathy | 204.37 various | 7440-28-0 | SKIN | 0.02 mg/m3 (I) |
| 689. | Bismuth telluride, doped as | Lung damage | 800.83 | 1304-82-1 | A4 | 5 mg/m3 |
691. Tellurium and compounds, as Te, Halitosis 127.60 13494-80-9 0.1 mg/m3
except hydrogen telluride various
692. Temephos Cholinesterase inhibitor 466.46 3383-96-8 A4, SKIN, IBEA 1 mg/m3 (IFV)693. Terbufos Cholinesterase inhibitor 288.45 13071-79-9 A4, SKIN, IBEA 0.01 mg/m3 (IFV) 694. Terphenyls Upper respiratory tract irritation 230.31 26140-60-3 P 5 mg/m3
696. Sodium tetraborate Respiratory tract irritation 291.35 12179-04-3 A4 2 mg/m3 (I) 6 mg/m3 (I)
pentahydrate upper
697. 1,1,2,2-Tetrabromoethane Upper respiratory tract irritation 345.70 79-27-6 0.1 ppm (IFV)699. 1,1,2,2-Tetrachloro-1,2- Liver and kidney damage; damage to 203.83 76-12-0 50 ppm
difluoroethane central nervous system
700. 1,1,1,2-Tetrachloro-2,2- Liver and kidney damage; damage to 203.83 76-11-9 100 ppm
difluoroethane central nervous system
701. 1,1,2,2-Tetrachloroethane Liver damage 167.86 79-34-5 A3, SKIN 1 ppm
702. Tetrachloroethylene Central nervous system damage 165.80 127-18-4 A3, IBE 25 ppm 100 ppm
703. Tetrachloronaphthalene Liver damage 265.96 1335-88-2 2 mg/m3
704. Carbon tetrachloride Liver damage 153.84 56-23-5 A2, SKIN 5 ppm 10 ppm
705. Tetraethyl lead, as Pb Central nervous system damage 323.45 78-00-2 A4, SKIN 0.1 mg/m3
706. Tetrafluoroethylene Liver and kidney damage; cancer of 100.20 116-14-3 A3 2 ppm| 709. | Germanium tetrahydride | Haematological effect | 76.63 | 7782-65-2 | 0.2 ppm |
| 710. | Silicon tetrahydride | Upper respiratory tract irritation | 32.12 | 7803-62-5 | 5 ppm |
711. Tetrakis(hydroxymethyl) chloride of Effect on body weight; 190.56 124-64-1 A4 2 mg/m3
phosphonium central nervous system;712. Tetrakis(hydroxymethyl) sulphate of Effect on body weight; 406.26 55566-30-8 A4, SEN 2 mg/m3
phosphonium central nervous system;| 714. | Tetramethyl lead, as Pb | Central nervous system damage | 267.33 | 75-74-1 | SKIN | 0.15 mg/m3 |
| 715. | Tetranitromethane | Upper respiratory tract irritation | 196.04 | 509-14-8 | A3 | 0.005 ppm |
724. p-Toluidine Methaemoglobinaemia 107.15 106-49-0 A3, SKIN, IBEM 2 ppm 725. Boron tribromide Upper respiratory tract irritation 250.57 10294-33-4 P 1 ppm
| 726. | Trichlorfon | Cholinesterase inhibitor | 257.60 | 52-68-6 | A4, IBEA | 1 mg/m3 (I) | |
| 727. | 1,1,2-Trichloro-1,2,2-trifluoroethane | Central nervous system damage | 187.40 | 76-13-1 | A4 | 1000 ppm | 1250 ppm |
| 728. | 1,2,4-Trichlorobenzene | Upper respiratory tract irritation | 181.46 | 120-82-1 | P | 5 ppm |
| 733. | Trichloronaphthalene | Liver damage; chloracne | 231.51 | 1321-65-9 | SKIN | 5 mg/m |
| 734. | 1,2,3-Trichloropropane | Liver and kidney damage; irritation | 147.43 | 96-18-4 | A3, SKIN | 10 ppm |
736. Triethanolamine Eye and skin irritation 149.22 102-71-6 5 mg/m3 737. Triethylamine Visual damage 101.19 121-44-8 A4, SKIN 1 ppm 3 ppm 738. Trifluorobromomethane Central nervous system damage 148.92 75-63-8 1000 ppm
742. Trimethylbenzene, mixture of Central nervous system damage; 120.19 25551-13-7 25 ppm
Isomers asthma; haematological effect
743. Trimethylamine Upper respiratory tract irritation 59.11 75-50-3 5 ppm 15 ppm 747. Tungsten, soluble compounds, Central nervous system damage; 183.85 7440-33-7 1 mg/m3 3 mg/m3
as W pulmonary fibrosis various
748. Tungsten, metal and compounds Respiratory tract irritation 183.85 7440-33-7 5 mg/m3 10 mg/m3
insoluble, as W lower various
749. Turpentine Respiratory tract irritation 136.00 8006-64-2 A4, SEN 20 ppm
upper and skin; damage to lung and to various 750. Natural uranium, compounds Kidney damage 238.03 7440-61-1 A1, IBE 0.2 mg/m3 0.6 mg/m3
soluble and insoluble, as U various
751. n-Valeraldehyde Upper respiratory tract irritation 86.13 110-62-3 50 ppm754. N-Vinyl-2-pyrrolidone Liver damage 111.16 88-12-0 A3 0.05 ppm 755. Warfarin Coagulation 308.32 81-81-2 0.1 mg/m3 756. m-Xylene α,α'-diamine Eye, skin and 136.20 1477-55-0 SKIN, P 0.1 mg/m3
763. Iodoform Central nervous system damage 393.78 75-47-8 0.6 ppm 764. Methyl iodide Eye damage; damage to system 141.95 74-88-4 SKIN 2 ppm